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 1 
1  Introduction 
1.1 Human African Trypanosomiasis 
1.1.1 Epidemiology 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is one of the “neglected tropical 
diseases” (Hotez and Kamath, 2009). The concept of neglected tropical diseases (NTDs) was first proposed 
in the 1970s by Ken Warren (Keating, 2014; Croft, 2016). He brought attention to a significant proportion of 
the human population that was poor, suffered from chronic, disabling but rarely fatal diseases, and who were 
often stigmatized and unemployed (Croft, 2016). Also, these diseases are neglected by the pharmaceutical 
companies, as affected low developed countries do not receive too many priorities for research funding and 
field investigations. 
HAT is a vector-borne parasitic disease which primarily affects poor rural populations in some of the least 
developed countries of East and Central Africa (Berriman et al., 2005). Moreover, HAT is the world’s third 
most important parasitic disease affecting human health after malaria and schistosomiasis as defined by the 
global burden of parasitic disease, calculated as the disability-adjusted life years lost (Kennedy, 2008). 
HAT is caused by two subspecies of Trypanosoma brucei, namely Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense, which are transmitted to the human host by tsetse flies. Other parasites like 
T. congolense or the subspecies (T. brucei brucei) are not human infective, but cause animal trypanosomiasis 
in wild and domestic animals (http://www.who.int/mediacentre/factsheets/fs259/en/). 
T. b. gambiense causes disease in Central and Western Africa that is called Gambian HAT (Figure 1.1). It is 
a chronic illness that can take years or decades before fatality (Checchi et al., 2008). It is an anthroponotic 
disease with a minor role for animal reservoirs. It is responsible for 98% of HAT cases reported in the last 
decade (Franco et al., 2014). T. b. rhodesiense causes disease in Eastern and Southern Africa that is called 
Rhodesian HAT (Figure 1.1). It is an acute disease causing death within weeks or months upon infection (Odiit 
et al., 1997). It is a zoonotic disease, affecting mainly animals (livestock and wildlife) (Franco et al., 2014). 
The prevalence of HAT is between 14o North and 29o South in many countries of sub-Saharan Africa. 
Therefore, about 60 million people are estimated to be at the risk of getting infected (Kennedy, 2013). 
Countries mostly affected are the Democratic Republic of Congo, Angola, and South Sudan, where it mainly 
affects impoverished rural communities. Several human epidemics of HAT have been recorded in Africa over 
the last century. The major one occurred between 1896 and 1906 and affected mostly Uganda and the Congo 
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basin. This outbreak was followed by one in 1920 which struck several African countries. The disease did 
resurge in the 1970s and led to alarming epidemics in the 1990s. In the Central African Republic, Chad, 
Democratic Republic of Congo, Cote d’Ivoire, Guinea, Malawi, Uganda and the United Republic of Tanzania 
the threat of HAT remains a significant public health problem, with 50-1000 new cases reported every year 
(www.who.int). Countries such as Burkina Faso, Cameroon, Equatorial Guinea, Gabon, Kenya, Mozambique, 
Nigeria, Rwanda, Zambia, and Zimbabwe are reporting fewer than 50 new cases per year (Figure 1.1). In 
countries such as Benin, Botswana, Burundi, Ethiopia, Gambia, Ghana, Guinea-Bissau, Liberia, Mali, 
Namibia, Niger, Senegal, Sierra Leone, Swaziland and Togo transmission seems to have stopped and no new 
cases have been reported for several decades (www.who.int). 
The steady decrease of HAT cases reported during the last 10 years in Africa has led the World Health 
Organization (WHO) to speculate about the elimination of HAT as a public health problem (defined as less 
than 1 annual case/10.000 inhabitants in HAT endemic foci) being achieved by 2020. However, it is estimated 
that a significant number of new cases are still unreported or undiagnosed (Brun et al., 2010; Fevre et al., 
2008; Kennedy, 2013). The non-diagnosed population has been recently explained by the discovery of healthy 
carriers, i.e. infected but asymptomatic patients (Capewell et al., 2016; Casas-Sánchez and Acosta-Serrano, 
2016; Sudarshi et al., 2014). This is supported by the recent description of skin or fat dwelling trypanosomes 
(Capewell et al., 2016; Trindade et al., 2016) and the meningeal stage from which trypanosomes could invade 
the brain via the Virchow-Robin space thereby bypassing the blood-brain barrier (Mogk et al., 2016). These 
results provide strong arguments to raise up attention on potentially overlooked human and animal reservoirs.  
 
 3 
 
Figure 1.1: Distribution of human African trypanosomiasis with incidences and risk for travelers. 
The black line divides the areas in which Trypanosoma brucei gambiense prevails and those in 
which Trypanosoma brucei rhodesiense predominates (Brun et al., 2010). 
 
1.1.2 Clinical Features 
The clinical presentation of HAT depends on the parasite species, the stage of the disease and the host. The 
signs and symptoms that characterize sleeping sickness are mainly the same for both forms of the disease but 
differ in their frequency, severity, and kinetics of appearance. Rhodesiense HAT is an acute illness, which 
progresses to second-stage within a few weeks and usually to death within 6 months. Gambiense HAT is a 
more chronic disease; the second stage is usually reached within weeks to months. Usually, both stages of the 
illness are considered fatal if untreated. The human population living in HAT endemic countries could be 
divided into different groups: susceptible (uninfected); infected asymptomatic and infected symptomatic. The 
healthy carriers or infected asymptomatic HAT patients are defined as people living symptomless with the 
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disease with up to several decades (Sudarshi et al., 2014). This indicates that many more people might be 
carrying the transmissible parasites and remained out of control in endemics countries.  
So far it has been described that both forms of HAT progress in two stages, the first called haemolymphatic 
stage and the second called meningo-encephalitic stage. The first stage starts when the parasite enters the 
human blood and lymph vessels, they spread into the lymph node and systemic organs like spleen, liver, eyes 
and endocrine organs. The second stage is when the parasite invades the CNS via crossing the  blood-brain 
barrier (BBB) or blood-CSF barrier (BCB). 
During the first or haemolymphatic stage of the disease, Gambiense HAT patients can present intermittent 
nonspecific symptoms such as fever, fatigue, headaches, arthralgies, and pruritus. Afterward, the cervical 
lymph nodes in the neck may swell, an often observed symptom called “the Winterbottom sign”. This 
observation was recognized as an alert sign for HAT long ago by Sir Thomas Masterman Winterbottom, who 
noted that slave traders in the last 18th century used neck swelling as an indicator of sleepiness or abnormal 
behavior that made particular slaves undesirable (Chappuis et al., 2005). 
During the second stage, the sleep disorder is the main major symptom. It leads to sleep-wake cycle disruption 
and sleep structure alterations (Buguet et al., 2005). The structure of sleep is altered and characterized by 
episodes of sleep-onset rapid eye movement (SOREM) (Buguet et al., 2001, 2005). The hallmark of sleeping 
sickness, i.e. changes of the sleep/wake cycles, leads to a profound polyphasic sleep-wake pattern, 
characterized by SOREM episodes, which may appear earlier than the sleep-wake alterations (Kristensson et 
al., 2010). 
The sleep structure alterations, including SOREM episodes, have been shown to recede or disappear after 
treatment of infection and improvements may take several months after treatment to unfold (Buguet, 1999). It 
has been indicated that sleep-wake changes in HAT are not directly related to the presence of the parasite in 
the brain, and points to slowly reversible functional alteration and/or to compensatory mechanisms over time, 
rather than to severe structural damage of sleep-wake regulating regions during the disease (Kristensson et al., 
2010). 
Based on our experimental findings that trypanosomes cannot survive in CSF, the cyclic appearance of the 
parasite in CSF, location of the parasite in the pia mater (meningeal stage) and the variability of the time 
interval from the initial infection (skin or blood stage) before brain invasion (encephalitic stage) are proof of 
the exitence of trypanosome populations in other tisues playing important to sustain the cycle infection versus 
transmission. Those findings reveal that the trypanosome must adapt itself for surviving at different selection 
pressure area during the HAT infection progression. Afterward, the selected survived parasite will spread from 
those various stages to susceptible tissues close to the ventricular system that does not have the blood-brain 
barrier like the circumventricular organs (CVOs) and pia matter or basal meninges. The localization of basal 
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meninge or CVOs trypanosomes may impair the CVOs physiological functions and correspond to commonly 
observed HAT symptoms. This lead us to recently propose a correlation between the symptoms and infected 
organs in a three-stage model (Mogk et al., 2016) (Figure 1.2). 
 
Figure 1.2: (A) Symptoms of HAT (Enanga et al., 2002). (*) symptoms only observed in East 
African trypanosomiasis, which is caused by T. brucei rhodesiense. Body scheme derived from 
Mikael Häggström (University of Uppsala). (B) Suggested correlation between symptoms and 
infected organs in a three-stage model of HAT infection (haemolymphatic, meningeal and 
encephalitic). (A) and (B) figures derived from Mogk et al., 2016. 
It was reported that molecules produced by trypanosomes, especially the prostaglandins D2 (Duszenko et al., 
2006; Figarella et al., 2005, 2006), may also be involved in the dysfunction of sleep-wake cycles (Urade and 
Hayaishi, 2011). 
Moreover, cytokines such us TNF-α and IFN-γ released by the host immune response may also trigger the 
sleep-wake deregulation during the HAT infection (Kristensson et al., 2010). 
Neurological and psychological symptoms have been observed during second-stage HAT such as personality 
changes, hallucination, and coma. 
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1.1.3 Diagnosis 
In general, clinical signs and symptoms such as fever, swollen lymph nodes or neurological signs are not 
unique to make HAT diagnosis specific. They just provide a hint for diagnosis but are not sufficient to start 
treatment. The correct diagnosis of HAT is therefore field- and laboratory-based and consists of three steps 
(Chappuis et al., 2005): screening, diagnosis confirmation, and staging of the disease. 
For screening of the Gambiense HAT infection, a card agglutination test for trypanosomiasis (CATT) was 
developed in the late 1970s that can be performed on blood and serum. CATT is a rapid, simple assay for the 
detection of specific antibodies in blood of Gambiense HAT patients (Lejon et al., 1998). The CATT antigen 
present on the card was raised against the complete bloodstream form of T. b. gambiense variable antigen type 
LiTat 1.3, i.e. containing also the invariant cross-reacting determinant. The sensitivity of CATT is about 87-
98% and the specificity about 93-95% (Brun et al., 2010; Chappuis et al., 2005). CATT is the best adapted 
and most efficient screening method and is widely used in endemics areas (Brun et al., 2010). However, the 
CATT is not available in a single format, requires a cold chain for storage, and uses equipment that requires 
electricity (Bisser et al., 2016).This challenge is ongoing to be solved by recent progress and development of 
acurate and sensitive rapid diagnostic test (RDT) for HAT (Bisser et al., 2016; Sternberg et al., 2014). 
For diagnostic confirmation, the demonstration of the parasite in body fluids provides explicit evidence of 
trypanosome infection. This diagnosis is made by microscopic examination using a lymph node aspirate or a 
blood sample. The delay between sampling and examination should be kept as short as possible to avoid lysis 
of trypanosomes. The sensitivity of lymph node palpation and aspiration varies from 40% to 80% dependent 
on parasite strains, stage of the disease (this test is more sensitive during the first stage) (Brun et al., 2010), 
and prevalence of other diseases that cause lymphadenopathy.  
Because examination of thin or thick blood films has very low sensitivity, concentration methods such as the 
microhaematocrit centrifugation technique (Woo and others, 1970), the quantitative buffy coat test (Ancelle 
et al., 1997; Truc et al., 1998), or the miniature anion-exchange centrifugation technique have been developed 
and are widely used (Lutumba et al., 2006, 2007). Molecular tests such as polymerase chain reaction (PCR) 
and loop-mediated isothermal amplification (LAMP) based on detection of the parasite’s nucleic acids (DNA 
or RNA) are attractive alternatives for parasite detection (Deborggraeve and Büscher, 2010, 2012; Hayashida 
et al., 2015).  
For staging of the disease, the presence of parasites, more than five white blood cells per µl, or an increased 
protein content (˃370 mg/L) within CSF defines the second stage according to WHO recommendations (Brun 
et al., 2010). This recommendation is now subjected to controversy that may have some impact on the staging 
decision. 
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Diagnosis of Rhodesiense HAT differs from that for Gambiense HAT in several ways. First, there is no 
serological screening test for Rhodesiense infections, and second, the parasitological confirmation is easier 
because the density of parasites in blood is usually higher than in Gambiense infections (Brun et al., 2010). 
Research and development of methods for diagnosis and staging of HAT are still under investigation through 
an initiative by WHO and the Foundation for Innovative New Diagnosis (FIND) (Brun et al., 2010). 
 
1.1.4 Treatment 
The chemotherapy of HAT has historical roots that date back to the pioneering work by Paul Ehrlich on dyes 
and arsenicals (Fairlamb, 2003). The drugs currently used depend on the stage of the disease. Unfortunately, 
they all have many adverse side effects. 
For early stage HAT, pentamidine and suramin are used for treatment. Pentamidine was developed in the 
1930s by the English chemist Arthur James Ewins, an employee of the May and Baker pharmaceutical 
company (Steverding, 2008). It is administered by intramuscular or intravenous injection once daily for 7 
days. The drug is effective but associated with pain at the injection site, hypo- or hyperglycemia, hypotension, 
leukopenia, a prolonged QT interval on electrocardiograms, nephrotoxicity and gastrointestinal symptoms 
(Nagle et al., 2014; Stein et al., 2014). 
It binds to tissue proteins, thus contributing to a large application volume, and has a long terminal half-life 
(Nagle et al., 2014). It does not cross the blood-brain barrier. It is concentrated in trypanosomes via uptake by 
aminopurin (P2) and other surface transporters (Nagle et al., 2014). The mechanism by which pentamidine 
kills the parasite is not well understood and nonspecific. It may act by binding to DNA or by disrupting 
mitochondrial functions. 
Suramin, introduced in 1922, is till today the first line drug to treat Rhodesiense HAT given by slow 
intravenous infusion every 3-7 days for a 4 week period (Brun et al., 2011). It is highly protein bound and has 
a very long terminal half-life of 41-78 days; it does not cross the blood-brain barrier (Nagle et al., 2014). 
Suramine adverse effects include neuropathy, rash, fatigue, anemia, hyperglycemia, hypocalcemia, 
coagulopathies, neutropenia, and nephrotoxicity (Stein et al., 2014). 
For late stage HAT, the arsenical melarsoprol or a nifurtimox-eflornithine combination therapy (NECT) are 
currently used for treatment. Arsenicals were the first drug group introduced in 1906 to treat HAT starting 
with a drug called atoxyl. It was often fatally or caused blindness due to optic nerve atrophy (Stein et al., 
2014). Melarsoprol drug was effective for treatment of late stage HAT due to T. b. rhodesiense and T. b. 
gambiense. It is extremely toxic with up to 10% of all patients developing a post-treatment reactive 
encephalopathy (PTRE) that lead to death in about 50% of these cases (Blum et al., 2001). It is also associated 
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with pyrexia, headache, pruritus, thrombocytopenia and heart failure (Stein et al., 2014). It is concentrated in 
trypanosomes via uptake by the aminopurin (P2) transporter and disrupts the redox environment within the 
cell by interacting with the protein trypanothione (Fairlamb et al., 1989; Nagle et al., 2014). 
Difluoromethylornithine (DFMO) (named: eflornithine) was repurposed from investigations as an anticancer 
agent (Stein et al., 2014). It is a specific inhibitor of ornithine decarboxylase (ODC) and the first enzyme that 
converts ornithine to its biogenic amine putrescine as the first step in polyamine biosynthesis. It acts on the 
mammalian enzyme as well as on the trypanosomal ODC but owing to the rapid turnover to the mammalian 
ODC; the drug exerts much less toxicity on host cells as compared to bloodstream trypanosomes (Stein et al., 
2014). DFMO is more efficient as melarsoprol and has a superior safety profile (Chappuis et al., 2005). It was 
called “resurrection drug” due to its spectacular effect on comatose sleeping sickness patients (Stein et al., 
2014). The problems with eflornithine are the dose regimen (administration is intravenous: 100 mg/Kg every 
6 h for 14 days) and the high cost of the production process (Stein et al., 2014). It is also associated with side 
effects such as fever, headache, hypertension, macular rash, peripherical neuropathy, tremor and 
gastrointestinal problems (Fairlamb, 2003; Stein et al., 2014). 
A significant advancement in HAT chemotherapy was the introduction of eflornithine combined with 
nifurtimox (NECT) to solve the problem of large dose intravenous infusion administration at 200 mg/Kg every 
12 h for 7 days (rather than 100 mg/Kg every 6 h for 14 days as monotherapy) combined with nifurtimox 
orally administered at 15 mg/Kg three times a day for 10 days (Priotto et al., 2009). Nifurtimox was repurposed 
as a drug for treating American trypanosomiasis (Chagas disease). However, the need of intravenous infusion 
coupled with the high cost of distribution remained the drawback of NECT. Therefore, more research efforts 
must be made to develop a better suited drug that is ideally easy to administer (preferably orally) over a short 
time course and effective against both, early and late stage HAT. 
At the moment, Fexinidazole and Oxaboroles (SCYX-7158) are drug candidates in clinical trials of HAT. 
Fexinidazole was initially identified through the screening of a collection of nitroheterocyclic molecules by 
the Drugs for Neglected Disease initiative (DNDi) (Jones and Avery, 2015). It is available in an oral 
formulation as nitroimidazole prodrug and has been shown to be active in vivo in both, acute T. b. rhodesiense 
and T. b. brucei CNS murine models; the compound entered clinical trials in 2014 (Kaiser et al., 2011; Torreele 
et al., 2010). For the phase I trials, it has been reported that Fexinidazole was well tolerated at doses up to 
3600 mg with headache and vomiting (that resolved spontaneously) being the only adverse effects (Tarral et 
al., 2014). Phase II/III (safety and efficacy) trials, evaluating this regimen in late-stage patient infections, are 
still ongoing in the Democratic Republic of the Congo (DRCongo) and the Central African Republic (CAR) 
under the direction of DNDi in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH). 
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The oxaborole (SCYX-7158) compound derived from a screening of a library of boron-based compounds 
from Anacor Pharmaceuticals against T. brucei cultures (Ding et al., 2010). It entered Phase I clinical trials 
for the treatment of HAT. Previous studies revealed that SCYX-7158 is an effective, safe, orally active 
treatment in both acute and chronic murine models of HAT. Pharmacokinetic studies suggest that once a day 
dosing would be sufficient due to the maintenance of drug concentrations above the minimum trypanocidal 
concentration for 14 to 20 h (Jacobs et al., 2011; Jones and Avery, 2015). Like fexinidazole, phase II/III trials 
evaluating the treatment are still ongoing in DRCongo and CAR. So far, preliminary outcomes from the trials 
have not been reported. 
 
1.2 Trypanosoma brucei as pathogen 
1.2.1 Taxonomy of trypanosomes 
Trypanosomes are flagellated protozoa that are classified as members of the kingdom of Excavata, the phylum 
Euglenozoa, and the phylogenetic order Kinetoplastida (Figure 1.3).  
Euglenozoa are cells with one or two flagella that emerge from an apical or subapical flagellar pocket. 
Kinetoplastida are Euglenozoa that contain a kinetoplast, which is a large mass of fibrillar DNA in the 
mitochondrion and closely associated with the flagellar bases. 
The taxonomy of Kinetoplastida is divided into two groups: Bodoninae and Trypanosomatinae, which is based 
on morphology and life cycles. The Bodoninae group is characterized by a large kinetoplast and two flagella. 
This group is formed by free-living organisms and parasites of fish and snails. The Trypanosomatinae have a 
smaller kinetoplast and a single flagellum. This group is formed by parasites of invertebrates. 
The phylogenetic tree of Trypanosomatinae was generated using the comparison of nuclear small and large 
ribosomal RNA gene sequences. It revealed that Trypanosoma is the most ancient Trypanosomatinae, 
followed by Blastocrithida and Phytomonas lineages, some time later Crithida and Leptomonas separated 
while Leishmania and Endotrypanum branched off after that. The genus Trypanosoma is divided into two 
sections: Salivaria and Stercoraria according to the place where the parasite develops in the insect host. 
Salivaria develop in the anterior portion of the digestive tract and within the salivary gland, while the 
Stercoraria develop in the hindgut. 
The section Stercoraria includes only the American trypanosome, T. cruzi, that causes Chagas disease. It is 
transmitted via the feces of its reduviid vector. T. brucei belongs to the Salivaria section consisting of the 
subspecies T. b. brucei that is not a human pathogen, as well as of T. b. gambiense and T. b. rhodesiense, 
which induce HAT. The Salivaria are injected into the mammalian lymph and blood system via the bite of a 
tsetse fly. 
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Figure 1.3: Systematic classification of Trypanosoma brucei. 
 
1.2.2 Morphology and Cell structure 
The African trypanosome is an elongated hemoflagellate containing a highly polarized cytoskeleton formed 
by microtubules (Matthews, 2005). The polarity of the cell is determined by the polarity of the microtubules 
comprising its cytoskeleton, with the positive pole as its posterior and its negative pole at its anterior end (Ooi 
and Bastin, 2013). The microtubular cytoskeleton defines the cell shape and remains intact throughout the cell 
cycle. During cell division, new microtubules are beeing assembled and interdigitated between existing 
microtubules, so that cytoskeletal inheritance is semiconservative (Sherwin and Gull, 1989).  
The trypanosome cell is about 14-40 µm long (Mogk et al., 2014), 5 µm thick (Field et al., 2004) and has a 
single flagellum that is responsible for the parasite’s motility. Trypanosomes can be easily identified 
microscopically using Giemsa or DAPI staining, which clearly labels the two essential nucleic acid containing 
organelles, the nucleus, and the kinetoplast. The single-copy organelles within trypanosomes (i.e. the flagellar 
pocket, flagellum, kinetoplast, mitochondrion, and nucleus) are precisely positioned within the cytoskeletal 
corset and are concentrated between the posterior end and the center of the cell (Figure 1.4) (Field et al., 2004). 
The single flagellum possesses a conventional axonemal structure consisting of a 9+2 array of microtubules 
and a large lattice-like structure called paraflagellar rod (PFR) (Vaughan and Gull, 2003). It exits from the 
 11 
flagellar pocket at the posterior end of the cell and attaches along exterior length of the trypanosome’s body 
via a specialized cytoskeletal structure termed flagellum attachment zone (FAZ). The FAZ is composed of a 
single protein filament and specialized four microtubules that associate with the smooth endoplasmic 
reticulum (Kohl et al., 1999). The FAZ protein composition is still not known, but some proteins have been 
localized to the FAZ filament. It has been shown that RNA interference (RNAi) inhibiting FAZ protein 
biosynthesis causes a defective cytokinesis (Morriswood et al., 2013; Vaughan et al., 2008; Zhou et al., 2011). 
In trypanosomatids, the flagellum beats from tip to the base, with anterior and posterior poles of the cell 
defined according to their position during motility (Robinson et al., 1995). 
The flagellar pocket is the only site of endo- and exocytosis (Engstler et al., 2004). Endocytosis is of great 
significance in bloodstream form trypanosomes, because essential exchanges into and out of the cell and VSG 
recycling occurs at the flagellar pocket (Ooi and Bastin, 2013). 
The nucleus is located in the central region of the cell and contains 11 diploid pairs of megabase chromosomes, 
1-5 intermediate chromosomes, and roughly 100 minichromosomes of unknown ploidy (Akiyoshi and Gull, 
2013). These chromosomes are linear and have typical telomeres repeats (TTAGGG) at the ends. It has been 
shown that all the trypanosome housekeeping genes are encoded mainly in the megabase chromosomes and 
are transcribed as long polycistronic units (Ersfeld, 2011). The 26-Mb megabase chromosomes genomes 
contain approximately 9000 genes, including 1000 non-expressed variant surface glycoproteins (VSG). The 
VSG is a single surface coat protein, highly immunogenic and expresses by T. brucei from one of 
approximately 15 expression sites (ESs), which are located to the telomeres of megabase or intermediate 
chromosomes (Akiyoshi and Gull, 2013). T. brucei as extracellular protozoa manage to escape the host 
immune system by switching the expression of VSG up to once per 100 cell divisions (Morrison et al., 2005; 
Mugnier et al., 2016; Turner, 1999). 
The kinetoplast is located at the posterior end of the cell. It is known to be the mitochondrial DNA that is 
associated with the base of the flagellum. This structure is significantly larger than the mitochondrial genomes 
in other eukaryotic cells. Hence it is prominently stainly with DNA-specific dyes. It comprises a series of 
intercatenated circular DNA molecules, including maxi-circles that encode a small proportion of the 
mitochondrial proteins and mini-circles that encode guide RNAs.  
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Figure 1.4: Morphologie of Trypanosoma brucei. The central image is a cartoon showing the 
location of the major organelles and structures. The endoplasmic reticulum (ER) has been omitted 
for clarity as this structure extends throughout the cell and forms the nuclear envelope. The 
structures shown are the basal body, the flagellar pocket, the nucleus, supellicular microtubular 
array (spa), the flagellum, the kinetoplast, endosomes, the Golgi apparatus, the mitochondrion, the 
endoplasmic reticulum (ER) and acidocalcisomes. Insets show examples of these structures as 
seen by thin section transmission electron microscopy (Field et al., 2004).  
 
1.2.3 Life Cycle 
Trypanosomes are transmitted by blood-feeding tsetse flies of the genus Glossinae (Figure 1.5). The life-cycle 
is relatively complex, with various stages of distinctive morphology, biochemistry and physiology in the 
mammalian hosts and in the insect vector (Figure 1.6). The transformation from bloodstream to insect forms 
includes degradation and finally loss of the variant surface glycoprotein (VSG) by coordinated action of a 
metalloprotease (named major metalloprotease B) MSP-B and the GPI-specific phospholipase C. Specifically, 
TbMSP-B seems to be responsible for the remodeling of VSG during differentiation (Donelson, 2003). 
The procyclic form expresses a different type of surface protein that has been named procyclin (Roditi et al., 
1989). Procyclic parasites replicate in the insect midgut before they migrate to the salivary gland. Here it 
differentiates to the epimastigote form that attaches with part of its flagellum to epithelial cells of the organ 
(Hendry and Vickerman, 1988; Vickerman et al., 1988).  
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The final differentiation step is the formation of the infectious free swimming metacyclic form, characterized 
by the acquisition of the protective variant surface glycoprotein coat (VSG). Trypanosomes contain several 
hundred VSG genes, out of which only one protein is expressed at a given time. This coat protects the parasite 
from the cellular immune system response and seems to inhibit complement reactions. The VSG coat is 
immunogenic and leads to the formation of specific antibodies that opsonize and eventually kill all parasites 
that carry this specific VSG type. However, due to antigenic variation, new populations appeare spontaneously 
carrying a different coat formed from VSG switch variants and escape the destruction by the immune system. 
Thus, the trypanosomal infection is characterized by an oscillating population density in blood. 
In addition to this host-induced density regulation, trypanosomes differentiate in blood from dividing long 
slender to a non-dividing stumpy form that is preadapted to survive in the insect’s midgut. This differentiation 
depends on the slender population density and is induced by a secreted low-molecular-weight factor (stumpy 
inducing factor (SIF) ) (Vassella et al., 1997) of so far unknown chemical identity that enriches in conditioned 
culture media (Hamm et al., 1990). SIF works like an autocrine mediator that is released from slender cells 
and induces slender cells to differentiate to the stumpy form, which cannot proliferate within the mammalian 
host but are needed for tsetse fly infection.  
Metacyclic forms are injected during a tsetse blood-meal and trypanosomes, injected subdermally, initially 
proliferate at the site of injection, often forming a reaction at the location of the tsetse fly bite called chancre, 
but concomitantly they also appear in the blood and lymphatic vessel. It has been recently demonstrated that 
infective metacyclic trypanosomes can be acquired from the dermis inoculation site immediately after the 
initial transmission and that intradermal parasite expansion induced skin surface temperature elevation (Caljon 
et al., 2016). 
In man, the life cycle of trypanosomes proceeds and ends with infection of the central nervous system (CNS). 
The parasite’s progression from the bloodstream to the CNS will take a latency of weeks (Rhodesiense HAT) 
or months to years (Gambiense HAT). The parasite will travel to the brain either by crossing the blood-brain 
barrier (BBB) and settle down in the brain parenchyma (Grab and Kennedy, 2008; Mulenga et al., 2001), or 
by crossing the blood-CSF barrier (BCB) (Mogk et al., 2016). There still is considerable controversy by which 
way trypanosomes invade the CNS: across the BBB or across the blood-CSF barrier (BCB)? Following the 
literature on trypanosome brain invasion, there is much experimental evidence showing that trypanosomes 
cross the BBB via different mechanisms, but it has been demonstrated that trypanosomes could not survive in 
the brain parenchyma (Wolburg et al., 2012). It has been shown by electron microscopy studies that 
trypanosomes first appear in the choroid plexus by crossing the fenestrated endothelium cell layer of plexus 
vessels. Some of the parasites die within the plexus’s stroma, but some trypanosomes make their way to the 
ventricle and move on to the sub-arachnoid space, where they finally settle between the cells of the pia mater 
(Wolburg et al., 2012). The pia mater is the innermost layer of the meninges (dura mater, arachnoidea mater 
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and pia mater), which surround the brain and the spinal cord. Trypanosomes cannot survive within the stroma 
of the plexus nor within the CSF as it contains a trypanocidal compound, the pia mater is safety place for 
living at all time of the infection (Wolburg et al., 2012). 
Mogk et al., 2014, showed that trypanosomes repeatedly cross the BCB depending on their cell density in the 
blood. Thus, Mogk et coworkers suggested the existence of an additional distinct meningeal stage from where 
the trypanosomes can invade the brain via the Virchow-Robin space thereby bypassing the blood-brain barrier. 
This mechanism would lead to three instead of two steps: first, the haemolymphatic stage; second, the 
meningeal stage; third, the encephalitic stage characterized by the invasion of the CNS and the occurrence of 
encephalopathy (Mogk et al., 2016). 
 
 
Figure 1.5: Trypanosomes within blood (A), and (B) the tsetse fly vector (Michael Duszenko, 
University of Tübingen, Germany). 
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Figure 1.6: Life cycle of African trypanosomes: In man, the bloodstream form shows a 
polymorphism (A) dividing (black arrows) slender forms, (B) intermediate forms, and (C) stumpy 
forms. In the tsetse fly vector, the stumpy form transforms to (D) the dividing midgut form, then 
to (E) the migrating epimastigote form, which multiplies in the salivary glands to (F) the infective 
metacyclic form, which is injected during the next blood meal into the mammalian host (Barrett 
et al., 2007). 
 
1.3 RNA interference in Trypanosoma brucei 
Fire et al. first described RNA interference (RNAi) during their research with the nematodes worm 
Caenorhabditis elegans and described post-transcriptional gene silencing of a target gene sequence, mediated 
by double-stranded RNA (dsRNA) (Fire et al., 1998).  
It has also been discovered to occur in Trypanosoma brucei. T. brucei transient expression, or electroporation 
of the dsRNA homologous to α-tubulin mRNA led to downregulation of α-tubulin synthesis because the 
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corresponding mRNA was degraded (Ngo et al., 1998). The silencing effect was not specific to α-tubulin 
mRNA but could be obtained with dsRNA homologous to other mRNAs (Ullu et al., 2002).  
After that, RNAi has been intensively studied in many other organisms, including the plant Arabidopsis 
thaliana, the fruit fly Drosophila and the Zebrafish of the carp family. However, RNAi is notably absent in 
protozoans closely related to T. brucei, such as T. cruzi and Leishmania major (Motyka and Englund, 2004).  
The existence of the RNAi system in T. brucei was confirmed by the identification of endogenous small 
interfering RNA (siRNAs) in T. brucei (Djikeng et al., 2001). Furthermore, two of the classical proteins 
required for the RNAi pathway namely, TbAGO1, a member of the Argonaute family of proteins (Kolev et 
al., 2011), and two Dicer-like homologs, TbDCL1 and TbDCL2 (Patrick et al., 2009; Shi et al., 2006) exist in 
T. brucei. 
Mechanistically, RNAi is a two-step process (Figure 1.7). During the first step, the dsRNA that triggers the 
silencing response is cleaved into small interfering RNAs (siRNAs) of 21-25 nucleotides. It is accomplished 
by Dicer, an RNase-III-family nuclease. In the second step, siRNAs are incorporated into a targeting complex, 
known as RISC (RNA-induced silence complex), which destroys mRNAs that are homologous to the integral 
siRNA (Balaña-Fouce and Reguera, 2007). The result is a suppression of the respective gene expression. 
RNAi has become the method of choice to elucidate the function of individual genes in T. brucei (Tschudi et 
al., 2003). It is relatively easy to apply and a fast option as compared to knockout experiments, on which 
ablation eliminates all copies of the gene of interest.  
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Figure 1.7: Representation of the RNAi pathway in trypanosomes (Balaña-Fouce and Reguera, 
2007). 
 
1.4 In vivo Protein Crystallization  
Protein crystallization is a mainstream research technique for the elucidation of protein function and structure 
based drug design. Protein crystallization is a multi-parameter process that is very difficult to predict 
(McPherson and Gavira, 2014). 
In the last decades great efforts have been made by structural biologists for developing crystallization tools or 
deciphering the mechanisms by which proteins crystallize and more to predict protein crystallizability based 
on the protein sequence.  
The formation of well-ordered protein crystals is still a challenge in X-ray crystallography. This is, in 
particular, the case for glycoproteins, lipoproteins, membrane proteins and large protein complexes which are 
attracting increasing interest due to their vital roles in biological process (McPherson and Gavira, 2014). 
The general procedures used to determine the structures of proteins involve many intricate and handling steps: 
1) cloning the target gene; 2) expressing of the protein in a suitable expression system; 3) purifying a good 
yield of the pure protein for crystallization and structure determination. This so-called in vitro protein 
crystallography is the major source of protein crystal structures in PDB database. Typically, in vitro 
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crystallization requires optimization of various conditions, including unphysiological pH values as well as 
exposure to potent precipitating agents and salts (Kang et al., 2013). 
It has been observed in the past that some proteins forms crystals in vivo (Doye and Poon, 2006). Prominent 
examples are (i) storage proteins in plant seeds, (ii) insulin in secretory granules of pancreatic ß-cells, (iii) 
alcohol oxidase in peroxisomes of methylotrophic yeast, (iv) insecticidal toxins in bacteria such as Bacillus 
thuringiensis and (v) polyhedrin in various types of baculoviruses (Doye and Poon, 2006). As indicated herein, 
intracellular crystallization is widely associated with cellular functions of protein storage and secretion, solid-
phase catalysis as well as environmental protection (Doye and Poon, 2006). Nevertheless, crystallization (and 
protein aggregation) inside cells also appears to be linked to the pathology of several diseases, either as one 
of the causes or as a harmful side effect of the disease (Doye and Poon, 2006). For this reason, crystal 
formation in vivo has classically been perceived as an unusual or lucky event and was disregarded from 
structural biology (Axford et al., 2014; Doye and Poon, 2006). 
Recently, in vivo crystallization has been observed several times as a result of heterologous overexpression, 
mostly within cell lines of insect or mammalian origin (Duszenko et al., 2015; Hasegawa et al., 2011). In this 
manner, the phenomenon of intracellular crystallogenesis has shifted more and more into scientific awareness. 
Nevertheless, the considerable small size of in vivo-grown crystals rendered them seemingly unsuitable for 
conventional X-ray analysis (Sanishvili et al., 2011; Schlichting and Miao, 2012). 
Only the advent of new X-ray sources and new data-processing tools such us XFEL/SFX opened the way for 
protein structure determination from nano-micro-sized crystals. Numerous independent expert investigators 
have already demonstrated the applicability of theses techniques (Axford et al., 2014; Gallat et al., 2014; Gati 
et al., 2014a; Jakobi et al., 2016; Muniyappan et al., 2015; Redecke et al., 2013a; Sawaya et al.,  2014), 
underlining the potential of in vivo crystals to become a feasible source of structural biology (Koopmann et 
al., 2012). 
Despite great high technologie tools and increasing numbers of successful examples, the process of in vivo 
crystallization itself is not yet understood in detail. Principally, the underlying mechanism is assumed to be 
similar to crystal formation in vitro (Duszenko et al., 2015).   
At first, a high local concentration of the recombinant protein is required to render crystallization 
thermodynamically favorable and, to some extent, by protein sorting into subcellular compartments offering 
only limited space (Duszenko et al., 2015). As a result of supersaturation, the equilibrium between liquid and 
solid phase is reestablished via displacement of protein surrounding water. This, in turn, will favor the 
formation of interprotein contacts, if suitably positioned interaction sites are accessible. Thereon, orderly 
associated protein molecules may act as nucleation centers providing surfaces for crystal growth progression. 
However, there are three examples known that challenge this presumption: (i) formation of in vivo crystals 
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from insecticidal Cry3A from Bacillus thuringiensis (Sawaya et al., 2014), (ii) insecticidal protein Cry1Ac 
from Bacillus thuringiensis (Evdokimov et al., 2014), and (iii) µNS viral protein in baculovirus-infected Sf9 
cells (Schönherr et al., 2015). The authors reported that in the former two cases a sporulation-like process 
occurred, while the viral protein in the latter case was involved in virus production and initiated a nucleation 
process within the host cell.  
So far, most examples of in vivo crystallization from heterologously expressed genes were obtained using the 
insect cell-baculovirus expression system (Duszenko et al., 2015). 
This system utilizes site-specific transposition to introduce a foreign gene of interest into the polyhedrin locus 
of baculoviral DNA. Thereby, the newly inserted gene substitutes the open reading frame of viral polh, placing 
the transgene under direct control of the polh promoter. This polyhedrin promoter is very robust and efficient. 
It induces a high concentration of intracellular protein, one the major prerequisite for in vivo crystallogenesis, 
and spontaneous crystallization will take place within infected insect cells. 
 
1.5 Structure determination from in vivo grown crystals 
In conventional X-ray crystallography (beam size ˃10 µm), crystal sizes of at least 20-30 µm in all three 
dimensions are required to obtain interpretable diffraction patterns and to withstand the large radiation dose 
that accumulates during the collection of a complete rotation series from a single crystal (Holton and Frankel, 
2010).  
In the case of smaller crystal diameters, as obtained by in vivo crystallization, the X-ray beam may only 
partially hit the mounted crystal. Thus, the proportion of the beam that does not intercept the sample 
contributes anything but the background to the diffraction image, thereby reducing the signal-to-noise ratio 
and, effectively, the resolution limit. The only way to overcome this bottleneck, the beam size need to be 
decreased, placing a stringent demand on the technical set-up (Sanishvili et al., 2011). Furthermore, there is a 
proportional relationship between crystal volume and observable spot intensities (Holton and Frankel, 2010), 
forcing usage of a high radiation dose to obtain sufficiently strong diffraction signals from small crystals 
(Chapman et al., 2011; Sliz et al., 2003).  
As a consequence thereof, the extent of radiation damage increases (Chapman et al., 2011; Sanishvili et al., 
2011). Recently, three important strategies have been developed which can bypass these limitations. 
Firstly, X-ray free-electron lasers (XFEL) combined with serial femtosecond crystallography (SFX) can 
provide high-resolution diffraction data from small crystals. The high-intensity beam obliterates the crystal 
after one exposure, but before the crystal is destroyed diffraction is collected. This avoids radiation damage 
by making use of the “diffraction-before-destruction” principle (Barty et al., 2013; Neutze and Moffat, 2012; 
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Schlichting and Miao, 2012). At this moment, a liquid jet of protein crystals at room temperature is 
continuously exposed to ultrashot X-ray FEL pulses, each of 10-100 fs duration (Neutze and Moffat, 2012) 
and with a 1012 times stronger peak intensity than obtained by synchrotron radiation (Fromme, 2015). Delivery 
of such high doses of photon energy ultimately destroys the sample. However, the pulse terminates before 
damage occurs, allowing to collect millions of diffraction pattern snapshots of the individual, randomly 
oriented crystals. Data sets are then applied to software algorithms for the three-dimensional structure model 
resolution. The shortcomings of XFEL are that the cost of the experiment is prohibitively high, instrument 
beam time availability is very low, and difficulties processing the large amount of data are considerable (Liu 
et al., 2016). Furthermore, recent studies indicate that even SFX data are affected by radiation damage (Nass 
et al., 2015). Additional complications arise from the variance in the exposed crystal volume during each shot 
and fluctuations in the pulse intensity. Scaling is achieved by merging the reflections originating from 
thousands of diffraction patterns (Kirian et al., 2010, 2011). In XFEL experiments, the sample delivery is 
commonly achieved via a nozzle that sprays grams of crystalline material at the diffraction beam. Therefore 
the sample requirement is high, and the delivery nozzle can quite frequently clog up, thus stopping the 
experiments (Liu et al., 2016). 
Secondly, serial synchrotron crystallography (SSX) used a third-generation synchrotron microfocus beamline 
(beam size reduced to ˂10 µm) as X-ray source and cryogenic crystals mounted into a rotating loop are serially 
illuminated with somewhat higher-than-conventional flux densities. In contrast to SFX, multiple diffraction 
patterns of the same crystal are obtained, increasing the redundancy of the data set. 
Thirdly, micro-electronmicroscopy diffraction (MicroED) is a recently developed method, which allows the 
collection of high-resolution diffraction data from tiny protein microcrystals using electron cryo-microscopy 
(cryo-EM) (Shi et al., 2016). MicroED has determined several protein structures. The first structure solved by 
still diffraction was that of lysozyme at 2.9 Å resolution (Shi et al., 2013) and 2.5 Å resolution by continuous 
rotation (Nannenga et al., 2014a). This was followed by the elucidation of the structures of catalyse at 3.2 Å 
resolution (Nannenga et al., 2014b) and of Ca2+/ATPase at 3.4 Å resolution (Yonekura et al., 2015). 
In late 2015, the toxic core of α-synuclein structure was determined at 1.4 Å resolution (Rodriguez et al., 
2015), and recently the structures of four prion peptides were solved at 1 Å resolution and direct phasing 
methods (Sawaya et al., 2016). 
 
1.6 Aims of this study 
Trypanosoma brucei is an extracellular hemoflagellated kinetoplastid protozoon and the causative agent of 
HAT. The genome sequence of T. brucei revealed that approximately 50% of genes which are uncharacterized 
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for their biochemical or cellular functions are identified as hypothetical proteins with no homologs in the 
human host. The hypothetical or uncharacterized proteins validated as essential for parasitic survival and 
infectivity opens possibilities for new target identification and drug discovery. Previous experiments 
discovered that T. brucei produces PGD2 PGE2 and PGF2α from exogenous arachidonic acid (Kubata et al., 
2000, 2007).  
It was also shown that PGD2 is one of the best-characterized sleep-inducing substances and PGD2 injected 
stereotactically into rat brain parenchyma induced directly sleep phenomenon (Hayaishi, 2000, 2002).  
This data joins the Pentreath et al. publication, 1990, showing that a high concentration of PGD2 is found in 
CSF of late stage sleeping sickness patients. This motivated us to analyze the prostaglandin biosynthetic 
pathways in detail and to search for biomolecules secreted by trypanosomes. Firstly, our group could show 
that PGD2 induces an apoptotic cells death in stumpy parasites, thus being involved in the parasite’s cell 
density regulation to sustain the infection within the host (Duszenko et al., 2006). Secondly, our group isolated, 
crystallized, structurally solved and enzymatically characterized the NADPH-dependent PGF synthase 
(TbPGFS) from T. brucei that catalyzes the reduction of PGH2 to PGF2 (Okano et al., 2002). Thirdly, we 
hypothesized that T. brucei might well possess a unique cyclooxygenase (COX)-like enzyme, developed by a 
co-evolution process, that is responsible for prostaglandins production. Based on literature searches, there is 
so far only one identified COX-like enzyme from Entamoeba histolytica, which also shows no clear structural 
similarity to other well-known cyclooxygenases in protein databases (PDB) (Dey et al., 2003). 
In the meantime, a peroxidase activity was detected in our group using Amplex Red in total trypanosome 
lysates, and a positive signal was obtained by Western bot analysis of total trypanosome lysates using a 
polyclonal cyclooxygenase ovine antibody (Barth, 2013). The specific band was cut-off for SDS-PAGE and 
mass spectrometry analysis to identify the proteins recognized by the above polyclonal antibody. This lead us 
to a list of known and hypothetical genes as putative T. brucei genes encoding for a putative cyclooxygenase-
like enzyme candidate (Barth, 2013).  
Among them, one gene (Tb427.10.13790/Tb927.10.13790/Tb10.61.3130), internally named putative 
cyclooxygenase-like gene from T. brucei, is annotated as a hypothetical protein in T. brucei genome databases 
(TriTrydb, Genedb & NCBI gene). Homologs of this gene are conserved in all three major kinetoplastids (T. 
brucei, T. cruzi and L. major). This gene was chosen for further experimental investigation. So far, our 
bioinformatic analyses using Pfam, Prosite, Swiss-Pro, InterPro, TMHHM and NetPhos databases revealed 
no convincing homolog protein in any other organisms. Additionally, these analyses revealed that the 
respective protein in trypanosomes carries no known signal peptide and no transmembrane domain, while 
extensive coil-coiled structures and multiple putative phosphorylation sites showed up. 
 22 
The main goals of this thesis were: 1) to clone and express this annotated hypothetical protein from T. brucei 
using E. coli and Sf9 insect cells as expression systems; 2) to investigate whether this annotated hypothetical 
protein could crystallize in vivo using Sf9 insect cells prior to structural analysis using serial-X-ray 
crystallography or free-electron laser (XFEL); 3) to investigate and validate the physiological function of the 
pTbCOX protein in the trypanosome SMB cell line using RNA interference; 4) to develop SMB trypanosomes 
expressing pTbCOX fused with GFP for localization studies. Our hope was that once identified and 
characterized, the pTbCOX protein may become a potential target for HAT therapy. 
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2  Research thesis description 
2.1 Statement of the problem 
Previous experiments on the prostaglandin (PG) metabolism have shown that trypanosomes produce PGD2, 
PGE2, and PGF2α from exogenous arachidonic acid (Kubata et al., 2000, 2007).  
Our group has previously shown that production of prostaglandin-like compounds was not inhibitable by the 
classical inhibitors of prostaglandin synthesis (NSAID) such as aspirin and indomethacin (Rawer, 2004; 
Duszenko, unpublished observation). PGD2 is known to induce sleep in mammals (Hayaishi, 2000, 2002). 
Since PGD2 is highly elevated in the cerebrospinal fluid of late stage sleeping patients (Pentreath et al., 1990), 
production of this molecule by trypanosomes would help to understand the sleeping induction mechanism 
which is one of the main symptoms observed during sleeping sickness.  
It is also known and well demonstrated that PGD2 induces a form of apoptosis in stumpy parasites for cell 
density regulation to sustain the infection within the host (Duszenko et al., 2006; Figarella et al., 2006). 
However, in view of the prostaglandin metabolism, structure and function of the COX-like enzyme is still 
poorly understood, since blast analysis of mammalian cyclooxygenase in higher eukaryotes did not reveal any 
sequences with significant homology. This fact is easily understood since the invention of prostaglandin 
synthesis during evolution occurred after the appearance of protozoa. Based on our experimental data and the 
fact that trypanosomes produce prostaglandins from arachidonic acid, we hypothesized that Trypanosoma 
brucei may well possess a unique COX-like enzyme that is responsible for prostaglandin production.  
However, if the hypothetical conserved pTbCOX protein would appear not to be a COX-like enzyme, we will 
delete the gene of this protein in T. brucei using RNAi to investigate whether it is essential (or not) and is thus 
a suitable or credible target for inhibitory drugs development against HAT. 
 
2.2 Justification 
Arachidonic acid (AA) metabolites are potent lipid mediators of physiological and pathological processes in 
humans and animals. The enzymes that catalyze the metabolism of AA are scientifically interesting for two 
major reasons: First, they can be a target of chemotherapeutic agents (specific inhibitors) used to control 
response mechanisms during inflammation; second, in vitro studies of these enzymes may well shed light on 
the biochemical pathways of AA metabolism and physiological relevance of the AA metabolites, namely the 
control of cell death mechanisms. 
Parasitic protozoa undergo complex transformations in specific environments during their life cycles. Such 
activities frequently involve an insect vector and a mammalian host.  
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The proliferation of the parasite within the mammalian host can cause disease and sometimes death. However, 
rapid death is not the preferred outcome of the infection, because the parasite depends on its host to complete 
its life cycle and propagate its progeny. Therefore, pathogenic parasites must have evolved mechanisms to 
regulate critical checkpoints in their developmental cycle and potentially modulate the local physiological 
response of the host. 
Successful pathogens must have erected platforms that allow crosstalk between developmental regulatory 
molecules of the parasite and those that regulate host cellular and tissue function. For this to occur, the parasite 
should employ similar regulators with “built-in” unique features that allow it to evade the detection and 
ultimately subvert such host functions. Arachidonic acid metabolites, i.e., PG, are suited for such a role 
because they are known to be strong local regulators of host cells and tissue functions. 
Despite PG association with the genesis of fever, somnolence, headache, ovarian dysfunction and immune 
suppression observed during parasitic protozoa infections, the etiologic agents have just recently been given 
a direct role in the production of these molecules. 
Furthermore, the biochemical pathways of AA metabolism in mammalian cells do exist. However, these 
biochemical pathways have not been unequivocally demonstrated in parasitic protozoa. Indeed, the knowledge 
that parasites actively synthesize and release molecules like PGs that potentially modulate host functions 
ascribes to the pathogen a more active role in the pathophysiology of the disease. In fact, PG production 
appears first in sponges during evolution, but not in protozoa. Accordingly, PG synthesis in trypanosomes is 
a typical co-evolutionary process that was probably established because of its benefits for the parasites. 
Hence, a better understanding of the basic biochemical pathways of the parasites may pave the road to establish 
new strategies for the development of more effective and less toxic drugs. The finding that PG-producing 
enzymes are distinct from their mammalian counterpart makes them a suitable drug target. 
As soon as some of the enzymes involved in PG synthesis in this parasite are discovered, genetic manipulation 
will allow a definitive understanding of the role of theses enzymes respectively in the pathogenesis of sleeping 
sickness and the life cycle of Trypanosoma brucei. 
The identification and purification of that putative COX-like enzyme from T. brucei would, therefore, be of 
great interest because it will bring new insights into the understanding of its role during the cell cycle, cell 
morphogenesis, and pathogenesis. On the other hand, as more crystal structures of this enzymatic system are 
determined, it will be possible to rationally design specific inhibitors and better drugs against sleeping 
sickness. 
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3  Materials and Methods 
3.1 Materials 
3.1.1 Bacteria strains 
Bacteria strains Supplier 
BL21-DE3 E. coli Invitrogen, Karlsruhe 
NEB Turbo Competent E. coli (High Efficiency) New England Biolabs, Frankfurt 
One Shot Top 10 Competent E. coli Invitrogen, Karlsruhe 
Max Efficiency DH10BacTM Invitrogen, Karlsruhe 
Rosetta Competent Cells Merck, Darmstadt 
3.1.2 Trypanosoma strains  
In this work, the monomorphic single marker bloodstream forms (BF SMB) strain EATRO 427 clone MITat 
1.2 (Molteno Institute Trypanozoon antigenic type, Cambridge) with the VSG (Variable Surface 
Glycoprotein) antigen variant 221 (Cross, 1975) were used for the pTbCOX knockdown and pTbCOX-eGFP 
expression experiments. The bloodstream forms SMB cells line (BF SMB) was used as wild type strains to 
generate all the transgenic cell line during this PhD project.  
The BF SMB/wild type strain and the transgenic cell line listed below have been named according to the T. 
brucei community nomenclature (Clayton et al., 1998). However, in some cases alternatives name will be 
used in this thesis to facilitate reading. 
1.  BF SMB (WT) 
Name according to nomenclature: MITat1.2 T7RNAP TETR NEO 
Selection marker: Geneticin (2 µg/ml) 
2.  BF pTbCOX-Knockdown 
Made by: Celestin Mudogo & Salesia Werner 
Name according to nomenclature: MITat1.2 T7RNAP TETR NEO RDNA::T7PROTi pTbCOX HYG 
Alternative name: pTbCOX-RNAi or pTbCOX-KD  
Plasmid name: p2T7Ablue  
Selection marker: Geneticin (2 µg/ml), Phleomycin (2.5 µg/ml) 
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3.  BF pTbCOX eGFP 
Made by: Celestin Mudogo & Danyang Xu 
Name according to nomenclature:  
MITat1.2 T7RNAP TETR NEO HYG RDNA::PGPEETTi pTbCOX-eGFPT7RNAP BLE 
Alternative name: pTbCOX-pCO57  
Plasmid name: pCO57  
Selection marker: Geneticin (2 µg/ml), Phleomycin (2.5 µg/ml) 
3.1.3 Spodoptera frugiperda (Sf9) insect cells 
Insect cells Sf9 (fall armyworm) stabilates were bought from Invitrogen, Germany, stored at -70°C and 
propagated at 27°C in an incubator. 
3.1.4 Antibodies 
Antibodies Supplier 
Anti-rabbit IgG alkaline phosphate conjugate Sigma-Aldrich, Steinheim 
Anti-His-Tag (6-histidine) rabbit Biomol, Hamburg 
3.1.5 Plasmids 
Plasmids Supplier 
pCR 2.1 Invitrogen, Karlsruhe 
pProExHTa Invitrogen, Karlsruhe 
pFastBacHTb Invitrogen, Karlsruhe 
p2T7Ablue George Cross, New York, USA 
pCO57 George Cross, New York, USA 
3.1.6 Primers/Oligonucleotides 
Primers (oligonucleotides) were purchased from Invitrogen and stored as 100 μM stock solution at -20°C. For 
the polymerase chain reactions (PCR), the stock solution was used in a dilution of 1:10. 
1.  Primers for pTbCOX in pProExHTa expression in E. coli  
Fw-BamHI-pTbCOX: 5´- GGATCCACCACGTTCTTTGGCATTTACTGA- 3´ 
Rv-HindIII-pTbCOX: 5´- AAGCTTTGGCATCAATTTTACCTACCC- 3´ 
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2.  Primers for pTbCOX in pFastBacHTb expression and in vivo protein crystallization in Sf9 insect 
cells 
Fw-BamHI: 5´- GGATCCATGGCAACCATAGCGGAGT- 3´ 
Rv-HindIII: 5´- AAGCTTTGGCATCAATTTTACCTACC- 3´ 
3.  Primers for pTbCOX RNAi experiments 
Fw-XhoI-pTbCOX-KD: 5´- CTCGAGAGATACGGGGAACACACGAG- 3´ 
Rv-BamHI-pTbCOX-KD: 5´- GGATCCAACGTGGAGAGGAACAGTGG- 3´ 
4.  Primers for qRT-PCR experiments 
Fw-pTbCOX-qPCR: 5´- AGGATTTGGAGGACGCGAAG- 3´ 
Rv-pTbCOX-qPCR: 5´- TAAGCACCTCAAGCATCCGT- 3´ 
Fw-ß-Tubulin-qPCR: 5´- TTCCGCACCCTGAAACTGA- 3´ 
Rv-ß-Tubulin-qPCR: 5´ - TGACGCCGGACACAACAG- 3´ 
5.  Primers for pTbCOXpCO57 or pTbCOX-eGFP expression in T. brucei  
Fw-HindIII-pTbCOX: 5´- AAGCTTATGGCAACCATAGCGGAGT- 3´ 
Rv-PvuII-pTbCOX: 5´- CAGCTGACCTTCAACTCGCGCTAG- 3´ 
3.1.7 Enzymes 
Enzymes Supplier 
BamHI Thermo Fisher Scientific, Braunschweig 
EcoRV Thermo Fisher Scientific, Braunschweig 
HindIII Thermo Fisher Scientific, Braunschweig 
PvuII Thermo Fisher Scientific, Braunschweig 
NotI Thermo Fisher Scientific, Braunschweig 
T4DNA Ligase Qiagen GmbH, Hilden 
DNase I Thermo Fisher Scientific, Braunschweig 
Accu Prime DNA Polymerase High Fidelity Thermo Fisher Scientific, Braunschweig 
HotStar Tag DNA Polymerase Qiagen GmbH, Hilden 
XhoI Thermo Fisher Scientific, Braunschweig 
3.1.8 General Chemicals 
Chemicals Supplier 
Acetone Sigma-Aldrich, Steinheim 
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Acetic acid Carl Roth GmbH, Karlsruhe 
Agar 100 Resin Agar Scientific Ltd., Stansted (UK) 
Agar-Agar Carl Roth GmbH, Karlsruhe 
Agarose Biozym Scientific GmbH, Oldendorf 
Ampuwa Fresenius Kabi, Bad Homburg 
10% APS Carl Roth GmbH, Karlsruhe 
L-Arginine Sigma-Aldrich, Steinheim 
Bathocuproinedisulfonic acid disodium salt (BCS) Sigma-Aldrich, Steinheim 
Benzyldimethylamine (BDMA) Agar Scientific Ltd., Stansted (UK) 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim 
Bradford protein assay reagent Bio-Rad, Munich 
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) Sigma-Aldrich, Steinheim 
Calcium chloride Merck Eurolab GmbH, Darmstadt 
Chloroform Merck Eurolab GmbH, Darmstadt 
Coomassie brilliant blue R-250 Serva, Heidelberg 
L-Cysteine Sigma-Aldrich, Steinheim 
4´, 6-Diamidino-2-phenylindole (DAPI) Sigma-Aldrich, Steinheim 
DEAE-Sephacel Sigma-Aldrich, Steinheim 
Digitonin Sigma-Aldrich, Steinheim 
Dimethyl formamide Sigma-Aldrich, Steinheim 
Disodium hydrogen phosphate Merck Eurolab GmbH, Darmstadt 
Dipotassium hydrogen phosphate Merck Eurolab GmbH, Darmstadt 
6X DNA loading dye Thermo Fisher Scientific, Braunschweig 
Dodecenylsuccinic Anhydride (DDSA) Agar Scientific Ltd., Stansted (UK) 
Doxycycline hyclate Sigma-Aldrich, Steinheim 
Epon Sigma-Aldrich, Steinheim 
Ethylenediaminetetraacetic acid disodium salt (EDTA) Carl Roth GmbH, Karlsruhe 
Ethyleneglycol-bis (ß-aminoethyl ether)-N,N,N´, N´-
tetraacetic acid (EGTA) 
Sigma-Aldrich, Steinheim 
Ethanol Carl Roth GmbH, Karlsruhe 
EX-CELL 420 serum free medium w/L-Glutamine Sigma-Aldrich, Steinheim 
Fetal calf serum (FCS) Invitrogen, Karlsruhe 
Formaldehyde (37%) Sigma-Aldrich, Steinheim 
GeneRuler 1 kb DNA Ladder Invitrogen, Karlsruhe 
O´Gene Ruler Ultra Low Range DNA Ladder Thermo Fisher Scientific, Schwerte 
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Gentamicin Sigma-Aldrich, Steinheim 
Geneticin (G-418) (50 mg/ml) Carl Roth GmbH, Karlsruhe 
D-Glucose monohydrate Sigma-Aldrich, Steinheim 
L-Glutamine Sigma-Aldrich, Steinheim 
L-Glutamic acid Sigma-Aldrich, Steinheim 
Glutaraldehyde 25% Carl Roth GmbH, Karlsruhe 
L-Glutathione reduced (GSG) Sigma-Aldrich, Steinheim 
L-Glutathione oxidized (GSSG) Sigma-Aldrich, Steinheim 
Glycerin 87% or 100% Sigma-Aldrich, Steinheim 
L-Glycine Sigma-Aldrich, Steinheim 
Guanidine hydrochloride Sigma-Aldrich, Steinheim 
Haemin Sigma-Aldrich, Steinheim 
HEPES Sigma-Aldrich, Steinheim 
L-Histidine Sigma-Aldrich, Steinheim 
Hydrochloric acid Merck Eurolab GmbH, Darmstadt 
Hygromycin B (50 mg/ml) Roche, Basel 
Hypoxanthine Sigma-Aldrich, Steinheim 
Imidazole Sigma-Aldrich, Steinheim 
Iscove’s Modified Dulbecco’s Medium (IMDM) Sigma-Aldrich, Steinheim 
L-Isoleucine Sigma-Aldrich, Steinheim 
Isopropanol Merck Eurolab GmbH, Darmstadt 
Kanamycin Merck Eurolab GmbH, Darmstadt 
Leupeptin Merck Eurolab GmbH, Darmstadt 
L-Lysine Sigma-Aldrich, Steinheim 
Magnesium chloride Merck Eurolab GmbH, Darmstadt 
Magnesium sulphate Merck Eurolab GmbH, Darmstadt 
MEM vitamin solution Sigma-Aldrich, Steinheim 
MEM amino acids Sigma-Aldrich, Steinheim 
Mercaptoethanol Merck Eurolab GmbH, Darmstadt 
Methanol Carl Roth GmbH, Karlsruhe 
L-Methionine Sigma-Aldrich, Steinheim 
Methyl-5-norbronene-2,3-dicarboxylic anhydride (MNA) Agar Scientific Ltd., Stansted (UK) 
Midori Green Advance DNA Stain Nippon Genetics, Düren 
Monopotassium phosphate Merck Eurolab GmbH, Darmstadt 
N-Lauroylsarcosine sodium salt Sigma-Aldrich, Steinheim 
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Nitro Blue tetrazolium (NBT) Sigma-Aldrich, Steinheim 
Nonidet P-40 Sigma-Aldrich, Steinheim 
L-Ornithine Sigma-Aldrich, Steinheim 
Osmium Tetroxide Carl Roth GmbH, Karlsruhe 
Paraformaldehyde Fluka, Buchs 
Penicillin/Streptomycin Sigma-Aldrich, Steinheim 
Pepstatin Sigma-Aldrich, Steinheim 
Pepton aus casein Carl Roth GmbH, Karlsruhe 
Phenol red Sigma-Aldrich, Steinheim 
L-Phenylalanine Sigma-Aldrich, Steinheim 
Polyethyleneglycol 6000 (PEG) Sigma-Aldrich, Steinheim 
Potassium acetate Merck Eurolab GmbH, Darmstadt 
Potassium chloride Merck Eurolab GmbH, Darmstadt 
Potassium dihydrogen phosphate Merck Eurolab GmbH, Darmstadt 
Potassium hydroxide Carl Roth GmbH, Karlsruhe 
Prestained protein ladder Thermo Fisher Scientific, Braunschweig 
Protein molecular marker Thermo Fisher Scientific, Braunschweig 
L-Proline Sigma-Aldrich, Steinheim 
Propidium iodide Sigma-Aldrich, Steinheim 
Propylene oxide Sigma-Aldrich, Steinheim 
Protease Inhibitor Cocktail Sigma-Aldrich, Steinheim 
Pyruvate Sigma-Aldrich, Steinheim 
Roti® Load-1 Carl Roth GmbH, Karlsruhe 
RNase away® Thermo Fisher Scientific, Braunschweig 
Sodium azide Sigma-Aldrich, Steinheim 
Sodium acetate Sigma-Aldrich, Steinheim 
Sodium cacodylate trihydrate Sigma-Aldrich, Steinheim 
Sodium chloride Fuka, Buchs 
Sodium bicarbonate  Sigma-Aldrich, Steinheim 
Sodium citrate dihydrate Carl Roth GmbH, Karlsruhe 
Sodium dihydrogen phosphate Merck Eurolab GmbH, Darmstadt 
Sodium dihydrogen carbonate Merck Eurolab GmbH, Darmstadt 
Sodium dodecyl sulphate Sigma-Aldrich, Steinheim 
Sodium hydroxide Sigma-Aldrich, Steinheim 
RNase away Fisher Thermo Scientific GmbH, Schwerte 
 31 
Saccharose Sigma-Aldrich, Steinheim 
Serum Plus SLBG4295 SAFC Biosciences, Hampshire (UK) 
10% SDS Carl Roth GmbH, Karlsruhe 
Sucrose Sigma-Aldrich, Steinheim 
TEMED Carl Roth GmbH, Karlsruhe 
Tetracycline Sigma-Aldrich, Steinheim 
L-Threonine Sigma-Aldrich, Steinheim 
Thymidine Sigma-Aldrich, Steinheim 
Tris-HCl Carl Roth GmbH, Karlsruhe 
Triton X-100 Carl Roth GmbH, Karlsruhe 
L-Tryptophane Sigma-Aldrich, Steinheim 
Tween 20 Carl Roth GmbH, Karlsruhe 
L-Tyrosine Sigma-Aldrich, Steinheim 
L-Valine Sigma-Aldrich, Steinheim 
Uranyl acetate Plane GmbH, Wetzlar 
Yeast extract Sigma-Aldrich, Steinheim 
3.1.9 Kits 
Kit Supplier 
AccuPrime Tag DNA Polymerase high fidelity Kit Invitrogen, Karlsruhe 
Bac-to-Bac Baculovirus Expression System Kit  Invitrogen, Karlsruhe 
HotStar Tag Master Mix Kit Qiagen GmbH, Hilden 
Dneasy Blood & Tissue Kit Qiagen GmbH, Hilden 
QIAquick gel extraction Kit Qiagen GmbH, Hilden 
QIAquick PCR purification Kit Qiagen GmbH, Hilden 
Qiagen Plasmid Midi Kit Qiagen GmbH, Hilden 
QIAprep Spin Miniprep Kit Qiagen GmbH, Hilden 
Power SYBR Green RNA-to CT 1-step Kit Thermo Fisher Scientific, Braunschweig 
Rneasy Mini Kit Qiagen GmbH, Hilden 
TOPO TA Cloning Kit Thermo Fisher Scientific, Braunschweig 
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3.1.10 Media 
3.1.10.1 Media for bacteria cell culture 
Luria-Bertani medium (LB-medium 2X) pH 7 
Tryptone  20 g/l 
Yeast extract  10 g/l 
NaCl 20 g/l 
Transformation medium for E. coli (TSS) 
Supplemented in LB-medium 
DMSO 5 % 
MgCl2  50 Mm 
PEG 6000   10 % 
SOB medium 
Tryptone     20 g 
Yeast extract         5 g 
NaCl     0.5 g 
Distilled water was added to above chemicals and mixed. The final volume of the solution was made to 1 liter 
and then autoclaved. Afterward, 10 ml of filter-sterilized 1M MgCl2 and 10 ml of filter-sterilized 1M MgSO4 
was added to this solution before use. 
SOC medium 
To the autoclaved SOB medium, 1 ml of filter-sterilized 2M glucose was added to a final volume of 100 ml. 
Subsequently, aliquots of 5 ml of the medium were made and stored at -20°C till further use. 
Ampicillin stock solution (1000X) 
Ampicillin (50 mg/ml) was dissolved in 70% ethanol and stored at -20°C. 
X-Gal stock solution (500X) 
X-Gal (20 mg/ml) was dissolved in dimethylformamide and stored at -20°C. 
Agar-Agar 2X 
Agar-Agar               40 g/l 
LB-Ampicillin Agar-culture plate  
Agar-Agar 2X           0.5 ml/ml 
LB-medium 2X         0.5 ml/ml 
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X-Gal (20 mg/ml)       2 µg/ml 
Ampicillin (50 mg/ml)     1 µg/ml 
3.1.10.2 Media for Sf9 cell culture 
EX-CELL® 420 serum-free medium with L-glutamine (Sigma-Aldrich, Steinheim) was used for the insect 
cell culture after the addition of 5 ml/l of a penicillin/ streptomycin stock solution. 
3.1.10.3 Media for Trypanosoma brucei cell culture 
1.  Basic medium pH 7.2 
IMDM  35.4 g/l 
Sodium Bicarbonate 3.02 g/l 
H2O distilled (d H2O) 900 ml/l 
Add 1 l d H2O 
2.  1X HMI-9 Medium/Complete bloodstream culture medium (BF-medium) pH 7.4 
Basic medium    890 ml/l 
L-Cysteine (18.2 mg/ml in d H2O)      11 ml/l 
Pyruvate (110 mg/ml in d H2O)    1.11 ml/l 
Thymidine (39 mg/ml in d H2O)    1.11 ml/l 
Hypoxanthine (13.6mg/10ml with 0.1N NaOH)   10 ml/l 
BCS (28.2 mg/ml in d H2O)    1.11 ml/l 
2-Mercaptoethanol    15.5 µl/l 
Penicillin/Streptomycin (100X)       11 ml/l 
FBS (Heat inactivated: 30 min. 56°C)     110 ml/l 
Serum Plus (No overheated)     110 ml/l 
The BF-medium was adjusted to pH 7.4 using NaOH. Afterwards, it was sterile filtered and stored at 4°C and 
can be used for up to 4 weeks. 
3.  Cytomix buffer 
Cytomix buffer was prepared to be use for stable transfection in T. brucei experiments. At first, preparation 
of the Phosphate buffer (8.66 ml/100 ml dH2O K2HPO4 (1M)/ 1.34 ml/100 ml dH2O KH2PO4 (1M) pH 7.6). 
Cytomix buffer: 
EGTA 0.76 g/l 
KCl 8.88 g/l 
CaCl2 x 2 H2O 19.2 mg/l 
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MgCl2 x 6 H2O 1.01 g/l 
Glucose 5.00 g/l 
Bovine Serum albumin 100 mg/l 
HEPES 5.96 g/l 
K2HPO4/KH2PO4 100 mg/l 
Hypoxanthine (1.36 g in 100 ml NaOH) 10 ml/l 
Add 1 l dH2O; adjust pH 7.6 and sterile filtration. 
4.  Trypanosome dilution buffer (TDB) pH 7.7 
Na2HPO4 X 12 H2O (18 mM) 6.45 g/l 
NaH2PO4 X H2O (2 mM) 0.28 g/l 
KCl (5mM) 0.37 g/l 
NaCl (80 mM) 4.67 g/l 
MgSO4 X 7 H2O (1mM) 0.25 g/l 
Glucose X H2O (20 mM) 3.96 g/l 
5.  Freezing medium for stabilates (TDB-Glycerin) 
77 ml/100 ml TDB 
23 ml/100 ml Glycerin 87% (20% end concentration) 
3.1.11 Buffers and solutions 
3.1.11.1 Buffers for agarose gel electrophoresis 
Agarose gel electrophoresis (1%) 
0.5 g/50 ml Agarose 
Add 50 ml TAE buffer (50X) pH 8.0. 
Heat the mixture in the microwave till the solution become clear without any particle. 
Add 2.5 µl/50 ml Midori Green Advance. 
TAE- buffer pH 8.0 (50X) 
Tris 242 g/l 
Na2EDTA 37.2 g/l 
Acetic acid  57.1 ml/l 
dH2O add to 1 l 
3.1.11.2 Buffers and solutions for 10% SDS-PAGE and Gel staining 
Running buffer pH 8.3 
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Tris  3.04 g/l 
Glycine 14.42 g/l 
SDS     1 g/l 
dH2O add to 1 l 
Resolving gel (for 4 gels) 
1 M Tris-HCl (pH 8.8) 8.60 ml 
dH2O  6.60 ml 
Acrylamide  7.60 ml 
10% SDS   228 µl 
10% APS      78 µl 
TEMED      24 µl 
Stacking gel (for 4 gels) 
1 M Tris-HCl (pH 6.8) 1.50 ml 
dH2O  8.40 ml 
Acrylamide  2.00 ml 
10% SDS   120 µl 
10% APS      60 µl 
TEMED      12 µl 
3.1.11.3 Coomassie staining 
Staining solution 
Coomassie Brilliant Blue R-250 1 g/l 
Ethanol 400 ml/l 
Acetic acid  100 ml/l 
dH2O  500 ml/l 
Coomassie Brilliant Blue R-250 was dissolved in ethanol. Subsequently, other solutions were added after 
Coomassie was completely solubilized and the volume was made up to 1 liter. 
Destaining solution 
Ethanol 400 ml/l 
Acetic acid 100 ml/l 
dH2O  500 ml/l 
3.1.11.4 Siver staining 
Fixation solution 
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Acetic acid    12% 
Ethanol   40% 
Formaldehyde (37%) 0.05% 
Wash solution 
Ethanol 50% 
dH2O  50% 
Pretreatment 
Na2S2O3 X 5H2O  0.2% 
Impregnation 
AgNO3 0.2% 
Formaldehyde (37%) 0.075% 
Development 
Na2CO3 6% 
Na2S2O3 X 5H2O (10% in dH2O) 0.004% 
Formaldehyde (37%) 0.005% 
Stop solution 
Ethanol 40% 
Acetic acid 12% 
All Silver staining solutions were made in distilled water (dH2O). 
Gel drying solution 
Glycerol 87% 2.3% 
Ethanol 25% 
The gel drying olution was made in dH2O and volume made up to 1 liter. 
3.1.11.5 Buffers and solutions for Western blot 
Transfer buffer pH 9.2 
Tris (48 mM) 5.82 g/l 
Glycine (39 mM) 2.93 g/l 
SDS (10%) 3.75 ml 
Methanol (20%) 200 ml/l 
Wash buffer pH 7.4 
Tris (10 mM) 1.21 g/l 
NaCl (150 mM) 8.766 g/l 
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Tween 20 (0.1%)    1 ml/l 
Tris Buffered Saline (TBS) pH 7.4 
Tris (25 mM) 5.82 g/l 
KCl  0.2 g/l 
NaCl  8 g/l 
Blocking solution 
Milk powder 10% in 2 X PBS 
2X Phosphate Buffered Saline (PBS) pH 7.4 
Na2HPO4 X 12H2O 7.26 g/l 
KH2PO4 0.48 g/l 
NaCl    16 g/l 
KCl 0.40 g/l 
Alkaline phospatase (AP buffer) pH 8.9 
Tris (20 mM) 2.42 g/l 
NaCl (150 mM) 8.77 g/l 
MgCl2 (10 mM) 2.03 g/l 
Color development solutions 
BCIP, Toluidine salt (fresh solution in 100% DMF) (0.38 Mm) 7 mg/250 µl 
NBT (fresh solution in 70% DMF)      16.25 mg/500 µl 
The BCIP and NBT solutions were dissolved in 50 ml AP buffer for each blot. 
Primary antibody (Anti-His (6x histidine) ) in TBS 1:1000 
Secondary antibody (Anti-Rabbit IgG, alkaline phosphatase conjugated) in TBS 1:10 000 
3.1.11.6 Buffers for transmission electron microscopy 
Cacodylate buffer (2x) 
Na-Cacodylate x 3 H2O 4.28 g 
Sucrose 8.00 g 
dH2O  add to 100 ml 
Glutaraldehyde in cacodylate buffer 
2% or 2.5% Glutaraldehyde in 1x cacodylate buffer 
Osmium tetroxide in cacodylate buffer 
3% OsO4 1:1 in 2x cacodylate buffer 
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Osmium tetroxide solution (3%) 
OsO4         0.25 g 
dH2O        8.18 ml 
Uranyl acetate (0.5%)  
Uranyl acetate           5 mg 
dH2O            1 ml 
Epon 
Agar  2 g 
DDSA 1 g 
MNA         1.08 g 
BDMA         0.04 g 
3.1.11.7 Buffers for Inclusions bodies (IBs) isolation and solubilization 
Lysis buffer pH 7.5 
Tris-HCl    20 mM 
EDTA    15 mM 
Triton X-100               1% 
IBs solubilization buffer pH 8 
Tris-HCl                 50 mM 
GuHCl          4 M 
BME    10 mM 
Additives used for Refolding procedure 
L-Arginine  0.4 M and 0.1 M 
L-Glutathione reduced          3 mM 
L-Glutathione oxidized    0.3 mM 
3.1.11.8 Buffers for Ni-NTA affinity chromatography using AKTA-FPLC 
Equilibration & Wash buffer pH 8 
Tris-HCl    20 mM 
NaCl           1 M 
Binding buffer pH 8 
Tris-HCl    20 mM 
NaCl  150 mM 
Imidazole                                   10 mM 
 39 
Triton X-100           0.1% 
Elution buffer pH 8 
Tris-HCl    20 mM 
Imidazole                                  500 mM 
3.1.12 Consumables  
Materials Supplier 
Balance Mettler PJ3000 Mettler-Toledo GmbH, Giessen 
Balance OHAUS® Analytical plus Ohaus Corporation, Giessen 
Beem - Blocks Plano GmbH, Wetzlar 
Cover slip slides Carl Roth GmbH, Karlsruhe 
Cryotubes Greiner Bio-One GmbH, Frickenhausen 
Electroporation cuvette 0.2 cm Bio-Rad Laboratories Inc., München 
Eppendorf cups (1.5 ml and 2 ml) Greiner Bio-One GmbH, Frickenhausen 
Falcon tubes (15 ml and 50 ml) Greiner Bio-One GmbH, Frickenhausen 
Flask cell culture T-25, T-75, T-150 Greiner Bio-One GmbH, Frickenhausen 
Grids Plano GmbH, Marburg Brand, Wertheim 
Hemocytometer (0.02 mm) Brand, Wertheim 
Hybond-ECL Nitrocellulose membrane Amersham Biosciences, Freiburg 
Nalgene Rapid-Flow 50 mm Bottle Top Filter Thermo Fisher Scientific, Karlsruhe 
Negative Film KODAK 4488/Caresteam Plano GmbH, Wetzlar 
Nitrocellulose Membrane GE Healthcare, Dornstadt 
Millex-PES-Filter (0.22 µm) Carl Roth GmbH, Karlsruhe 
Object slides Carl Roth GmbH, Karlsruhe 
Object Polylysine slides Gerhard Menzel GmbH, Braunschweig 
Parafilm American Can Go, Chicago (USA) 
PCR-Tubes Greiner Bio-One GmbH, Frickenhausen 
Petri dishes Greiner Bio-One GmbH, Frickenhausen 
Sterile pipette Greiner Bio-One GmbH, Frickenhausen 
Sterile filter (0.22 µm) Carl Roth GmbH, Karlsruhe 
UV-Cuvette, Mikro Carl Roth GmbH, Karlsruhe 
6/12/24/48 and 96 well platte Greiner Bio-One GmbH, Frickenhausen 
96-well reaction plate (0.1 ml) Applied Biosystems, Fisher Scientific GmbH, 
Schwerte 
Whatman paper Whatman, Maidstone (USA) 
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3.1.13 Equipments 
Equipments Supplier 
ÄKTA FPLC GE Healthcare, München 
Autoclave  Münchner Mechanik, Stadlern 
Beckmann Centrifuge Beckmann, München 
Beckmann TI-100 Ultracentrifuge Beckmann, München 
Centrifuge Heraus Multifuge 1L-R Heraus, Osterode 
Centrifuge Sigma 3K12 Bachoder, Reutlingen 
Incubator Hera Cell (37°C, 5% CO2) Heraus, Osterode 
Incubator 37°C Infos AG, Bottmingen 
Inverted Microscope ID02 Zeiss, Oberkochen 
Light Microscope Axiostar plus Zeiss, Oberkochen 
Light Microscope Leica DM IL LED Leica Microsystems CMS GmbH, wetzlar 
Fluorescence Microscope (AG Dodt and AG 
Jansen) 
Carl Zeiss AG, Oberkochen 
Fluorescence Microscope BH2 RFCA Olympus, Hamburg 
Microscope-Camera U-PMTVC Olympus, Hamburg 
Microprocessor pH-Meter Bachofer, Reutlingen 
Microwave Panasonic, Wiesbaden 
Micro centrifuge Pico17 Heraus, Osterode 
Mini Centrifuge MiniStar Galaxy VWR International GmbH, Erlangen 
Nanodrop ND-1000 (AG Thilo Sthele) PreqLab, VWR International GmbH, Erlangen 
Oven drying machine BINDER GmbH, Tuttlingen 
Pressure Cooker CS Solingen, Solingen 
pH-Meter WTW, Weilheim 
Photometer Ultraspec 3000 Pharmacia Biotech, Wien 
Power Supply EPS301 for Gel electrophoresis Amersham pharmacia biotech, Freiburg 
Pyramitome 11800 LKB Ultramicrotome Laboratory 
Shaker Brau, Melsungen 
Spectrophotometer GeneQuant 1300 GE Healthcare, München 
Sterilbank LaminAir HLB 2248 GS Heraus, Osterode 
SteOnePlus® Real-time PCR System Applied Biosystems, Thermo Fisher Scientific, 
Braunschweig 
Transmission electron microscope EM10 Zeiss, Oberkochen 
Ultramicrotome OM U3C Reichert, Wien 
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Vortex Mixer NeoLab, Heidelberg 
Water bath Gesellschaft für Labortechnik, Burwedel 
3.1.14 Databank and Softwares 
Software Supplier /Web site links 
AxioVision LE v4.8.2.0 Carl Zeiss AG, Oberkochen 
Blast Local Alignment Search Tool (BLAST) 
(NCBI) 
https://blast.ncbi.nlm.nih.gov/Blast.cgi 
DNAman Lynnon Biosoft, Quebec (CA) 
Endnote X7.3.1 Thomsom Reuters, New York (USA) 
LOMETS V.4 (Local meta-threading-server for 
protein structure prediction) 
http://zhang.compbio.ku.edu/LOMETS 
FastGene® Gel Pic Nippon Genetics, Düren 
GeneDB http://www.genedb.org 
GNU Image Manipulation Program v2.8.4 
(GIMP) 
http://www.gimp.org 
Image J  https://imagej.nih.gov/ij/ 
NetPhos 2.0 (Protein Phosphorylation Prediction 
Server) 
http://www.cbs.dtu.dk/services/NetPhos/np.html 
OriginPro 8 OriginLab, Northampton (USA) 
Pfam database http://pfam.xfam.org 
Primer 3 v0.4.0 http://www.bioinfo.ut.ee/primer3-0.4.0/ 
Primer-BLAST (NCBI) http://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
PubMed Central (NCBI) http://www.ncbi.nlm.nih.gov/pmc/ 
SnapGene Viewer v2.8.2 GLS Biotech LLC, Chicago (USA) 
StepOne Software v2.2 Applied Biosystems, Thermo Fisher Scientific, 
Braunschweig 
TriTrypDB http://www.tritrypdb.org/tritrpdb/ 
TrypanoFan http://trypanofan.bioc.cam.ac.uk/trypanofan/main/ 
Zotero https://www.zotero.org/ 
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3.2 Methods and Protocols 
3.2.1 Standard protocols for molecular biology 
3.2.1.1 Extraction of genomic DNA from T. brucei bloodstream form (BF221) 
Genomic DNA from T. brucei BF221 was extracted using a DNeasy Blood & Tissue Kit QIAGEN (Hilden, 
Germany). The extraction procedure was accomplished according to the manufacturer’s instructions as 
follows: Per column 1x106 cells were added, the cells were centrifuged at 3000g for 5 min at 4°C. DNA was 
eluted with 100 µl elution buffer per column and stored at -20°C. 
3.2.1.2 Polymerase chain reaction (PCR) 
The full length pTbCOX gene (Tb427.10.13790/Tb927.10.13790/Tb10.61.3130) was amplified from T. 
brucei BF221 bloodstream form genomic DNA using AccuPrime Tag DNA Polymerase High Fidelity 
(Thermo Fischer Scientific, Germany). The AccuPrime PCR reaction mixture and program used for the 
pTbCOX amplification are described below: 
AccuPrimeTM PCR reaction mixture  AccuPrimeTM PCR -Program 
10xAccuPrimeTM PCR Buffer 5.00 µl      Denaturation 94°C 30 sec 1X 
Fw-pTbCOX Primer, 10 µM 1.00 µl      Denaturation 94°C 30 sec  
Rv-pTbCOX Primer, 10 µM 1.00 µl      Annealing 56°C 30 sec 30X 
T. brucei gDNA (28 ng/µl) 1.00 µl      Elongation 68°C 2 min  
AccuPrimeTM DNA Polymerase (5 U/µl) 0.20 µl      Cooling 4°C 24 h 1X 
3.2.1.3 Agarose gel electrophoresis 
The pTbCOX PCR product as well as products obtained by restriction digestion were subjected in 1% agarose 
(w/v) (Biozym Scientific, Germany) dissolved in 1x TAE buffer (50x TAE: 242,0 g/l, 57,1 ml/l acetic acid, 
37,2 g/l EDTA). After heating in the microwave until the solution became clear, Midori Green Advance DNA 
stain (Nippon Genetics, Germany) was added to a ratio of 5 µl/100 ml gel. Samples were mixed with an 
appropriate volume of 6x DNA Gel Loading Dye (Thermo Fischer Scientific, Germany) to reach an end 
concentration of 1x DNA Gel Loading Dye. For size reference, 1 kb Gene Ruler (Thermo Fischer Scientific, 
#SM0311, Germany) was used. Depending on the gel size, electrophoresis was performed for 45 min or 1 
hour at 80-100 V. The gel was visualized using LED illuminator. 
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3.2.1.4 DNA Gel Extraction and DNA concentration 
After detection of the pTbCOX PCR product in Agarose gel electrophoresis, the product of interest was 
extracted using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol.  
The DNA concentration of isolated pTbCOX PCR product was measured using a Nanodrop ND-100 (PeqLab, 
AG Stehle). The quotient E260nm/E280nm was utilized to determine protein contaminations. Pure DNA has an 
E260nm/E280nm quotient of 1.8. 
3.2.1.5 Ligation into pCR2.1®-TOPO® TA vector 
A TOPO TA Cloning Kit was used for subcloning the pTbCOX amplified PCR product into pCR 2.1 plasmid 
vector. The Taq DNA polymerase used for PCR as described above contains a non-template-dependent 
terminal transferase activity that adds a unique deoxyadenosine (A) to the 3' ends of PCR products. The 
pCR2.1®-TOPO® TA vector has single 3´-thymidine (T) overhangs. Therefore, PCR inserts can ligate 
efficiently with the vector and are covalently attached to it by topoisomerase I. Ligation was performed using 
following reaction mixture: 
Ligation pTbCOX into pCR 2.1 reaction mixture   
pCR 2.1 vector (25 ng/µl) 2 µl  
T4 DNA Ligase 2 µl  
10X T4 DNA Ligase buffer 1 µl  
pTbCOX PCR product (50 ng/µl) 1 µl  
Ampuwa water 4 µl  
Total Volume 10 µl  
The reaction mixture was performed overnight in a thermocycler repeating the following temperature steps: 2  
h at 22°C, 1 h at 16°C and 1 h at 4°C (Lund et al., 1996).   
3.2.1.6 Ligation into the donor plasmid pFastBacHTb 
Both DNA Strands (subcloning/target vector) fragments, respectively the pTbCOX fragment as well as the 
donor plasmid pFastBacHTb previously digested with BamHI and HindIII restriction enzymes, were used for 
sticky-end ligation. Both clones were ligated in a 1:1 and a 1:3 ratio of the target gene and target vector. The 
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ligation mixture for the proportion 1:1 was set up for a total volume of 20 µl, whereas the ligation mixes for 
the ratio 1:3 were prepared for a total volume of 30 µl (see description below). 
Components  Volume for 1:2 ratio Volume for 1:3 ratio 
Vector pFastBacHTb 5 µl 5 µl    
pTbCOX 5 µl 15 µl  
10X T4 DNA Ligase buffer 2 µl 3 µl  
T4 DNA Ligase 1 µl 1 µl  
Ampuwa water 7 µl 6 µl  
Total Volume 20 µl 20 µl  
The reaction was performed overnight in a thermocycler, repeating the following temperature steps: 2 h at 
22°C, 1 h at 16°C and 1 h at 4°C (Lund et al., 1996). 
3.2.1.7 Transformation of chemically competent E. coli 
Immediately after ligation, the freshly ligated DNA construct was transformed into NEB® Turbo Competent 
E. coli (New England Biolabs, Germany) or One Shot Top10 E. coli (Invitrogen, Germany) and in expression 
grade BL21-DE3 competent cells using a protocol from Stratagene. The tubes of competent cells were thawed 
on ice for 10 min. Then, 10 µl ligation product was gently added into pre-chilled 100 µl tubes of competent 
bacteria cells. The tubes were incubated on ice for 30 min. 
Afterward, a heat shock was applied for 30 sec at 42°C, using a prewarmed water bath. The duration of the 
heat shock was critical for maximum efficiency. Thereon, the cells were supplemented with 200 µl of 
prewarmed SOC medium and incubated for 1 h at 37°C at 225 rpm in a shaking incubator.  
Finally, the cells were plated on LB agar plates containing appropriate antibiotic (and containing X-gal and 
IPTG if blue-white screening was desired) for selection purposes. 
After overnight incubation at 37°C, single colonies were picked and screened for true uptake of the transgene 
by colony PCR, plasmid purification, and restriction digestion. Colonies validated to carry the desired 
construct were used to prepare long-term cryostock stabilates. 
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3.2.1.8 Bacterial colony PCR 
The PCR was performed using HotStarTaq® Master Mix Kit (Qiagen). A single bacterial colony was picked 
with a sterile pipette tip and transferred into the prepared PCR mix.  
The components of the PCR reaction mixture and the Master mix PCR program ran in the thermocycler are 
shown below: 
PCR reaction mixture  Master mix PCR-Program 
HotStarTag®Master Mix (5 U/µl) 10.00 µl   Activation 95°C 15 min 1X 
Fw-pTbCOX Primer, 10 µM 1.00 µl   Denaturation 94°C 1 min  
Rv-pTbCOX Primer, 10 µM 1.00 µl   Annealing 56°C 1 min 30X 
Bacteria from single colony -   Elongation 68°C 2 min  
Ampuwa water 0.20 µl   Final Extension 4°C 24 h 1X 
3.2.1.9 Plasmid purification from E. coli  
Plasmid mini-preparation 
After transformation, the colonies were selected and inoculated with a sterile pipette tip into respective 6 ml 
LB medium with appropriate selective antibiotics (i.e. 50 mg/ml ampicillin). The cultures were propagated at 
37°C with shaking at 225-250 rpm. After overnight incubation (17 h), the plasmid purification was done using 
QIAprep Spin Miniprep Kit (Qiagen, Germany). The starter culture was harvested by centrifugation at 13000 
rpm (Amicon microcentrifuge MC13) for 2 min. The supernatant was discarded, and the pellet was re-
suspended in 250 µl P1 buffer, incubated for 5 min at room temperature. The re-suspended cells were lysed 
by adding 250 µl alkaline P2 buffer, gently inverting the solution 4-6 times and stand for 5 min. The solution 
was neutralized with 350 µl N3 buffer.  
The precipitate was spun down at 13000 rpm for 10 min. The supernatant was transferred to a QIAprep spin 
column and centrifuged at 13000 rpm for 1 min. The column was washed with 0.5 ml buffer PB and 0.75 ml 
buffer PE. DNA bound to the column was eluted with 50 µl H2O or elution EB buffer and stored at -20°C.  
Plasmid midi-preparation  
For plasmid midi-preparation, the QIAprep Spin Midiprep Kit (Qiagen, Germany) was utilized. 50 ml E. coli 
overnight culture at 37°C respectively inoculated with the colonies and under specific antibiotics selection 
pressure were centrifuged at 6000g for 15 min at 4°C and then the bacterial pellet resuspended in 4 ml P1 
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buffer (add RNase A solution to buffer P1 before to use, mix, and store at 2-8°C). The resuspended cells were 
lysed by adding a 4 ml P2 buffer, mix thoroughly by vigorously inverting 4-6 times, and incubated for 5 min 
at room temperature. The solution was neutralized with 4 ml prechilled P3 buffer, mix thoroughly by 
vigorously inverting 4-6 times, and incubated for 15 min on ice. The precipitate was spin down at 14000-
18000g for 10 min at 4°C.  
At the same time, the QIAGEN-tip column was equilibrated by applying 4 ml QBT buffer. The supernatant 
was gently transferred to the QIAGEN-tip column and allowed it to enter the resin by gravity flow. 
The column was washed 2 times with 10 ml QC buffer, and the DNA was eluted with 5 ml QF buffer into a 
clean 15 ml vessel. The DNA was precipitated by adding 3.5 ml isopropanol at room temperature to the eluted 
DNA and spin down by centrifugation at 15000g for 30 min at 4°C. The supernatant was carefully discarded, 
and the pellet was washed with 70% ethanol at room temperature, centrifuged down at 15000g for 10 min. 
The supernatant was again discarded and the pellet was air-dry or dried with a SpeedVac Vacuum 
Concentrator and resolved in 150 µl appropriate buffer (e.g. sterile Ampuwa water, TE buffer, pH 8.0, or 10 
mM Tris-Cl, pH 8.5). 
3.2.1.10 Bacmid purification for Sf9 transfection (Minipreparation) 
The bacmid purification was performed using the DNA Purification Kit (Qiagen). White colonies from 
DH10Bac transformation were grown overnight at 37°C in 6 ml 1x LB under antibiotic selection (kanamycin, 
50 µg/ml; gentamycin, 7 µg/ml; tetracycline, 10 µg/ml). On the next day, the bacterial suspension was 
centrifuged at 17000g for 3 min. The supernatant was discarded, whereas the cell pellet was resuspended in 
300 µl P1 buffer. By the addition of 300 µl P2 lysis and incubation at room temperature for 2-5 min, lysis was 
induced. 300 µl N3 buffer was used to neutralize and, thus, to stop the lysis.  
After 10 min incubation on ice, the sample was centrifuged at 17000g for 10 min. Bacmid precipitation was 
achieved by mixing the supernatant with 800 µl 100% isopropanol. After 10 min incubation on ice, 
centrifugation at 17000g for 10 min was performed. Further on, the pellet was washed with 500 µl 70% ice-
cold ethanol and dried at room temperature. Finally, the dry bacmid pellet was resuspended in sterilized water, 
and the DNA concentration was measured at Nanodrop ND-1000 (PeqLab, AG Stehle). This experiment 
produced a high yield of bacmid DNA (˃ 1000 ng/µl) which was stored at -20°C till further used.  
3.2.1.11 Restriction digestion analysis 
Different restriction enzymes and respective buffers were used to digest the pTbCOX-pCR 2.1 subcloning 
(BamHI and HindIII), pTbCOX-pFastBacHTb constructs (BamHI and HindIII), pTbCOX-KD-pCR 2.1 
subcloning (XhoI and BamHI) and pTbCOX-pCR 2.1 subcloning (HindIII and PvuII). According to required 
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analysis, the plasmid and plasmid constructs with the gene of interest (pTbCOX) were checked for suitable 
restriction enzyme using DNAMAN software. The reaction mixture consisted of full DNA plasmid constructs, 
a respective buffer for each enzyme, restriction enzyme and elution buffer to make up a volume of 35 µl. The 
reaction mixture was incubated for 1 h or overnight at 37°C. Afterwards the restriction products were analyzed 
by agarose gel electrophoresis and purified according to the instruction of the QIAquick gel extraction kit. 
The reaction mixture as an example for the restriction digestion using BamHI and HindIII was done as 
described below. 
Double restriction digest with BamHI & HindIII  
DNA (subcloning/target vector) 15.0 µl  
10x Buffer BamHI 3.5 µl  
BamHI (10 U/µl) 0.5 µl  
HindIII (10 U/µl) 1 µl  
Ampuwa water 15.0 µl  
Total Volume 35 µl  
3.2.1.12 DNA sequencing 
The isolated plasmid constructs after verification on agarose gel electrophoresis and DNA concentration were 
sent for sequencing to Eurofins Genomics or GATC Biotech in the concentration of 30-100 ng/µl.  
The results of sequenced DNA were analyzed with DNAMAN software or NCBI blast by alignment with the 
gene of interest or plasmid sequence. 
3.2.2 Cultivation and handling of organisms 
3.2.2.1 Escherichia coli 
3.2.2.1.1 Cultivation on agar plates 
The bacterial cells were cultivated on agar-agar with LB-medium and ampicillin. LB-medium was prepared 
as 2X stock solution and mixed with pre-warmed 2X agar-agar under sterile conditions. After cooling to room 
temperature, ampicillin (1 ml/l) and X-gal (2 ml/l) were immediately added and poured into culture plates. 
The plates were left to solidify. When the agar was solidified, the plates were packed under sterile conditions 
and stored at 4°C till further use. 
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3.2.2.1.2 Preparation of competent E. coli cells (Chung et al., 1989) 
Competent E. coli cells were inoculated into 5 ml LB-medium with specific antibiotics selection pressure and 
incubated at 37°C with shaking at 225 rpm for overnight (17 h). After the overnight incubation, 1 ml of the 
starter culture was inoculated into 100 ml LB-medium with the right antibiotics selection and propagated at 
37°C with shaking at 225 rpm till the absorbance reached 0.8 at 600 nm.  
Then the cells were harvested at 5000 rpm for 5 min at 4°C, and the cell pellet was re-suspended in 10 ml TSS 
medium. Subsequently, 100 µl aliquots were made in cryogenic vials which were immediately frozen in liquid 
nitrogen and stored at -80°C. 
3.2.2.1.3 Preparation of long term storage of E. coli – Cryostabilates 
The new starter culture of tested clones and sterile 50% glycerol were added in volumes of 700 µl and 300 µl, 
respectively in cryotubes. The tubes were immediately shock-frozen in liquid nitrogen and stored in the liquid 
nitrogen tank. 
3.2.2.2 Spodoptera frugiperda (Sf9 insect cells) 
Insect cells Sf9 (fall armyworm) were bought from Novagene, Germany as frozen vials, stored in the liquid 
nitrogen tank and propagated in adherent and suspension culture at 27°C in an incubator.  
These cells were used for protein expression by following the Bac-to-Bac® Kit manual (Invitrogen, Germany) 
as the basis for the cultivation, transfection of Spodoptera frugiperda (Sf9) insect cel ls and in vivo protein 
crystallization experiments. 
3.2.2.2.1 Culturing Sf9 insect cells 
A cryo-stabilate of 2 × 107 Sf9 insect cells was removed from the nitrogen tank and rapidly defrosted at 27°C 
in a water bath. After the external disinfection of the cryotube, i t was opened under a sterile bank and 
transferred to a 25 cm2 cell culture flask. Subsequently, 10 mL of pre-warmed EX-CELL 420 Serum-Free 
Medium was added drop-by-drop. After an incubation period of one hour at 27°C, the vital cells had 
accumulated to form a monolayer at the bottom of the cell culture flask so that the medium with the non-
adherent cells and the medium could be removed. Subsequently, a further 10 mL pre-warmed EX-CELL 420 
Serum-Free Medium was carefully added to the cell culture flask. After that incubation was carried out at 
27°C until the monolayer had a confluence of about 90%. Then the culture could be used to start and maintain 
a Sf9 insect cells suspension culture. 
Cultivation of Sf9 insect cell monolayer culture 
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Monolayers of adherent insect cells were grown in different-sized culture flasks with sterile filter covers at a 
temperature of 27°C. Once a confluence of the cells of about 90% had been achieved, the old medium was 
removed, and fresh medium was added. Subsequently, the monolayer was detached from the floor by rinsing 
with a pipette or by careful scraping with a cell scraper and brought into suspension. The vitality of the insect 
cells could be examined microscopically, and the cell density was determined using a Neubauer 
hematocytometer. After that, the Sf9 insect cell culture could be diluted and transferred into a new culture 
flask with a larger volume: 
Type of Culture Flasks  Number of cells Volume of Medium 
       25 cm2 Flask 1 x 107 10 mL   
       75 cm2 Flask 3 x 107 20 mL  
       150 cm2 Flask 6 x 107 40 mL  
 
Cultivation of Sf9 insect cell suspension culture 
To be able to cultivate higher cell densities, suspension cultures with an initial cell concentration of 8 x 105 
cells/ml could be generated from monolayers, which had previously been passed at least twice. These 
suspension cultures were shaken at 100 rpm and incubated at 27°C. The same culture flask was used for the 
suspension cultures as in the cultivation of monolayers.  
During the cultivation, the culture flask stood at a 45° angle on the shaker. It is important in the case of 
suspension cultures, that there is a good supply of oxygen to the cells, so that a sufficiently large vascular 
volume may be selected for the respective cultures.  
The cell density of the suspension culture was determined twice a week using a Neubauer hematocytometer , 
and the cells were kept between 1 x 106 and 8 x 106 cells/ml. When the cells density reached the upper limit, 
cell density was adjusted to 1 x 106 cells/ml by dilution. The passage numbers should not exceed 30. 
Preparation of Sf9 insect cell stabilates 
Cells with a low passage number were frozen as reserves. After the absolute cell number of a suspension 
culture was determined, this was centrifuged, and the insect cells were adjusted to a concentration of 4 × 106 
cells/ml in a fresh EX-CELL 420 Serum-Free Medium. The Sf9 cells were then cooled to a temperature of 
4°C, and the same volume of pre-cooled medium was added with the addition of 20% (v/v) DMSO. Then, 4 
x 106 cells/ml insect cells were distributed to each cryotube for 12 hours at -20°C, then overnight at -80°C, 
and finally stored as stabilate in the nitrogen tank. 
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3.2.2.2.2 Transformation in DH10Bac competent cells 
The purified validated pTbCOX-pFastBacHTb plasmid was used for transformation of DH10Bac E. coli 
competent cells (Thermo Fisher Scientific). Aliquots of 100 µl competent DH10Bac E. coli (stored at -80°C) 
were thawed on ice. Then, 5 µl of the pTbCOX-pFastBacHTb construct were added, followed by 30 min 
incubation on ice. 
Next, a heat shock was applied for 45 sec at 42°C using a pre-warmed water bath. Thereon, cells were 
supplemented with 200 µl SOC medium. After 4 h incubation at 37°C, while shaking, the cells were plated 
on LB-agar plates. The agar was previously prepared with various antibiotics (kanamycin, 50 µg/ml; 
gentamycin, 7 µg/ml; tetracycline, 10 µg/ml); as well as X-Gal (100 µg/ml) and IPTG (40 µg/ml) which allows 
selection of recombinant E. coli cells. The plates were incubated for 48-72 h at 37°C. Afterward, the white 
DH10Bac colonies were used for Bacmid purification (see 3.2.1.10). 
3.2.2.2.3 Transfection of Sf9 insect cells 
The recombinant bacmid purified (see 3.2.1.10) and validated by Bacmid PCR analysis (Bac-to-Bac® Kit 
manual) was used to transfect the Sf9 insect cells. The X-tremeGENE HP DNA Transfection Reagent (Sigma-
Aldrich, Germany) was used for the transfection of Sf9 insect cells experiments.  
The transfection was performed by Bac-to-Bac® Kit manual (Invitrogen, Germany) with some minor 
modifications. The numbers and volume given here are sufficient to transfect two wells of a standard 6-well 
plate and to prepare two wells as negative controls. 
The cell density of a Sf9 suspension culture was determined using a Neubauer hematocytometer. The first 
requirement is that the cells should grow in the log-phase (1.5-2.5 x 106 cells/ml) with greater than 95% 
viability). Next step, the cell density was adjusted to 8 x 105 cells/ml (10 ml in total, use medium without 
antibiotics), and 2 ml/well were seeded thereof into four wells of the six-well plate. The cells were allowed to 
attach for 15-45 min at room temperature.  
In the meanwhile, the lipofection mixture was prepared: X-tremeGENE HP DNA Transfection Reagents was 
carefully mixed, and 6-8 µl of this reagent were transferred into 100 µl of EX-CELL 420 serum-free medium 
(without antibiotics). Thereupon, the mixture was briefly vortexed and kept at room temperature.  
Next step, 5 µl recombinant bacmid DNA (1 µg DNA) was added to 100 µl of EX-CELL 420 serum-free 
medium (without antibiotics) and gently mixed. Both, X-tremeGENE in medium and DNA in the medium 
were then combined to give a total volume of ~209 µl. After the expiration of a 15-30 min incubation period 
at room temperature, 150 µl of the mixture were added dropwise onto the cells in the first well. The remaining 
50 µl were used to transfect the second well equally. Control wells were treated with the same volumina (150 
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µl and 50 µl) of the serum-free media. The plate was incubated for 4 h at 27°C, but before, it was slightly 
wiggled to ensure even distribution of the DNA.  
As soon as the incubation period was finished, the transfection mixture was carefully removed by pipetting 
and subsequently replaced by 2 ml EX-CELL 420 serum-free medium (with or without antibiotics optionally). 
After 72 h incubation at 27°C, the cells were daily inspected under a light microscope for signs of viral 
infection, such as swollen cell bodies, increased cellular granularity, and reduction of confluence.  
3.2.2.2.4 Isolation of virus stock 
After the Sf9 cells had been transfected with the pTbCOX bacmid, the first virus generation (P1) was isolated 
approximately 7-10 days post transfection, as soon as about 90% of the cells were lysed. Therefore, the 
medium of infected cells was carefully collected, transferred into a sterile 15 ml tube and centrifuge at 3500 
rpm for 5 min. The supernatant, now representing P1 viral stock, was then moved to a new tube, protected 
from light, and stored at 4°C. Further virus stock generations were obtained in the same way.   
The P1 viral stock will be used for the virus stock amplification as described in the protocol of Bac-to-Bac® 
Kit manual (Invitrogen, Germany) by the manufacturer’s instructions. 
3.2.2.2.5 Determination of the virus titer using the Reed-Muench method 
The infectivity of the generated virus stock (plaque-forming units/ml) was estimated using an endpoint 
dilution assay method developed by Reed and Muench (Reed and Muench, 1938), using adopted equations as 
described by O’Reilly et al. (1994). In a 96 well plate, Sf9 insect cells were prepared monolayer cultures of 
200 µl/well by letting the cells attach for 30 min.  
The virus stock, whose titer should be determined, was diluted to achieve final concentrations of 10 -3, 10-4, 
10-5, 10-6 and 10-7. For each dilution stage, seven technical replicates were prepared, and the monolayer cells 
were infected. As a negative control, seven wells were left uninfected. The plate was incubated at 27°C. After 
incubation of seven days, the cells were analyzed by light microscopy. Each well was assessed for signs 
indicating a viral infection and based on this; it was scored either as infected (+ sign) or uninfected (- sign). 
The total number of uninfected and infected cells were determined by summed up over all uninfected wells of 
higher virus concentration (corresponding to lower dilution) (“top-down”). We assumed that all wells 
uninfected at that dilution would also have stayed uninfected at all higher dilution rates (less virus). 
Conversely, the total number of infected wells was obtained by summing up over all infected wells of lower 
virus concentration (corresponding to higher dilution) (“bottom-up”), assuming that these wells would equally 
have been infected at all lower dilutions. Further, the total percentage of infected wells for each dilution were 
calculated.  
 52 
Therefore, we estimated the dilution, which would give rise 50% infected cultures, by linear interpolation. In 
doing so, we determined the next dilution above to 50% (termed A) and the next below 50% (termed B). Then, 
calculation of the proportionate distance (PD) between these two dilutions (A and B) was done according to 
equation (1). 
(1)  PD =  % in A −  50%/% in B    
The dose that would have given a 50% response (50% tissue culture infective dose, TCID50) is then calculated 
using equation (2). 
(2) TCID50 =  10((Exponent of dilution in A) –  PD) 
The TCID50 was converted to plaque forming units (pfu) per milliliter. According to Poisson distribution, the 
mean distribution of infectious units at 50% infection rate is equal to ln(2) = 0.69. 
(3)  Virus titer =  1/TCID50 x ln(2) x 1000 µl/ml/µl of virus/well 
Equation (4) was used to assess the number of particles that were available per cell (multiplicity of infection, 
MOI) in retrospect. 
(4)  MOI =  virus inoculum x virus titer / number of cells  
For further used of the stock, the inoculum required to infect cells at a certain MOI was calculated according 
to Equation (5). 
(5) Inoculum (ml)  =  MOI (pfu/cell) x number of cells / virus titer (pfu/ml)  
3.2.2.2.6 Trypanosoma brucei  
Cultivation of monomorphic bloodstream form trypanosomes (SMB cell line) in vitro  
Single marker bloodstream form (SMB) stored in the liquid nitrogen were used for axenic cultures of parasites. 
The stabilates were quickly thawed under warm water; the thawed parasite suspension was then transferred to 
a falcon tube containing 10 ml cold HMI-9 medium and then centrifuged (1500 g, 10 min, 4°C). The 
supernatant was eliminated, and the cellular pellet was resuspended in 500 µl – 1 ml bloodstream medium 
(HMI-9 medium) to determine cell density using a Neubauer hemocytometer. The cell suspension preculture 
was started by adjusting the cell density to 1 x 105 parasites per ml with pre-warmed bloodstream medium 
(10-50 ml HMI-9 medium). The cultivation of trypanosomes was carried out at 37°C in a water-saturated 
atmosphere containing 5% CO2. After the 8-16 h incubation period, the cell density of the preculture was 
determined again to verify that the cells had entered the logarithmic growth phase. If the cells reached 2.5 x 
105 cells/ml, the culture was adjusted by dilution to 1 x 105 cells/ml to be sure that the cell will not exceed the 
critical value of 8 x 105 cells/ml after 24 h incubation time. Approximately after 24 h post incubation, the 
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started preculture was counted for the growth curves, cells doubling timing and maintained by daily dilution 
to 1 x 105 and 1 x 106 cells/ml.  
Depending on the daily cell counting results, the cells were placed in standard and synchronized cells density 
for growth curves experiments. Others cell cultures vessels were maintained or prepared to reach the high cell 
density cultivation required for further investigations. Geneticin G-418 2 µg/ml was systematically added to 
the SMB trypanosomes cell line to prevent the loss of the T7 RNAP and encoding TetR genes. The stable 
transfected SMB trypanosomes cells were cultivated with additionally selection pressure of 2 µg/ml 
Hygromycin. 
Stable electroporation of SMB trypanosomes cells 
SMB trypanosomes at a cell density between 2.5 and 4 x 107 cells/ml were harvested by centrifugation (1500 
g, 10 min, RT). The supernatant was decanted, and the pellet was resuspended in 25 ml Cytomix. The 
resuspension cell-Cytomix was centrifuged at 1500g for 10 min at room temperature, and the supernatant was 
carefully discarded. The cell pellet was resuspended in 500 µl Cytomix.  
The cell density of this suspension was dissolved in 1:100 dilution, counting using Neubauer hemocytometer 
to prepare the required cells concentration for the transfection.  
For each transfection approximately 1 x 107 cells/ 400 or 440 µl in Cytomix were transferred into a sterile 
cuvette together with 10 µg linearized plasmid DNA (1µg/µl). The electroporation was performed with Gene 
Pulser Xcell using a single pulse at 1400 V, 25 µF, ∞ Ω for 0.3 ms. The number of surviving cells was 
determined by counting in 1:100 dilution. After electroporation, cells were transferred immediately into 36 ml 
pre-warmed HMI-9 medium, cells counted again and the culture was incubated for 6 h at 37°C in a water-
saturated atmosphere containing 5% CO2. 6 hours after incubation of the transfection the selection marker was 
added in the appropriate concentration.  
For the knockdown induction experiment, Geneticin (2 µg/ml) and Hygromycin (2 µg/ml) or Phleomycin 
(2.5µg/ml) were used for the pTbCOX-pCO57 expression in SMB trypanosomes experiments. After added 
those respective selective antibiotics to the 36 ml cells culture, the culture was distributed in 1 ml per well into 
24-well plates and then incubated at 37°C and 5% CO2. After 4-6 days, the transfectants were usually analyzed 
by light microscopy and counting surviving cells. Later, positive clonal transfectant cells were pooled and 
transferred to large culture volume for subsequent experiments and production of transgenic stabilates for 
long-term storage in liquid nitrogen. 
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3.2.3 Quantitative Real-time PCR (qRT-PCR) 
3.2.3.1 RNA isolation 
The first requirement before proceeding with RNA isolation, the RNA bench surfaces and equipment were 
cleaned with potassium hydroxide (10 M) and RNase away®. Only the certified RNase-free materials and 
chemicals were used and stored in separate RNA bench cabinets. The samples were always kept on ice during 
all the practical steps procedure. 
Isolation of the RNA from Trypanosoma brucei was carried out using the QIAGEN Rneasy kit according to 
the manufacturer’s instructions. 5 x 107 trypanosomes cells/ml were harvested by centrifugation (1500 g, 5 
min, 4°C) and washed once with 20 ml TDB buffer. The supernatant was completely removed and the cell 
pellet resuspended in 350 µl of buffer RLT (lysis buffer). For the completion of the lysis of the cells, the 
samples were vortexed for about 1 min. 350 µl of 70% (v/v) ethanol was then added, and the lysate was 
transferred to Rneasy ion exchange columns. After 15 seconds of centrifugation at 13000 rpm, the columns 
were washed once with 700 µl of buffer RW1 and twice with 500 µl of buffer RPE.  
The elution was done using 30 µl of RNase-free water. 3 µl of the eluates were transferred to PCR tubes for 
RNA concentration determination. The RNA concentration determination was carried out on a Nanodrop ND-
1000 against RNase-free water as a blank.  
The ratio 260/280 nm of the isolated RNA should be in the range between 2.0-2.2 to ensure a sufficiently high 
degree of purity. The remaining 27 µl of the eluates were stored at -80°C for further experimentations. 
3.2.3.2 DNAsing of RNA  
To ensure that the RNA used for the qRT-PCR had no DNA contamination, the freshly isolated RNA (see 
3.2.3.1) was digested with DNase I (Thermo Fisher Scientific, Germany). The DNAsing of RNA was 
performed following the reaction mixture DNase I digestion: 25 µl of RNA eluate (Qiagen RNeasy Kit), 3 µl 
of 10x reaction buffer, 1.5 µl of DNase-free water and 0.5 µl of DNase I (1 U/µl). The control was prepared 
with 25 µl instead of RNA eluate which served as a blank for later RNA concentration determination. All 
samples DNasing were incubated for 30 min at 37°C. Finally, 1.5 µl EDTA (50 mM) was added, and the 
enzyme was inhibited by heating at 65°C for 10 min. The RNA concentration of the samples was determined 
again as described above (see 3.2.3.1). 
3.2.3.3 Quantitative Real-time PCR (qRT-PCR) 
The Power SYBR® Green RNA-to-CTTM 1-Step Kit from Applied Biosystems (Thermo Fisher Scientific, 
Schwerte) was used for quantitative RT-PCR. The reference gene for the quantification of the mRNA level of 
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the putative TbCOX gene (pTbCOX) was β-tubulin (TbTub) as housekeeping gene. Since the 1-Step Kit 
already contains all reagents required for reverse transcription and subsequent PCR, the isolated RNA (see  
3.2.3.1) could be used directly as a template. The RNA concentrations of all samples were adjusted to 20 ng/µl 
by appropriate dilution with RNase-free water. A total of 60 ng RNA per reaction batch was used. Primer 
stock solutions (100 μM) were diluted 2:100 with RNase-free water and adjusted to a final concentration of 2 
μM. To ensure that the levels of all components (primers, enzymes, SYBR fluorescent dye) were identical in 
all approaches, the next master mixes were prepared according to the manufacturer’s instructions. This 
indicated quantity (52x) is sufficient for the investigation of 11 samples in triplicates in a total volume of 10 
μl (including dilution series and negative controls).  
 Mix 1 (pTbCOX) Mix 2 (TbTub) 
2x SYBR® Green RT-PCR-Mix 260,00 µl 260,00 µl  
fw-Primer (2µM) 52,00 µl 52,00 µl  
rv-Primer (2µM) 52,00 µl 52,00 µl  
RT Enzyme Mix 4,16 µl 4,16 µl  
A 96-well reaction plate (Applied Biosystems) was charged with 7 μl of the master mixes. Subsequently, 3 μl 
of DNase I-digested RNA (20 µg/ml) were added each time, so that the final volume per well was 10 μl. To 
the negative controls, 3 μl of RNase-free water was added instead of the RNA. Each RNA sample was 
measured in triplicate in master mix 1 (amplification of pTbCOX mRNA) and also as triplicate in master mix 
2 (amplification of β-tubulin mRNA). 
An RNA sample (SMB, not transfected) was diluted in a dilution series by a factor of 1:5 to determine the 
efficiency of the qRT-PCR (see 3.2.3.4), and the resulting amounts of RNA were added to both master mixes.  
The reaction plate was sealed with an adhesive film and briefly centrifuged before the start of the reaction. 
The reaction was carried out in a StepOnePlus™ Real-Time PCR System from Applied Biosystems.  
The temperature profile is shown in the table below. The data were evaluated using the StepOne software v2.2 
(see 3.1.14) 
Cycles Programm Temperature Ramp Rate [°C/s] Time 
  1X Reverse Transcription 48°C  4,4  30 min  
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  1X Activation 95°C  4,4  10 min  
 Denaturation 95°C  4,4  15 s  
  40X Annealing/Elongation 60°C    1,5 min  
 Measurement of fluorescence 72°C  4,4  10 s  
  Melting curve     
  1X Denaturation 95°C  4,4  5 s  
  1X Annealing 60°C  2,2  1 min  
  1X Measurement of fluorescence 95°C  0,11  -  
  1X Cooling 40°C  2,2  30 s  
Melting curve analysis was used to verify the specificity of the PCR products. Also, agarose gel 
electrophoresis in a 5% TAE agarose gel (see section 2.3.2.2) was used to determine whether the fragments 
produced in the batches had the expected sizes of 165 bp (pTbCOX amplicons) or 76 bp (TbTub amplicons). 
3.2.3.4 Determination of qRT-PCR efficiency 
The analysis of the measured data was carried out with the help of the manufacturer software StepOne 
Software v2.2 (Applied Biosystems). The software automatically calculates a CT value (threshold cycle) for 
each sample – this value indicates the number of cycles at which the fluorescence of the sample increases 
significantly over the background fluorescence (baseline) for the first time. The relative determination of the 
transcript quantity was performed according to the efficiency-corrected relative quantification model 
according to Pfaffl (Pfaffl, 2001, 2004). 
1. For the determination of the qRT-PCR efficiency E, the CT values of the two-dilution series were first 
plotted against the nanoprobes and subsequently logarithmized RNA quantity. E is obtained from the slope m 
of the compensating straight line according to the following formula: 
(𝟔)     𝐸𝐺𝑒𝑛 = 10
−
1
𝑚 
2. The differences in the CT values (ΔCT) between induced samples and control samples (non-transfected 
SMB cells) were calculated by differentiation according to the formula (7). To compensate for fluctuations 
due to pipetting inaccuracies, the mean CT values of all three replicates of a sample were used for these 
calculations. 
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(𝟕)     ∆𝐶𝑇,𝐺𝑒𝑛 = 𝐶𝑇,𝐶𝑜𝑛𝑡𝑟𝑜𝑙̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅  − 𝐶𝑇,𝑖𝑛𝑑𝑢𝑐𝑒𝑑̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅  
3. The relative expression difference was calculated by the formula (8), which correlates the PCR efficiencies 
and the ΔCT values of the target gene (pTbCOX) and reference gene (TbTub). 
(𝟖)    𝑅 =
𝐸𝑇𝑏𝐶𝑂𝑋
𝛥𝐶𝑇,𝑇𝑏𝐶𝑂𝑋
𝐸
𝑇𝑏𝑇𝑈𝐵
𝛥𝐶𝑇,𝑇𝑏𝑇𝑈𝐵
 
The values calculated in this way are to be understood as arbitrary units. 
3.2.4 DAPI staining of Trypanosoma brucei cells 
DAPI is a fluorescent dye that specifically binds to AT-rich regions of DNA. Its absorption maximum is in 
the ultraviolet range; the emitted light has a blue color (maximum emission 453 nm) (Kapuscinski, 1995). As 
DAPI can easily pass through an intact cell membrane, it was used to stain the nucleus and Kinetoplast of 
noninduced and induced pTbCOX knockdown trypanosomes cells at different time post doxycycline 
induction. Approximately 1 x 106 cells/ml were harvested by centrifugation (1500g, 5 min, RT). The cell pellet 
was washed twice with TDB buffer and then resuspended in 100 µl of TDB buffer. 50 µl of the cell suspension 
were coated on a slide and dried in the air for 15-30 min. Subsequently, the cells were fixed by gently dropping 
2-3 drops of ice-cold methanol (-20°C). After incubation at -20°C of the slide for 10 min, 50 µl of DAPI 
staining solution (1 µg/ml) were dropped, distributed on the entire surface by pivoting the slide and incubated 
for 5 min at RT in the dark. 
The staining evaluation was carried out on an Olympus BH2 fluorescence microscope, equipped with a 
ColorView12 digital camera and the analysis software from Soft Imaging System GmbH (Münster), by 
counting Kinetoplast and nuclei from at least 100 cells. 
3.2.5 Electron Microscopy 
3.2.5.1 Transmission electron microscopy (TEM) 
For TEM, SMB trypanosomes at a cell density between 2 x 107 and 1 x108 cells/ml were harvested after 
different induction time (0 h, 6 h, 18 h, 24 h, 42 h) by centrifugation (1500g, 10 min). The supernatant was 
removed, and the cell pellet was washed once with TDB or MEM salts. The cell pellet was fixed in 2% 
glutaraldehyde (cross-linking fixative, dissolved in 1 x sodium cacodylate buffer, v/v) for 1 h at 4°C.  
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After washing four times (10 min each incubation on ice and termination by centrifugation 30 sec, RT, 
Beckmann Microfuge E) and storage overnight in 1 x cacodylate buffer, cells were postfixed in osmium 
tetroxide (1.5%, w/v) and stained with 0.5% uranyl acetate at RT for 60 min and washed with distilled water.  
The fixed cells were dehydrated using ethanol solutions of increasing concentrations (50%, 70%, 95%, 100%, 
5 min incubation, then 1 min centrifugation in Beckmann Microfuge E, RT) and washed 3 times 10 min each 
with propylene oxide. The samples were incubated with Epon: propylene oxide (1:1, 60 min, RT), infiltrated 
with pure Epon (60 min, RT) and transferred to Beem®-cups. The polymerization was carried out for 12 h at 
45°C and 24 h at 60°C. 
After polymerization, the sample was removed from the Beem®-cups using a scalpel and was trimmed into 
trapezium shape on LKB 11800 Pyramitone. The sample was sectioned using an Ultramicrotome OM U3 and 
fished with the copper grids. The grid was contrasted on a 100 µl 0.5% uranyl acetate drop (60 min, RT, face 
down) (Lewis and Knight, 1977). The grid was washed with distilled water and incubated in lead citrate 
solution (30 sec, RT) and again washed and dried. 
TEM images were collected at a Zeiss EM 10 transmission electron microscope, and the photographs were 
developed using an automated Konica SRX-101A developer machine. 
3.2.5.2 Scanning Electron Microscopy (SEM) 
The SEM procedures were used to prepare the pTbCOX in vivo micro-sized crystals with Sf9 insect cells and 
pTbCOX SMB knockdown trypanosomes (5 x 107 – 2 x 108 cells/ml) post-induced with doxycycline (1 µg/ml) 
at the different time point (0 h, 6 h, 24 h). TEM procedures above described were followed for SEM pTbCOX 
micro-sized crystals with Sf9 insect cells samples preparation. For the pTbCOX SMB knockdown 
trypanosomes, SEM sample was fixed using 4% (w/v) glutaraldehyde and 4% (w/v) paraformaldehyde in 1 x 
cacodylate buffer overnight at 4°C. After washing four times (10 min each incubation on ice and termination 
by centrifugation 30 sec, RT, Beckmann Microfuge E), the cells were treated with 1.5% (w/v) osmium 
tetroxide with 70 Mm HgCl2 in 1 x cacodylate buffer for 1 h at 4°C. Next step, the cells were washed one time 
with 1 x cacodylate buffer and three-time with distilled water. SEM samples were dehydrated up to 70% 
ethanol and stored overnight at 4°C. The subsequent steps for the preparation of SEM samples as well as SEM 
picture were carried out by Mrs. Meinert in the laboratory of Prof. Oliver Betz (Institute of Evolution and 
Ecology, University of Tübingen). 
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3.2.5.3 Negative staining  
Approximately 5 x 107 cells (absolute) from a main culture in the logarithmic growth phase were harvested  
by centrifugation (1500g, 5 min, 4°C). The resulting cell pellet was washed twice in TDB (1500g, 5 min, 4°C) 
and subsequently resuspended in 0.2-1 ml TDB.  
The cell density was examined by light microscopy. Depending on this, approximately 10-100 μl of the cell 
suspension were pipetted onto the bright side of a mold-coated copper grid. For this and all subsequent steps, 
a petri dish lined with parafilm served as a support. The grid was dried for at least 10 min at room temperature 
and then transferred to a drop of PEME + Nonidet P-40 (1%) with the shiny side facing downwards. After 2 
min incubation, it was transferred to a drop of PEME + glutaraldehyde (2%) and incubated to fix the cells for 
5 min. Subsequently, the grid was dried by carefully dabbing the liquid on filter paper and immediately 
transferred to a drop of 0.5% uranyl acetate for 30 s.  
The preparation was terminated by washing in 3-5 drops of distilled water. After complete drying of the grids, 
they were analyzed and photographed on the Zeiss EM10 transmission electron microscope. 
3.2.6 Standard protocols for protein biochemistry 
3.2.6.1 Expression of rpTbCOX in BL21-DE3 E. coli strains as inclusion bodies 
The pTbCOX-pProExHTa construct was transformed into the BL21-DE3 strain of E. coli. A 100 ml culture 
using LB medium containing ampicillin (50 µg/ml) and chloramphenicol (34 µg/ml) in the ratio of 1:1000 
was grown overnight shaking at 37°C and used to inoculate 500 ml or 1 L of LB medium in a 2L flask.  
The experiments on isopropyl ß-D-1-thiogalactopyranoside (IPTG) concentration and induction time were 
performed for better expression of the rpTbCOX. It was found that addition of 2Mm IPTG at a culture optical 
density (600 nm) of 0.6 – 0.8 and subsequent culturing for 4 hours at 37°C yielded the highest expression of 
the putative rpTbCOX in bacterial inclusion bodies (IBs). The cells were harvested by centrifugation at 10000 
rpm or 4500g at 4°C for 10 min and stored frozen at -20°C. 
3.2.6.2 Isolation of inclusion bodies and dialysis for protein refolding 
Cells were resuspended in 25 ml or 50 ml of lysis buffer (20 mM Tris-HCl, pH 7.5, 15 mM EDTA, 1% Triton 
X-100 with the addition of Complete Protease Inhibitor Tablet (Roche)).  
The cells were mechanically disrupted by sonication using short pulses of 20 seconds on ice in a Sonifer cell 
disruptor B-30. Protein refolding by stepwise dialysis was performed with slight modifications following the 
protocol developed by Buchner and Rudolph (Buchner and Rudolph, 1991) for refolding Fab fragment and 
by Tsumoto (Tsumoto et al., 1998) for the refolding of two scFv constructs. The inclusion bodies were isolated 
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from the cell supernatant by centrifugation at 10000 rpm at 4°C for 20 min. Inclusion bodies were solubilized 
in resuspension buffer (50 mM Tris-HCl, pH 8, 4 M GuHCl, 10 mM BME), incubated 10 min on ice, to allow 
denaturation and solubilization, and then centrifuge again at 10000 rpm at 4°C for 20 min to remove any 
residual insoluble material.  
The resuspended protein solution was dialyzed against buffers containing decreasing amounts of guanidine 
hydrochloride (GuHCl) by stepwise dialysis, as well as adding additives like L-Arginine and the redox pair of 
oxidized and reduced glutathione (3 mM reduced glutathione (GSH)/ 0.3 mM oxidized glutathione (GSSG)) 
during 4 days.  
The resuspended protein was dialyzed overnight at 4°C in snakeskin dialysis tubing against 1 L (10 ml vol. 
protein solution) or 2 L (30-40 ml vol. protein solution) of buffer # 1 (50 mM Tris-HCl, pH 8, 2 M GuHCl). 
The following day the dialysis buffer was changed to 1 or 2 L of dialysis buffer # 2 (50% dilution buffer # 1 
with water, 0.4 M L-Arginine, 3 mM GSH, 0.3 mM GSSG) for overnight dialysis at 4°C.  
The following day the dialysis buffer was diluted 50% with water (buffer # 3), and dialysis continued 
overnight. Any insoluble material was centrifuged at 10000 rpm at 4°C for 20 min and the protein solution 
dialyzed overnight at 4°C against 1 L or 2 L of buffer # 4 (50 mM Tris-HCl, pH 8, 300 mM NaCl, 0.1 M L-
Arginine, 3 mM GSH, 0.3 mM GSSG) to remove the remaining GuHCl. The following day, the protein 
solution was centrifuged at 3000 rpm for 10 or 20 min to remove any insoluble material and then run a 10% 
SDS-Page and Western blot analysis. The remaining final protein solution after step-wise dialysis was stored 
at 4°C and ready to be used for Ni-NTA purification under AKTA-FPLC system. 
3.2.6.3 Purification of (His)6 – tagged rTbCOX by Ni-NTA affinity chromatography 
The final dialyzed protein solution (5 ml) was loaded onto a Protino® Ni-NTA (Macherey-Nagel, Germany) 
His-tag affinity column pre-equilibrated with an equilibration buffer (20 mM Tris-HCl, pH 8, 1 M NaCl) using 
an AKTA-FPLC system. The column was loaded with binding buffer (20 mM Tris-HCl, pH 8, 500 mM NaCl, 
10 mM Imidazole, 0.1% Triton X-100) followed by a wash with equilibration buffer to remove the Triton X-
100 for 30-45 min. The pTbCOX was eluted and collected in 1 ml different fractions from the resin column 
using a 100% linear gradient (0-500 mM) elution buffer (20 mM Tris-HCl, pH 8, 500 mM Imidazole). The 
equilibration-washing and elution steps were done respectively at a flow rate of 0.2 ml/min and 0.5 ml/min. 
Each eluted fraction was quickly analyzed by SDS-PAGE, gel silver staining and western blot analysis to 
identify the target fraction after the one step Ni-NTA affinity chromatography. Those fractions containing the 
eluted pTbCOX were pooled, dialyzed overnight at 4°C against 20 mM Tris-HCl, pH 8, 300 mM NaCl and 
concentrated using centricon filter MWCO 10 kDa.  
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3.2.6.4 Radioactive thin layer chromatography (TLC) cyclooxygenase activity assay 
To determine the activity of the purified pTbCOX thin layer chromatography and C-14 arachidonic acid (2.5 
µCi) as substrate were used. For this purpose, the solvent system containing 98.5:1:0.5 vol/vol/vol Diethyl 
ether/Methanol/Acetic acid was prepared and allowed to stand in a close chromatography tank at -20°C. Then 
497 µl of the purified rTbCOX (200 ng) was incubated with 3 µl C-14 arachidonic acid (2.5 µCi) in COX 
activity buffer (see 3.1.11.3) at room temperature for 1 h. The reaction mixture was stopped by the addition 
of 100 µl of 1 M HCl and cold ethyl acetate. After vortex for 10 sec, the reaction mixture was centrifuged at 
1000g at 4°C for 10 min. After that, the aqueous phase and the ethyl acetate phase were clearly separated from 
one another.  
The ethyl acetate phase was transferred to an Eppendorf vessel, and the aqueous phase was extracted again 
with ethyl acetate. The collected extracted samples were then dried in speed vacuum centrifuge. The pellet 
was dissolved in 50 µl of ice-cold ethanol and place on ice for 30 min.  
10 µl of sample was applied to the thin layer chromatography on a silica gel plate (20x20 cm) under an a ir 
stream and placed directly into the chromatography tank containing the solvent system at -20°C. After 45 min, 
the dry silica plate was exposed to X-ray film (KODAK MR Film) and radioactive products will be visualized 
after 7 days by autoradiography. 
3.2.6.5 Protein concentration determination using Bradford assay 
The protein concentration was determined by Bradford protein assay (Bradford, 1976). Therefore, Bio-Rad 
Protein Assay was utilized and diluted 1/5 with deionized water. The diluted reagent was pipetted in a volume 
of 900 µl in each cuvette. As a reference, 100 µl deionized water for standards or buffer for samples was used.  
All measurements were performed in duplicate. The reaction mixtures were incubated for 5 min in the dark at 
room temperature, and then the protein concentration was determined by photometric measurement at 595 nm. 
The protein concentration was determined by comparison of the measured extinction values to a standard 
curve. 
3.2.6.6 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
At first, the glass plates, assembly, comb, and spacers were cleaned with ethanol. The glass plates with spacers 
were fixed inside the assembly. As mentioned above in section 3.1.11.2, separating gel mixture was poured 
carefully in between glass plates taking care not to let air bubbles in the solution and the gel was polymerized 
(polymerization time was for 30 min) with an overlay of deionized water. After the gel had polymerized, 
stacking gel mixture was poured above the gel carefully and immediately added comb on top of it till 
completely immersed between plates.  
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The polymerization time was 45 min, and during this time, protein samples were prepared after protein 
estimation from Bradford method from 10 to 60 µg protein concentration per sample. The reducing sample 
diluting buffer was added to samples and adjusted the volume accordingly. The samples were heat denatured 
by boiling at 100°C for 5 min and loaded into respective wells with Page Ruler Prestained Ladder as molecular 
protein marker.  
The water cooling system was attached to the assembly, and running buffer was added in upper and lower 
reservoir.  
The electrodes were attached accordingly into the power supply, and SDS-PAGE was run at the voltage of 80 
V, and then after the sample has moved into the stacking gel, the voltage was increased to 160 V till the 
bromophenol boundary reached the bottom of the gel. The gel was removed carefully from the plates and 
placed in Coomassie solution for 1 h and then destained or in fixation solution for silver staining (see 3.1.11.3 
and 3.1.11.4) or followed immediately for Western blotting. 
3.2.6.7 Western blot analysis 
The protein samples were resolved in SDS-PAGE and immediately blotted. The gel was placed on an anode 
plate in Semi-Dry apparatus.  
It was overlaid onto blotting paper (Hybond-ECL nitrocellulose membrane) sandwiched between three layers 
of Whatman filter papers soaked with transfer buffer (see 3.1.11.5) on each side respectively. It was carefully 
assembled to remove any air bubbles in between the membrane, gel and filter papers. The electrotransfer was 
carried out at about 20 V (400 mA) for 45 min.  
After that protein transfer from SDS gel to a nitrocellulose membrane, the membrane was blocked with 10% 
milk powder in 2 X PBS for 1 h at room temperature or overnight at 4°C with gentle shaking. 
After the blocking step, the membrane was washed 5 times for 5 min in washing buffer and then incubated 
the first antibody diluted in TBS (1:1000) for 1 h at room temperature in new disposable bags with gently 
shaking. The membrane was washed again as above and incubated with the second antibody (coupled with 
alkaline phosphatase) diluted in TBS (1:10000) for 1 h at room temperature. After that, the membrane was 
washed 5 times for 5 min with gently shaking using TBS. Finally, the developing solution containing BCIP 
and NBT was added to the membrane and color development was observed carefully. When the bands 
appeared, the reaction was stopped with PBS and blot was scanned after drying on filter paper. 
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3.2.6.8 Gel staining 
Following the SDS-PAGE run, the gels were stained with 1 mg/ml Coomassie blue R for at least 1 h at room 
temperature or overnight at 4°C. The gels were destained in destaining solution (10% acetic acid, 40% ethanol) 
till the respective bands appeared clear on the gels. 
Silver staining also was performed as more sensitive than the staining by Coomassie blue dye. The gels were 
fixed in fixative solution (see 3.1.11.4) for 10 min at room temperature, washed with 50% ethanol 3 times for 
10 min and then incubated in impregnation solution (see 3.1.11.4) for 3 min at room temperature with gently 
shaking.  
The gels were washed 3 times for 1 min with water and then incubated with silver stain solution for 20 min 
(in the dark). The gels were further washed 2 times for 2 min with water. After that, the gels were soaked in 
developing solution (see 3.1.11.4) until the bands or protein spots appeared.  
The gels were treated with stop solution (see 3.1.11.4) for 10 min at room temperature and were washed with 
50% ethanol for 20 min. Later the gels were preserved by “sandwiching” the gels between two sheets of wet 
cellophane in gel storage solution (gel drying system) (see 3.1.11.4). Excess solution and air bubbles between 
the cellophane sheets and the gels were expelled by applying pressure using a ruler. 
3.2.7 Biophysics Methods 
3.2.7.1 Second Order Nonlinear Imaging of Chiral Crystals (SONICC) 
Second order nonlinear imaging of chiral crystals (SONICC) was used to detect the isolated pTbCOX crystals. 
Using the SONICC method, the isolated pTbCOX crystals are irradiated with a 1064 nm fs laser pulse, which 
leads to a frequency doubling of the photon in the case of a chiral crystal.  
The resulting signal of this second harmonic generation (SHG) process can thus be detected at a wavelength 
of 532 nm. The experiments were done using SONICC benchtop device (formatrix) with an SHG exposure 
time of 30 seconds. SONICC measurement, Dynamic Light Scattering (DLS) and CD spectroscopy on the 
pTbCOX crystals samples were carried out as cooperation project in the laboratory of Prof. Christian Betzel 
(Institute of Biochemistry and Molecular Biology, DESY – Hamburg). 
3.2.8 In vivo crystallization in Sf9 insect cells 
3.2.8.1 pTbCOX crystals production and isolation 
The pTbCOX P3 virus stocks with respectively MOI 0.1 pfu/cell and 0.2 pfu/cell were used to infect the Sf9 
insect cells for crystals production. For this experiment, 1 x 106 Sf9 cells/ml (monolayer culture, 60% 
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confluent) were infected in 6-well plate or 10 ml in T-flask 25 cm2 for crystals production (virus dilution 
1:1000). The infected Sf9 insect cells were incubated at 27°C for 2-3 weeks. The cells and crystals were 
visualized using an optical light microscope.   
The produced pTbCOX crystals were isolated in principle by separation of crystals and cells by centrifugation. 
The Sf9 insect cells and crystals suspensions were centrifuged at 1500g for 10 min. The supernatant was 
collected and check for crystals under the light microscope. 
The supernatant containing the tiny pTbCOX crystals was overnight dialyzed against water at 4°C using 
membrane filter 12-14 kDa cut-off membrane. The next day the crystals sample was visualized and counted 
under the light optical microscope using Neubauer chamber.  
The crystals samples were concentrated using 10 kDa centricon (Millipore) at 15000g at room temperature 
until the desired concentration is reached.  
The concentrated pTbCOX samples were then solubilized with sodium acetate pH 3.6 for SDS-PAGE and 
Western blot analysis. 
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4 Results 
4.1 Description of the pTbCOX gene 
 (Tb427.10.13790/Tb927.10.13790/Tb10.61.3130) and pTbCOX protein 
The genome database of T. brucei contains the annotated gene Tb927.10.13790/Tb427.10.13790 that encodes 
a hypothetical conserved protein and is located on chromosome 10. This gene showed up in our search for a 
putative cyclooxygenase like enzyme in Trypanosoma brucei using Western blot analysis with a polyclonal 
anti-cyclooxygenase antibody from ovine, an enzyme assay for peroxidase activity with Amplex Red reagent, 
mass spectrometry analysis of the protein bands detected by Western blotting and a bioinformatic search 
(Barth, 2013). It was selected and postulated as a putative cyclooxygenase-like enzyme from Trypanosoma 
brucei (pTbCOX) to be further characterized in this thesis. The pTbCOX gene has a length of 2043 base pairs 
(bp) and has ortholog and paralog genes within the kinetoplastid family, however, all of them are still 
annotated as hypothetical conserved proteins. The pTbCOX gene encodes a pTbCOX protein which contains 
680 amino acids and has a predicted molecular weight of 74.68 kDa. Bioinformatic analyses using Pfam, 
Prosite, Swiss-Pro, InterPro, TMHMM, Signal P, LOMET and NetPhos did not reveal any putative signal 
peptide or a transmembrane domain and no convincing homolog proteins in any other organism. The analyses 
revealed, however, the presence of -helices, ß-strands and considerable coiled-coil structures and a large 
number of putative phosphorylation sites (Ser/Thr/Tyr) (Figure 4.1 and Figure 4.2).  
Furthermore, the hydrophobicity or hydrophilicity of pTbCOX was evaluated using the Expasy ProtScale 
software. The Kyte-Doolittle scale revealed the hydrophobic amino acid within the pTbCOX sequence (Figure 
4.3). 
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Figure 4.1: pTbCOX 680 amino acids sequence and protein structure prediction using 
LOMETS V.4 (Local Meta-Threading-Server) software. This analysis revealed the presence of 
Helix, ß strand and more coiled-coil structure within the pTbCOX protein sequence.   
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Figure 4.2: Phosphorylation sites prediction in pTbCOX sequence. The image is showing the 
numbers and position of Serine-Threonine-Tyrosine phosphorylation sites within the pTbCOX 
amino acid sequence using the NetPhos 2.0 bioinformatic software tool. 
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4.2 Expression, refolding and purification of pTbCOX  
Following the T. Barth dissertation, the pTbCOX gene was successfully cloned into a pProExHTa plasmid 
(Invitrogen). This plasmid was introduced into the E. coli strain BL21(DE3) for heterologous protein 
expression as a recombinant His-tagged protein (rpTbCOX).  
The rpTbCOX was found almost entirely in an insoluble form inside inclusion bodies (IBs) after gene 
induction with isopropyl ß-D-1-thiogalactopyranoside (IPTG) (see details in section 3.2.6.1). I first solubilized 
the inclusion bodies using N-lauroylsarcosine detergent. However, many different attempts to purify this 
rpTbCOX by a native purification strategy or by using a lauroylsarcosine-triton X-100 mix in the buffer system 
throughout the purification were not successful. The inclusion bodies were finally solubilized using 4 molar 
guanidine hydrochloride (GuHCl) and the protein was re-folded step-wise by GuHCl gradient dialysis with 
 
Figure 4.3: Kyte-Doolittle-Hydropathy Plot for pTbCOX. The hydropathy score is plotted on 
Y-axis and the amino acids number on X-axis. The positive score of the hydropathy indicated 
the hydrophobic segment within the pTbCOX protein sequence. 
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the introduction of a redox agent (reduced and oxidized glutathione) and L-arginine, following the protocol 
described in section 3.2.6.2. Following the refolding procedure, rpTbCOX was subjected to 10% SDS-PAGE 
and Western blot analysis using the ovine anti His-tag antibody (Figure 4.4 and Figure 4.5). 
 
Figure 4.4: rpTbCOX expression in E. coli strain BL21 (DE3) and inclusion body preparation 
with lauroylsarcosine.  
(A) Following induction with IPTG, the bacteria were lysed by sonication and the cell supernatant 
was separated from the pellet by centrifugation. Shown is the 10% reducing SDS-PAGE analysis 
of uninduced and induced cell lysates. The subsequent pellet fractions were used for inclusion 
body preparation with lauroylsarcosine. Lane M: prestained molecular weight marker; lane 1: 
pellet fraction from uninduced cells; lane 2: pellet fraction from induced cells; lane 3: supernatant 
fraction from inclusion body preparation with lauroylsarcosine; lane 4: inclusion body preparation 
with lauroylsarcosine. The gel was stained with Coomassie Brilliant Blue. 
(B) Shown is the Western blot analysis of the former SDS PAGE gel using the antiHis-tag 
antibody. Upon addition of IPTG (+), the cells efficiently express the rpTbCOX protein. Lane M: 
prestained molecular weight marker; lane 1: protein extract from uninduced cells; lane 2: protein 
extract from induced cells; lane 3: supernatant from inclusion body preparation with 
lauroylsarcosine; lane 4: inclusion body preparation with lauroylsarcosine.  
 70 
 
Figure 4.5: SDS-PAGE and Western blot analysis of rpTbCOX after the redox refolding 
procedure to determine the approximate size and yield. The recombinant rpTbCOX was quite 
stable to be load onto a Ni-NTA column after the refolding procedure under ÄKTA-FPLC. Lane 
M: protein molecular weight marker; lane 1: inclusion bodies solubilized with GuHCl, ß-
mercaptoethanol and step-wise dialysis with GSH/GSSH plus L-arginine. 
The rpTbCOX was successfully purified by one-step affinity chromatography using a Ni-NTA column on the 
ÄKTA-FPLC system following the protocol described in section 3.2.6.3. The protein profile (of the 
rpTbCOX) as eluted from the Ni-NTA column after the ÄKTA-FPLC run is presented in Figure 4.6. The flow 
through and elution fractions were immediately analyzed by SDS-PAGE and silver staining (Figure 4.6 B). 
Mass spectrometry confirmed the identity of the purified protein. 
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Figure 4.6: IMAC purification of the GuHCl-denatured rpTbCOX after refolding of the protein 
from inclusion bodies. (A) Chromatogram of the Ni-NTA chromatography illustrating the flow 
through (FT) and the Elution peak (E) of rpTbCOX. The Y-axis shows arbitrary absorbance units 
at 280 nm; the X-axis shows different fractions collected. The green solid line represents the 
imidazole gradient from 0 to 500 mM, passing through the elution peak (E).  
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The fractions A1 to A12 were pooled and loaded onto the gel as shown in Figure 4.4 B. (B) Silver 
stained SDS-PAGE gel, indicating the identity of the purified rpTbCOX. Lane M: protein 
molecular weight marker; lane 1: pooled eluted fractions A1 to A12; lane 2: pooled eluted fractions 
A1 to A12 after concentration using centricon with a molecular weight cut-off (MWCO) of 10 kDa 
(Millipore). 
The pooled and concentrated elution fractions did not show any cyclooxygenase activity after performing a 
thin layer cyclooxygenase activity assay (section 3.2.6.4) (data not shown). 
 
4.3 Cloning and expression of pTbCOX in Sf9 insect cells and in vivo 
 protein crystallization 
The pTbCOX gene sequence (Tb427.10.13790/Tb927.10.13790) was obtained from the T. brucei genome 
databank (Tritrypdb or Genedb). For PCR amplification of the pTbCOX, specific forward and reverse primers 
with BamHI and HindIII restriction sites were designed using Primer 3 software (see section 3.1.6). The 
pTbCOX gene was amplified by PCR using the above primers, AccuPrime Tag DNA polymerase (Invitrogen) 
and the trypanosome genomic DNA as a template (see section 3.2.1.1), following the protocol described in 
section 3.2.1.2. The TbCOX gene was successfully amplified and visualized in 1% agarose gel electrophoresis. 
The expected size of the TbCOX PCR product was 2079 bp and a band was seen at 2 kb. The respective gel 
is presented in Figure 4.7. 
 
Figure 4.7: PCR amplification of the pTbCOX gene from Trypanosome genomic DNA using 
Accu Prime Tag DNA Polymerase. A 1% (w/v) agarose gel electrophoresis confirming the correct 
pTbCOX gene amplification. Lane M: molecular marker, 1 kb Gene Ruler; lane 1: pTbCOX PCR 
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product at 2 kb. 
The pTbCOX PCR product was excised and extracted from the agarose gel and the DNA concentration was 
determined following the protocol described in section 3.2.1.4. The excised PCR product was first ligated into 
pCR 2.1-TOPO TA as a subcloning vector (see section 3.2.1.5) and then transformed using chemically 
competent E. coli cells (see section 3.2.1.7). The pTbCOX-pCR 2.1 recombinant clone was digested with 
BamHI and HindIII restriction enzymes (see section 3.2.1.11) and validated to be the correct construct by 
DNA sequencing analysis (see section 3.2.1.12). 
The sample obtained by restriction digestion analysis was loaded on a 1% (w/v) agarose gel and subjected to 
electrophoresis. The result is shown in Figure 4.8.  
 
Figure 4.8: Agarose gel electrophoresis after digestion of the pTbCOX-pCR 2.1 recombinant 
clone with BamHI and HindIII. Lane M: Molecular weight marker, 1 kb Gene Ruler; lane 1: 
sample run, the upper band corresponds to the size of the vector pCR 2.1 (3929 bp), the lower 
band corresponds most likely to the size of pTbCOX (2079 bp). 
The digested product was then ligated into the target vector pFastBacHTb previously prepared and digested 
with the same restriction enzymes (BamHI and HindIII). Formation of the pTbCOX-pFastBacHTb construct 
was done following the protocol described in section 3.2.1.6. 
After ligation of the excised DNA into the donor plasmid pFastBacHTb, each ligation product was used for 
transformation of competent E. coli cells (see section 3.2.1.7). The clones were analyzed by bacterial colony 
PCR (see section 3.2.1.8) using specific pTbCOX primers. The clone containing the pTbCOX insert was 
subjected to restriction digestion analysis using BamHI and HindIII after plasmid mini -preparation (see 
section 3.2.1.9) and submitted for DNA sequencing. The sequencing results were analyzed with the NCBI 
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blast 2 sequence program, which showed that the sequence of pFastBacHTb was correct and that pTbCOX-
pFastBacHTb had no mutations. 
Figure 4.9 shows the result of the agarose gel electrophoresis for the pTbCOX-pFastBacHTb recombinant 
clones after digestion with BamHI and HindIII restriction enzymes. 
 
 
Figure 4.9: Agarose gel electrophoresis after digestion of pTbCOX-pFastBacHTb recombinant 
clones with BamHI and HindIII. Lane M: Molecular marker, 1 kb Gene Rule; lane 1 and 2: sample 
run, the upper band corresponds to the size of the vector pFastBacHTb (3930 bp), the lower band 
corresponds most likely to the size of pTbCOX (2079 bp). 
In the next step, DH10Bac E. coli cells were transformed with pTbCOX-pFastBacHTb recombinant clones to 
generate a recombinant bacmid following the protocol described in section 3.2.2.2.2. After transformation, 4 
white clones of the putative TbCOX-pFastBacHTb vector were picked and used for overnight cultures. 
Bacmid PCR analyzed the selected clones with M13 reverse and forward primers for the right clone selection 
containing the recombinant bacmid. Bacmid PCR was done following the Bac-to-Bac baculovirus expression 
system manual (Invitrogen, Germany). Figure 4.10 shows the results of the Bacmid PCR product analyzed 
with agarose gel electrophoresis. Obviously, the pTbCOX-pFastBacHTb clones contained the recombinant 
bacmid, since a band appeared at the expected size of 4509 bp (2430 bp + 2079 bp). 
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Figure 4.10: The results of the 1% (w/v) agarose gel electrophoresis showing the presence of the 
recombinant bacmid band at the expected size of about 4500 bp (4509 bp) in all four pTbCOX-
pFastBacHTb clones analyzed by Bacmid PCR. 
In the next step, the recombinant bacmid was isolated from overnight cultures of pTbCOX-pFastBacHTb 
clones following the protocol described in section 3.2.1.10. Then, the isolated bacmid containing the inserted 
pTbCOX encoding gene was used for the transfection of Sf9 insect cells (see section 3.2.2.2.3) and consecutive 
infections to produce three virus generations (P1, P2, P3). Sf9 insect cells showed first signs of infection 72 h 
after the transfection (increased cell diameter, bigger cell nuclei). 120 h or 5 days after transfection, late signs 
of infection in 80% of Sf9 insect cells were apparent (cessation of cell growth, granular appearance, 
detachment from substrate, cell lysis). 
The pTbCOX-pFastBacHTb P1 viral stock was isolated and used to generate a high titer P2 stock. 120 h after 
infection 80% of Sf9 cells showed late signs of the infection. Therefore pTbCOX-pFastBacHTb P2 viral stock 
was isolated and used to generate a high titer P3 virus stock. The above process of virus stock isolation and 
amplification was performed following the protocol described in section 3.2.2.2.4. Afterward, the virus titer 
of the P3 virus stock was determined using the Reed-Muench method (section 3.2.2.2.5).  
In the next experiment, Sf9 insect cells in 6-well plates were infected with a pTbCOX P3 virus with a MOI of 
0.1 pfu/cell and 0.2 pfu/cell for crystal production and pTbCOX protein expression (section 3.2.8.1). Figure 
4.11 showing the pTbCOX microcrystal structure obtained after 14 days post infection with pTbCOX P3 virus 
stock.  
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Figure 4.11: Light micrograph of Sf9 insect cells showing A) non-infected Sf9 cells as a negative 
control and B) P3 infected Sf9 cells containing pTbCOX microcrystals 14 days post infection. 
(Black arrows: needle shaped pTbCOX microcrystals).  
The pTbCOX crystals were isolated by centrifugation (section 3.2.8.1), concentrated (3x106 crystals/ml), 
solubilized using sodium acetate pH 3.6 (section 3.2.8.1) and identified by Western blot analysis using Anti-
His Tag antibody (section 3.2.6.7) and scanning electron microscopy (section 3.2.5.2) (Figure 4.12 and Figure 
4.13).   
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Figure 4.12: Images are showing: (A) phase contrast microscopy picture of pTbCOX isolated and 
concentrated crystals (arrowhead indicates pTbCOX crystals) and (B) Western blot analysis of 
pTbCOX solubilized crystals at ca. 74.68 kDa. Lane M: protein molecular weight marker (Page 
Ruler Prestained from Thermo Scientific); lane 1: pTbCOX crystals isolated non-concentrated; 
lane 2: pTbCOX crystals isolated and concentrated using centricon 30 kDa (Millipore). 
 
Figure 4.13: Scanning electron micrograph images of pTbCOX in vivo crystals protruding in /out 
Sf9 insect cells. Blue arrowhead indicates normal Sf9 insect cells without crystals, and the white 
arrowhead indicates pTbCOX in vivo crystals. 
The pTbCOX isolated crystals (1 x 106 crystals/ml) were analyzed by second order nonlinear optical imaging 
of chiral crystals (SONICC), based on second harmonic generation (SHG) microscopy as an approach for 
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detection and characterization of protein crystals (section 3.2.7.1). Figure 4.14 presenting the results of 
SONICC and conventional optical methods for protein crystal detection of pTbCOX. 
 
Figure 4.14: Analysis of pTbCOX crystals by SONICC. From left to right: Comparison of visible, 
second harmonic generation (SHG) and conventional UV-excited fluorescence (UV). The 
resulting signal of this second harmonic generation (SHG) process can be detected at a wavelength 
of 532 nm with SHG exposure time of 30 second. The tiny pTbCOX crystals and signal of SHG 
are shown inside the different circle. 
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Figure 4.15: X-ray powder diffraction analysis of pTbCOX crystals. The pTbCOX crystals 
showed diffraction patterns using powder diffraction. Lysozyme nanocrystals were used for 
comparison and control. 
The pTbCOX isolated in vivo crystals were solubilized with 200 µl 50 mM sodium acetate at pH 3 and 
concentrated using centricon 30 kDa centrifugal filter units (Millipore) at a centrifugation speed of 15000g at 
room temperature till approximately 30 µl volume was left. Immediately afterwards, the DLS measurement 
and CD spectroscopy were performed using Spectro Light 300 (Xtal-Concepts, Hamburg, Germany) and CD 
spectrometer J-815 (Jasco, UK) at DESY – Hamburg (Prof. Christian Betzel Laboratory). DLS measurement 
was performed with 15 µl at 20°C for 20 times 30-second measurements and CD spectroscopy was done over 
a wavelength area of 190-260 nm (15 measurements were accumulated and the buffer signal subtracted). 
The DLS measurement of sample 1 performed after pTbCOX crystals solubilization with 200 µl 50 mM 
sodium acetate pH 3.6 using a sample concentration of 6 mg protein per ml showed highly aggregated protein 
molecules (Rh around 300 nm) (Figure 4.16). 
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Figure 4.16: DLS measurement of pTbCOX crystals solubilized with 50 mM sodium acetate at 
pH 3.6 and the respective histogram plot showing highly aggregated pTbCOX protein, Rh ca. 300 
nm and MW between 1.923GDa to 1.578GDa. Sample concentration: 6 mg/ml. 
The DLS measurement of sample 2 was done by resolving pTbCOX crystals with 200 µl 50 mM sodium 
acetate at pH 3.6 using the same purification procedure as before until a volume of 30 µl was left.  Then 300 
µl of 5 mM sodium acetate buffer (1:10 dilution of 50 mM sodium acetate buffer in bidistilled water) was 
added. The above sample was centifuged again at 15000g at RT using the centrion until a volume of 30 µl left 
and then diluted 1:10 with bidistilled water. The final solution containing the pTbCOX crystals in 0.5 mM 
sodium acetate at pH 3.6 was transferred to a new Eppendorf vessel and centrifuged for 1 h at 15000g to get 
rid of any remaining precipitate. The final sample concentration was 1 mg protein per ml and showed 
monomeric protein molecules with Rh 4.30 ± 0.50 nm and a MW of approximately 89 kDa (Figure 4.17). The 
CD spectroscopy was performed by resolving the pTbCOX crystals in 50 mM sodium acetate pH 3.6 after 1:3 
dilution with bidistilled water (16.7 mM sodium acetate pH 3.6). The CD spectra showed that pTbCOX protein 
is stable and properly folded in the above optimal buffer condition (Figure 4.18 A). The pTbCOX protein 
secondary structure estimated by using Yang’s reference (Yang et al., 1986) revealed 25.7% helix, 27.7% beta 
sheet, 16.4% beta turn and 30.2% random (Figure 4.18 B). 
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Figure 4.17: DLS measurement of pTbCOX crystals solubilized with 0.5 mM sodium acetate at 
pH 3.6 and the respective histogram plot showing monomeric protein molecules with Rh 4.30 ± 
0.50 nm and a MW of approximately 89 kDa. Sample concentration 1 mg/ml.  
 
Figure 4.18: Circular Dichroism spectra of the pTbCOX crystals resolved in 16.7 mM sodium 
acetate pH 3.6. (A) CD spectrum of pTbCOX and (B) Secondary Structure Estimation of pTbCOX 
using Yang’s reference (Yang et al., 1986). 
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4.4 pTbCOX RNA interference (RNAi) studies and phenotypes analysis 
To investigate and validate the physiological function of the pTbCOX hypothetical protein (Tb427.10.13790) 
in T. brucei, a pTbCOX-knockdown (pTbCOX-KD) fragment of the encoding gene (position 427 bis 991, 
size: 565 bp) was cloned into an RNAi expression vector (p2T7Ablue) (Figure 4.21 A) which contained two 
opposing promoters and allowed transcription of the double-stranded RNA upon doxycycline or tetracycline 
induction.  
For PCR amplification of the pTbCOX-KD fragment, specific forward and reverse primers with XhoI and 
BamHI restriction sites were designed using TrypanoFAN (Trypanosoma brucei Functional Genomic Project) 
(see 3.1.14). 
The pTbCOX-KD fragment was amplified by PCR using the above primers, high proofreading AccuPrime 
Tag DNA polymerase (Invitrogen) and the trypanosome genomic DNA as a template following the protocol 
described in section 3.2.1.2. 
The pTbCOX-KD fragment was successfully amplified and visualized by 1% agarose gel electrophoresis. The 
expected size of the TbCOX-KD PCR product is 577 bp. The results of the gel for pTbCOX-KD fragment 
amplification from trypanosome genomic DNA as template are presented in Figure 4.19. 
 
Figure 4.19: PCR amplification of a pTbCOX-KD fragment from trypanosome genomic DNA 
using Accu Prime Tag DNA Polymerase. A 1% (w/v) agarose gel electrophoresis suggesting the 
pTbCOX-KD fragment amplification. Lane M: Molecular marker, 1 Kb Gene Ruler (Thermo 
Fisher Scientific); lane 1: pTbCOX-KD PCR product sized range of about 577 bp. 
The pTbCOX-KD fragment was excised and extracted from the agarose gel and the DNA concentration was 
determined following the protocol described in section 3.2.1.4.   
The pTbCOX-KD PCR product was first ligated into pCR 2.1-TOPO TA as a subcloning vector (see section 
3.2.1.5) and transformed using chemically competent E. coli cells (see section 3.2.1.7). The pTbCOX-KD-
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pCR 2.1 recombinant clones were digested with XhoI and BamHI restriction enzymes (see section 3.2.1.11) 
and validated to be the correct construct by DNA sequencing analysis (see section 3.2.1.12). 
The sample from the restriction digestion was analyzed by agarose gel electrophoresis. Figure 4.20 shows the 
result of the agarose gel electrophoresis.  
 
Figure 4.20: Agarose gel electrophoresis after digestion of the pTbCOX-KD-pCR 2.1 
recombinant clones with XhoI and BamHI. Lane M: Molecular marker, 1 Kb Gene Ruler (Thermo 
Fisher Scientific); lane 1: Clone 1; lane 2: Clone 2. The upper band corresponds to the size of the 
vector pCR 2.1 (3929 bp), and the lower band corresponds to the size of pTbCOX-KD (577 bp). 
The pTbCOX-KD digest product was then ligated into the RNAi vector p2T7Ablue (6740 bp) (see Figure 
4.21) previously prepared and digested with the same restriction enzymes (XhoI and BamHI). The production 
of the pTbCOX-KD-p2T7Ablue construct was done following the protocol described in section 3.2.1.5. After 
ligation of the pTbCOX-KD fragment into the RNAi vector p2T7Ablue, each ligation product was used for 
transformation of competent E. coli cells (see section 3.2.1.7) and the clones were analyzed by bacterial colony 
PCR (see section 3.2.1.8) using specific pTbCOX-KD fragment primers (Figure 4.21).  
The clone that contained the pTbCOX-KD insert was subjected to restriction digestion analysis using XhoI 
and BamHI after plasmid mini-preparation (see section 3.2.1.9) (Figure 4.21) and submitted for DNA 
sequencing. The results were analyzed with the NCBI blast 2 sequence program. The pTbCOX-KD-
p2T7Ablue construct contained one single point mutation, which was not relevant for the further experiments 
in respect to RNAi mechanisms consisting of the depletion of mRNA of the target gene using the RNAi 
enzymatic machinery to cleave the translated dsRNA into small interfering RNA (25 nt). 
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Figure 4.21: A) p2T7Ablue RNAi vector (6470 bp) picture from TrypanoFan; B) Validation of 
the pTbCOX-KD-p2T7Ablue construct by colony PCR; and C) Restriction analysis of the 
pTbCOX-KD-p2T7Ablue construct using XhoI and BamHI. A 1% (w/v) agarose gel 
electrophoresis confirms the pTbCOX-KD-p2T7Ablue. Lane M: Molecular marker, 1 Kb Gene 
Ruler (Thermo Fisher Scientific); Lanes 1, 2 and 3 represent different pTbCOX-KD-p2T7Ablue 
recombinant clones. 
After the cloning strategy of the pTbCOX RNAi construct (pTbCOX-KD-p2T7Ablue construct) was 
successful, bloodform SMB trypanosomes were prepared in cell culture as described in section 3.2.2.2.6. SMB 
trypanosomes were transfected with the pTbCOX-KD-p2T7Ablue construct (10 µg), afore linearized with 
NotI restriction enzyme, by electroporation following the SMB transfection protocol (see 3.2.2.2.6). 
The NotI linearization of pTbCOX RNAi construct was confirmed and visualized by agarose gel 
electrophoresis (Figure 4.22). 
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Figure 4.22: NotI linearization of the pTbCOX-KD-p2T7Ablue construct visualized by agarose 
gel electrophoresis. Black narrow shows the 6473 bp size expected of the recombinant pTbCOX-
KD-p2T7Ablue construct after NotI single digestion. 
The transfected pTbCOX-KD SMB cells were selected and maintained by in vitro cultivation as described in 
section 3.2.2.2.6 under Geneticin (2 µg/ml) and Hygromycin (2 µg/ml) antibiotics selection pressure for 
further experiments. During this investigation, two different clones of pTbCOX-KD SMB cells were generated 
and cryopreserved, named pTbCOX RNAi clone T1.1 and pTbCOX RNAi clone T2.2, respectively. Both cell 
lines were picked from different electroporation experiments 2 and 5 days post electroporation. 
After selection of transgenic clones, post-transcriptional silencing of the pTbCOX target gene was validated 
and confirmed by quantitative real-time PCR (qRT-PCR) as a standard gold method for measuring the steady 
state of mRNA levels (see 3.2.3). For the qRT-PCR experiments, specific primers were designed respectively 
for pTbCOX (target gene-sized 165 bp) and for ß-tubulin (reference gene-sized 76 bp) using Primer 3 and 
Primer NCBI blast software (see 3.1.6). 
The “Power SYBR® Green RNA-to-CTTM” 1-Step Kit from Applied Biosystems, which combines reverse 
transcription and qPCR in a buffer system, was used to perform the qRT-PCR as described in section 3.2.3.3.  
Since the SYBR® Green fluorescence signal, which is used to quantify the amplified amount of DNA, does 
not allow any conclusions to be drawn about the quality and specificity of the qRT-PCR amplification, these 
parameters had to be examined separately. 
The specificity and the degree of purity of the PCR products were carried out immediately following the qRT-
PCR by melting curve analysis. The melting curve showed symmetrical peaks with identical peak maxima.  
This symmetrical peak is an indication of the quality of primers and confirms the emergence of a single PCR 
product. The resulting qR-PCR products were validated for pTbCOX (target gene) and ß-tubulin (reference 
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gene) by gel electrophoresis analysis. The observed bands (Figure 4.23) are approximately the same as the 
expected product sizes. 
Therefore, these results suggested the correct and specific amplification of the designated cDNA sequence 
regions for both the β-tubulin (reference gene) and the pTbCOX (target gene). 
 
Figure 4.23: 5% (w/v) agarose gel electrophoresis for validation of the qRT-PCR products. Lane 
M: O’GeneRuler Ultra Low Range DNA Ladder. Expected product sizes were 76 bp for ß-tubulin 
and 165 bp for the pTbCOX. 
The evaluation of the qRT-PCR was carried out as described under 3.2.3.4, according to the method of Pfaffl 
(2001). From the CT values of the dilution series, a standard curve was created for each primer pair (Figure 
4.24). 
The qRT-PCR amplification efficiency could be determined from the resulting slope of the compensating 
straight lines. For pTbCOX, the efficiency was E pTbCOX of 2.11, and for β-tubulin, an E β-tubulin of 2.16 
was obtained. 
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Figure 4.24: Standard curves for qRT-PCR amplification efficiency. 
Figure 4.25 presents the results of pTbCOX mRNA levels following 18 h, 42 h and 66 h of RNAi induction 
of the pTbCOX RNAi clone T1.1 and pTbCOX RNAi clone T2.2. The concentration of pTbCOX-mRNA 
decreased in both clones to approximately 50% after 18 h and 42 h post-induction by doxycycline and in clone 
T2.2 to about 25% 66 h post-induction in comparison to the 100% SMB non-transfected cells.  
 
Figure 4.25: qRT-PCR analysis of pTbCOX mRNA levels after 18 h, 42 h and 66 h of RNAi 
induction by doxycycline, 1 µg/ml. Data were normalized to ß-tubulin mRNA expression. Data 
represent the means ± SD of three independent experiments. 
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Next, both clones (T1.1 and T2.2) were characterized individually to assess the effects of the pTbCOX gene 
depletion on the proliferation of T. brucei bloodstream forms.  
RNAi was induced by addition of doxycycline (1 µg/ml), and the cell growth was monitored daily using a 
hemocytometer (Neubauer). Cells culture densities were maintained between 2.5 x 104 and 1 x 106 cells/ml 
for keeping the cell growing by daily dilution. The results shown in Figure 4.26 reveal that the pTbCOX RNAi 
progressively decreases the proliferation of T. brucei bloodstreams forms in both, clone T1.1 and T2.2, as 
compared to the non-transfected SMB trypanosomes (WT). 
 
Figure 4.26: Growth curves of RNAi cells lines following the presence (+ Doxy) or absence (- 
Doxy) of 1 µg/ml doxycycline, in comparison to non-transfected SMB cells lines. The data 
represent the means ± SD of two biological replicates. 
After the in vitro proliferation experiments of RNAi cells lines after doxycycline induction, the RNAi-
mediated knockdown of the pTbCOX gene caused dramatic changes in the morphology of T. brucei 
bloodstreams forms. We thus moved forward to fully characterize the morphology of the pTbCOX depleted 
cells using light, fluorescence and electron microscopy. The control SMB trypanosomes cells (without RNAi 
induction) and the cells depleted of pTbCOX by RNAi were fixed, either DAPI stained or negative stained 
and examined by light or electron microscopy at different times (0 h, 6 h, 24 h, 48 h, and 72 h) after induction 
of RNAi by 1 µg/ml doxycycline.  
Interestingly, the functional analyses of the pTbCOX gene by RNAi resulted in the appearance of two major 
phenotypes: 
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(i) Monster cells with multiple nuclei and multiple flagella, thus suggesting a direct or indirect role in cell 
division coordination. Those cells progress through multiple rounds of organelle replication but were not able 
to complete cytokinesis (see Figure 4.27 and Figure 4.28). 
(ii) Trypanosomes either multi-nucleated or not, displaying a massive enlargement of the flagellar pocket (“big 
eye” phenotype) (see Figure 4.28 and Figure 4.29). 
Afterward, we produced real time videos of pTbCOX knockdown trypanosomes (data not shown). Our live 
videomicroscopy showed representatives pTbCOX-KD trypanosomes monster cells and big eye phenotypes. 
Trypanosomes showing a knockdown of pTbCOX were fixed and DAPI stained to analyze the kinetoplast-
nucleus configuration at various times post doxycycline induction (0 h, 24 h, 48 h, and 72 h). Figure 4.30 
shows the result of the pTbCOX silencing. Obviously, the knockdown causes a partial cell cycle arrest and 
led to accumulation of bloodstream cells with abnormal karyotypes. 
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Figure 4.27: (A) Scanning electron micrographs of pTbCOX RNAi cells 24 h post-induction of 
RNAi showing monster cells with multiples nuclei and multiple flagella. (B) Electron micrographs 
of whole-mount negative stained trypanosomes 96 h after doxycycline induction. The cells show 
3 nuclei, 3 basal bodies and 3 flagella. (C) Transmission electron micrograph taken 42 h after 
doxycycline induction shows multiple nuclei and flagella as well as protrusion of the cell body 
associated with peripheral flagella, corresponding to giant cells. Abbreviations: N, nucleus; F, 
flagellum; FT, flagellar pocket; M, mitochondrion and BB, basal bodies. 
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Figure 4.28: (A) and (B) are representative images of DAPI-stained pTbCOX RNAi clone T1.1 
at different time points in the presence of doxycycline (1 µg/ml). (A) representative images of 
multinucleated and multi-flagellated phenotypes observed after 6 h doxycycline induction; (B) 
shows mainly the “Big Eye” phenotype. The images were made using a Zeiss Fluorescence 
Microscope. Abbreviations: N, nucleus; K, kinetoplast, and Dox, doxycycline. 
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Figure 4.29: Representative images of the morphological changes of the pTbCOX depleted cells 
after RNAi induction. (A) Electron micrographs are showing negative stained pTbCOX RNAi 
trypanosomes 6 h after doxycycline induction and Transmission electron micrograph showing 
pTbCOX RNAi trypanosomes 42 h after doxycycline induction. The flagellar pocket is 
significantly enlarged. (B) Scanning electron micrograph of pTbCOX RNAi cells 24 h after 
doxycycline induction showing the “Big Eye” phenotype: parasites displaying a massive 
enlargement of the flagellar pocket. Abbreviations: N, nucleus; F, flagellum; FT, flagellar pocket; 
G, glycosome; M, mitochondrion; AC, acidocalcisome. 
 93 
 
Figure 4.30: Kinetoplast-nucleus configurations of the pTbCOX-KD RNAi cell line at various 
time points post-induction. Parasites with abnormal karyotypes are subcategorized into multi-
nucleated flagellated cells (˃2K2N) and other (0K1N, 1K0N, 1K2N, 0K2N). Fluorescence 
microscopy assessed the number of kinetoplasts (K) and nuclei (N) following DNA-staining with 
DAPI. At least 100 individual cells were analyzed at each time point. Non-transfected SMB cell 
line (NT) served as a control. 
 
4.5 Cloning, expression, and localization of an eGFP fused with pTbCOX 
 protein in Trypanosoma brucei  
For PCR amplification of the pTbCOX, specific forward and reverse primers with HindIII and PvuII restriction 
sites were designed using Primer 3 software (see section 3.1.6). The pTbCOX gene was amplified by PCR 
using high fidelity AccuPrime Tag DNA polymerase (Invitrogen) and the trypanosome genomic DNA as a 
template (see section 3.2.1.1) following the protocol described in section 3.2.1.2. The TbCOX gene was 
successfully amplified and visualized in 1% agarose gel electrophoresis. The expected size of the TbCOX 
PCR product is 2079 bp (2 kb). Figure 4.31 shows the results of the pTbCOX gene amplification from 
trypanosomal genomic DNA as template. 
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Figure 4.31: PCR amplification of the pTbCOX gene from trypanosome genomic DNA using 
Accu Prime Tag DNA Polymerase. A 1% (w/v) agarose gel electrophoresis confirming the 
pTbCOX gene amplification. Lane M: Molecular marker, 1 Kb Gene Ruler (Thermo Fisher 
Scientific); Lane 1: pTbCOX PCR product sized range of 2079 bp (2 kb). 
The pTbCOX PCR product was excised and extracted from the agarose gel. The DNA concentration was 
determined following the protocol described in section 3.2.1.4. The pTbCOX PCR product was first ligated 
into pCR 2.1-TOPO TA as a subcloning vector (see section 3.2.1.5) and transformed using chemically 
competent E. coli cells (see section 3.2.1.7). The pTbCOX-pCR 2.1 recombinant clone was validated to be 
the correct construct by colony PCR and DNA sequencing analysis (see section 3.2.1.12). Figure 4.32 shows 
the results of the colony PCR analysis using agarose gel electrophoresis. 
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Figure 4.32: Colony PCR of pTbCOX-pCR 2.1 recombinant clones after chemical transformation 
in E. coli. A 1% (w/v) agarose gel electrophoresis suggested the pTbCOX gene amplification. 
Lane M: Molecular marker, 1 Kb Gene Ruler; lane 1 to 3: colonies from pTbCOX-pCR 2.1 from 
the plate (pTbCOX insert ca. 2 kb). 
The pTbCOX-pCR 2.1 was digested with HindIII and PvuII restriction enzymes (see section 3.2.1.11) and the 
sample from the restriction digestion analysis was loaded onto a 1% (w/v) agarose gel. Figure 4.33 shows the 
result of the above restriction digestion analysis by agarose gel electrophoresis.  
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Figure 4.33: A) Illustration of restriction digestion analysis of pTbCOX-pCR 2.1 using 
DNAMAN software showing in lane 1: pTbCOX-pCR 2.1 single digests with HindIII; lane 2: 
pTbCOX-pCR 2.1 single digest with PvuII; and lane 3: pTbCOX-pCR 2.1 digests with HindIII 
and PvuII. B) 1% (w/v) agarose gel electrophoresis of the pTbCOX-pCR 2.1 digested with HindIII 
and PvuII. Lane 1: pTbCOX-pCR 2.1 digests with HindIII and PvuII like predicted in A lane 3. 
C) 1% (w/v) agarose gel electrophoresis of the band ca. 2000 bp lane 1 in B excised and extracted 
showing a single band of pTbCOX at the right bp size. 
The pTbCOX gene was ligated into the pCO57 vector. This vector allows the expression of eGFP fusion to 
the c-terminus of the desired protein and contains an inducible T7 expression site, which is regulated by a 
tetracycline operator. Figure 4.34 A shows the results of the ligation and double digestion analysis of the 
pTbCOX-pCO57 construct with HindIII and PvuII restriction enzymes by agarose gel electrophoresis 
analysis. 
The right and validated pTbCOX-pCO57 construct was linearized with EcoRV (Figure 4.34 B) and then 
electroporated into SMB cells, which express a T7RNA polymerase and a tetracycline repressor. The 
electroporated pTbCOX-pCO57 SMB cells line were selected and maintained in in vitro culture as described 
in section 3.2.2.2.6 under Geneticin (2 µg/ml) and Phleomycin (2.5 µg/ml) antibiotics selection pressure for 
expression of the pTbCOX fused with eGFP in Trypanosoma brucei. 
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I observed that the expression of the green fluorescence pTbCOX protein was leaky and resulted in the death 
of the electroporated SMB cells 4 days after transfection. Using Zeiss fluorescence microscopy, live imaging 
of SMB trypanosomes produced single or multi punctuated green fluorescent signals (see Videos).  
Next, the electroporated pTbCOX-pCO57 SMB cells line were fixed in 2.5% glutaraldehyde and DAPI stained 
for fluorescence microscopy analysis. This experiment showed that the pTbCOX green fluorescent protein 
was not located in the cytosol but appeared as a single dot near the kinetoplast or between kinetoplast and 
nucleus (Figure 4.35). The pTbCOX fused eGFP overexpression was extremely fast lethal for bloodstream 
form parasites. 
 
Figure 4.34: A) 1% (w/v) agarose gel electrophoresis after digestion of the pTbCOX-pCO57 
recombinant clones with HindIII and PvuII. Lane M: Molecular marker, 1 Kb Gene Ruler; lane 1: 
Non-digested pTbCOX-pCO57 plasmid; lane 2: digested pTbCOX-pCO57 construct. The upper 
band corresponds to the pTbCOX-pCO57 HindIII & PvuII digested (ca. 6000 bp), and the lower 
band corresponds to the size of pTbCOX (ca. 2000 bp). B) 1% (w/v) agarose gel electrophoresis 
of EcoRV linearization the pTbCOX-pCO57 construct prior to electroporation in SMB 
trypanosomes cells. Lane 1: pTbCOX-pCO57 plasmid and lane 2: pTbCOX-pCO57 EcoRV 
linearized. 
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Figure 4.35: Fluorescence micrographs of SMB trypanosomes expressing pTbCOX fused with 
eGFP protein. A) The image is showing green dot signal near the kinetoplast and B) Image 
showing green dot signal between the kinetoplast and nucleus. The images were made from Zeiss 
Fluorescence Microscope (exposure time: DAPI: 50ms, GFP: 200ms and BF: 100ms) and 
prepared using image J software. Abbreviations: N, nucleus and K, kinetoplast. 
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5  Discussion 
5.1 Bioinformatics analysis of the hypothetical protein pTbCOX 
A hypothetical protein from T. brucei was found in our search for a putative COX-like enzyme (pTbCOX) 
using Western blot analysis, peroxidase activity assay and mass spectrometry analysis.  
We were interested to analyze pTbCOX using different bioinformatic tools. No hit was found in terms of 
specific motif domains, such as signal peptides or membrane anchors. More importantly, however, no 
homolog proteins have been detected in human or other organisms, except kinetoplastida. pTbCOX is a 74.68 
KDa protein encoded by a 2043 bp gene. Blast analysis using NCBI showed 100% identity with other 
conserved hypothetical proteins of other kinetoplastid species. The facts that, firstly, no homolog proteins 
seem to exist in other organisms, secondly, pTbCOX seems to be a well conserved protein expressed in the 
whole kinetoplastids family, and thirdly, it is essential for T. brucei, renders this protein into an interesting 
target for new drugs against kinetoplastid diseases. However, this protein remains to be assessed against other 
drug target validation criteria such as structure information, assayability, druggability, selectivity/  toxicity and 
resistance potential (Agüero et al., 2008; Field et al., 2017). 
Furthermore, the bioinformatic analysis of pTbCOX revealed the presence of -helices and ß-strands, 
considerable coiled-coil structures and a large number of putative phosphorylation sites (Ser/Thr/Tyr) (Figure 
4.1 and Figure 4.2). Cellular signaling is driven mainly by protein phosphorylation and de-phosphorylation 
events, which are controlled by protein kinases and protein phosphatases (Batista et al., 2017). It has been 
shown that protein phosphorylation is a key regulator of signal transduction pathways that, thus far, has been 
studied in T. brucei principally through the knockdown of putative kinases and the observation of resulting 
phenotypes (Nett et al., 2009).  
Unfortunately, our blast analysis of pTbCOX with well known protein kinases or other kinase-like proteins in 
T. brucei genome did not reveal any similarity in terms of specific or characterized kinase catalytic domains. 
To the best of our knowledge, pTbCOX is so far not listed in any research study attempted to identify 
trypanosomal phosphoprotein using phosphoproteomics approaches (Jones et al., 2015; Marchini et al., 2014; 
McAllaster et al., 2015; Nett et al., 2009; Urbaniak et al., 2013). 
The fact that pTbCOX possesses several phosphorylation sites (Ser/Thr/Tyr) may suggest that a cellular 
activity associated with cell proliferation and differentiation is at work, and this shall be addressed in the future 
by using mass-spectrometry based phosphoproteomics and RNA-Sequencing. 
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5.2 Heterologous expression, refolding and purification of pTbCOX 
The pTbCOX was amplified and successfully cloned in E. coli. Heterologous expression of pTbCOX was 
clearly achieved, but the protein formed inclusion bodies (IB). Inclusion bodies are insoluble protein 
aggregates that often occur during high level expression of hydrophobic proteins. Recombinant protein 
synthesis in E. coli, especially when driven by a strong promoter such as the T7 promoter, happens at a faster 
rate which leads to misfolding and accumulation of insoluble protein within the cells (Lebendiker and Danieli, 
2014; Rosano and Ceccarelli, 2014). In this study, cloning of the pTbCOX gene was done in a pProExHTa 
vector system. The protein was highly expressed, but always found in the pellet fraction despite the use of 
different IPTG concentrations and induction times. Multiple attempts were made to modify the level of protein 
expression and to promote the solubility of pTbCOX in E. coli. Many studies showed that growing host cells 
at lower temperatures, co-expressing the protein of interest with chaperones and foldases and using other 
solubilizing Tag-fusion partners (MBP, NusA and GST) might improve the solubility of the protein expression 
in bacteria (Deller et al., 2016; Lebendiker and Danieli, 2014; Walls and Loughran, 2011). 
A number of host cells are available which have been reported to be efficient in soluble protein expression. In 
this study, the host strains used were E. coli BL21 (DE3). This strain was designed to enhance the expression 
of eukaryotic proteins that either may be toxic to the host cell or may be cleaved by endogenous proteases. 
For this purpose, it contains the T7 polymerase that is activated only after IPTG induction, and this strain is 
deficient of Lon and omp-t proteases and is therefore suitable for protein expression (Deller et al., 2016). 
Many factors have been reported to lead to protein instability and aggregation. First, once the recombinant 
protein is expressed in a new E. coli microenvironment which may differ from that of the original source in 
terms of pH, redox potential, osmolarity, cofactors, and folding mechanisms (Deller et al., 2016). Second, the 
recombinant protein contains a considerable number of hydrophobic amino acids that may co-interact thus 
leading to protein aggregation and inclusion body formation (Baneyx and Mujacic, 2004). This last scenario 
fits well with pTbCOX, because the hydrophobicity plot analysis revealed a high content of hydrophobic 
amino acids within the sequence (Figure 4.3). It has been demonstrated that the high numbers of aromatic and 
aliphatic residues (ala, cys, val, ile, leu, met, phe, and tryp) are thought to decrease the solubility of proteins 
during refolding and contribute to the aggregation of protein folding intermediates (Burgess, 1996, 2009).  
Since the commonly used methods to express soluble protein were not successful with pTbCOX, a more 
laborious technique known as inclusion body solubilization and refolding was performed to obtain soluble 
pTbCOX, properly fold and in its active forms.  
This technique is time consuming and often yields a poor recovery (Yamaguchi and Miyazaki, 2014), but 
many studies have shown that it is possible to successfully refold inclusion body proteins to their biologically 
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active states. The inclusion body form of pTbCOX was solubilized first using the weak ionic detergent 
lauroylsarcosine, which was reported to effectively reduce hydrophobic aggregation and allow the recovery 
of monomeric, active protein molecules from inclusion bodies (Burgess, 1996, 2009). The results of this first 
approach are presented in chapter 4 (Figure 4.4). 
In a second approach, strong denaturants such as guanidine hydrochloride and step-wise dialysis was used as 
refolding strategy. Many studies have shown that protein refolding from denatured protein is influenced by 
several factors, including solubility of the respective protein, removal of denaturants, and assistance of 
refolding by a co-solute or by other additives (Yamaguchi and Miyazaki, 2014). 
Unfortunately, all the afore mentioned attempts to purify pTbCOX using affinity chromatography on the 
ÄKTA FPLC system from the lauroylsarcosine approach were unsuccessful, because the pTbCOX was not 
binding to the Ni-NTA column and appeared always in the flow through.  
The final approach, i.e. treating the pTbCOX inclusion bodies with high grade strong denaturant GuHCl plus 
the reducing agent ß-mercaptoethanol and a step wise dialysis refolding by adding GSH/GSSH and L-arginine 
were reasonably effective for refolding pTbCOX. This step wise dialysis technique included denaturation, 
reduction of the disulphide bonds and then generation of the corrected bond configuration by includi ng 
GSH/GSSH to prevent protein aggregation of partially folded intermediates by addition of L-arginine. This 
technique has been used previously for the refolding of two ScFv antibodies constructions (Arakawa and 
Ejima, 2014). 
Arginine hydrochloride or arginine has been applied for refolding of a variety of proteins from inclusion 
bodies, such as casein kinase (Lin and Traugh, 1993), gamma interferon (Arora and Khanna, 1996), p53 tumor 
suppressor protein (Bell et al., 2002), and interleukin-21 (Asano et al., 2002). The exact molecular mechanism 
of arginine is still not well understood. Arginine hydrochloride has a guanidinium group (Gdn) at the distal 
end of its side chain, similar to GuHCl. The Gdn strongly interacts with hydrophobic amino acids in hen egg-
white lysozyme (Mande and Sobhia, 2000) and act as a strong chaotropic agent. The crystal structure of the 
lysozyme-arginine complex showed that arginine bound at sites different from those of Gdn, and mildly 
interacted with nearby hydrophobic amino acid of the protein surface (Ito et al., 2011). These interactions 
included electrostatic, hydrophobic and cation-π interactions. Compared with Gdn, the amino and carboxyl 
groups of arginine form weaker hydrogen bonds with the denatured protein and water. Thus, arginine might 
act as an aggregation inhibitor due to its moderate binding to protein (Matsuoka et al., 2009). 
In addition, proline has also been reported to enable proteins to refold to their native (active) conformations. 
It was proposed that proline inhibits protein aggregation by binding to the folding intermediate in the 
supramolecular assembly with proline (Samuel et al., 2000). 
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The pTbCOX refolding strategy using the second approach was successful to purify the protein applying a 
one-step Ni-NTA affinity chromatography on an ÄKTA FPLC. The results are presented in Figure 4.5 and 
Figure 4.6. 
The purified pTbCOX was than dialyzed overnight and checked for stability. DLS measurement, however, 
demonstrated that the purified pTbCOX was highly aggregated (data not shown) and the COX activity test 
performed using sensitive TLC radioactive assay on the pTbCOX was negative (data not shown).  
 
5.3 Heterologous expression of pTbCOX in Sf9 insect cells and in vivo 
 protein crystallization 
In order to produce a proper folded and active pTbCOX with post-translational modifications, a new construct 
was generated using the baculovirus expression vector pFastBacHTb for production of this protein in Sf9 
insect cells and in vivo protein crystallization. In vivo protein crystallization has been mostly reported by using 
a heterologous expression system based on the polyhedrin promoter (Koopmann et al., 2012; Redecke et al., 
2013a; Schönherr et al., 2015). Using this system, several proteins with unrelated functions, structure and 
physico-chemical properties have now been reported to crystallize in vivo, suggesting that this strategy could 
be routinely used for structure determination alongside classical crystallographic approaches (Boudes et al., 
2016; Duszenko et al., 2015). We have employed this baculovirus system in the past to produce in vivo protein 
crystals of cathepsin B and inosine monophosphate dehydrogenase from T. brucei (Duszenko et al., 2015). 
TbCatB in vivo crystals have been subjected to free-electron laser based serial femtosecond crystallography 
(SFX), performed in collaboration with Prof. Christian Betzel and Prof. Henry Chapman (DESY, Hamburg) 
and yielded the TbCatB structure at a resolution of 2.8 Å (Gati et al., 2014b; Redecke et al., 2013b) 
The pTbCOX was expressed in the pellet fraction or insoluble fraction (membrane-attached protein like the 
expression experiment using bacteria BL21(DE3) system) at different days post-infection and led us to 
observe an in vivo crystal-like structure inside cells after 14 days after transfection with the P3 virus stock 
(Figure 4.11 B).  
 
5.4 Characterization of pTbCOX crystals 
The pTbCOX crystals were first confirmed to consist solely of pTbCOX by Western blot analysis. For this 
purpose, in vivo crystals were isolated, concentrated, solubilized and run on SDS gels. For detection a 
polyclonal anti-his antibody was used after transfer of the protein to a nitrocellulose membrane (Figure 4.12 
B). Unfortunately, we were not able to obtain positive mass spectrometry signals of the pTbCOX because of 
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its low concentration and weak signal in the SDS-PAGE even after multiple concentration efforts using either 
Coomassie or silver staining. 
The pTbCOX was then analyzed by scanning electron microscopy. We observed the micro sized needle shaped 
crystals progressed from the Sf9 insect cells or on top of Sf9 insect cells. The mechanism by which protein 
crystallize at a specific location within the cell is still not yet clear understood. So far it has been well 
demonstrating that high local concentration of the recombinant in baculovirus-infected insect cells is the prior 
requirement to induce in vivo crystallogenesis within an organelle (Duszenko et al., 2015; Koopmann et al., 
2012). 
SONICC based SHG imaging (Figure 4.14) and X-ray powder diffraction (Figure 4.15) in Prof. Christian 
Betzel’s group at DESY were performed to confirm the crystallinity of the pTbCOX crystals. The SONICC 
revealed positive signals of the pTbCOX crystals. It has been demonstrated that the SONICC measurement is 
a selective and sensitive method for detection and characterization of protein crystals. SHG identifies protein 
crystals by imaging the samples with infrared light and detecting the frequency-doubled response specific of 
chiral crystals (Boudes et al., 2014). The SHG signals revealed the proteinaceous nature of the pTbCOX 
crystals because it has been shown that amorphous aggregation or salt crystals do not produce SHG signals. 
It should be noted that SHG imaging has its limitations: it can give false-negative results in rare instances 
when the crystal packing is of high symmetry and it can generate false-positive results if, for example, a salt 
crystal appears (Wampler et al., 2008). Subsequently, the pTbCOX crystals vs lysozyme crystals as positive 
control analyzed by powder diffraction showed diffraction ring up to 4-5 Å resolution (Figure 4.15), 
confirming a crystalline state of pTbCOX crystals. Both experiments support preliminary characterization of 
the pTbCOX in vivo crystals prior to XFEL beam or MicroED for data collection. The success of a XFEL or 
MicroED experiment is highly dependent on crystal quality, size, density and quantity. 
The solubilized pTbCOX crystals were used to assess the stability of the pTbCOX protein at the level of 
secondary structure using DLS and CD spectroscopy methods. Interestingly, DLS measurement of the 
pTbCOX crystals solubilized with different concentrations of sodium acetate buffer revealed the aggregation 
tendency behaviors of the pTbCOX protein. This screening step demonstrated the optimal condition or 
treatment by which the pTbCOX switch from a large oligomer or aggregate (Figure 4.16) to monodisperse 
molecules with a radius corresponding to the monomeric pTbCOX protein (Figure 4.17). Due to our 
observation of the pTbCOX expression in bacteria as an insoluble protein and multiple rescue procedures 
developed during this thesis including: such as refolding of denatured pTbCOX using lauroylsarcosine and 
guanidine hydrochloride plus L-arginine, alternative expression systems such as yeast, decreasing the culture 
temperature have proven not effective in producing soluble pTbCOX from T. brucei because of its high 
tendency to aggregate.  
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This result could be proposed as a new way to rescue pTbCOX so far insolubly expressed in bacteria into 
inclusion bodies to be easily solubilized by the addition of sodium acetate during bacteria cell lysis. Thus, this 
protocol should allow us to recover pTbCOX in a soluble and correctly folded form for conventional 
crystallography and structure determination. 
CD spectroscopy of pTbCOX was also done and confirmed the stability of the pTbCOX properly folded at 
12.5 mM sodium acetate buffer pH 3.6. Using this buffer, the secondary structure was estimated for the first 
time and identified the percentage of helix, sheet, turn and random-coiled of the pTbCOX using Yang’s 
reference (Figure 4.18). Therefore, the sodium acetate buffer pH 3.6 stabilizes pTbCOX and can be used for 
conventional crystallography trials and for biological assays of pTbCOX. 
 
5.5 Knockdown studies of pTbCOX gene and phenotypes analysis 
RNAi was employed to investigate the essentiality of pTbCOX in the trypanosome SMB cell line. Therefore, 
the pTbCOX-KD fragment from the encoding gene was successfully cloned into the p2T7 expression vector 
which contains two opposing promoters and, hence, allowed transcription of double stranded RNA upon 
doxycyclin induction (Figure 4.21). The recombinant vector construct was then transfected into bloodstream 
form T. brucei by electroporation. This resulted in the production of two different transgenic clones named 
pTbCOX RNAi clone T1.1 and pTbCOX RNAi clone T2.2 for further investigations. 
RNAi knockdown was efficiently and effectively confirmed by quantitative real time PCR (qRT-PCR). The 
pTbCOX mRNA levels decreased in both clones to approximately 50% after 18 h and 42 h post-induction by 
doxycycline and in clone T2.2 to about 25% 66 h post-induction in comparison to the 100% SMB non-
transfected cells (Figure 4.25). Quantitative real-time PCR demonstrated that the doxycycline mediated 
induction of RNAi resulted in a significant reduction of the pTbCOX mRNA level compare to the WT mRNA 
level. It has been observed in T. brucei knockdown experiment that reduction of mRNA level measured by 
qRT-PCR does not necessarily have to be correlated with the protein level measured by Western blot analysis 
(Clayton and Shapira, 2007). Since the level protein were not measured because of the lack of specific 
antibody against pTbCOX, we can assume that the pTbCOX was decreased more significantly in our pTbCOX 
RNAi cell lines that showed apparition of phenotypes. 
However, the use of very accurate tools such as Northern blot analysis or RNA-Sequencing are still necessary 
to be performed for the validation of the efficiency of the pTbCOX knockdown study at the RNA and pTbCOX 
expression level in T. brucei. 
Interestingly, depletion of the pTbCOX mRNA produced a progressively decrease of growth (Figure 4.26), 
gross morphological defects including multiflagellated and big eye phenotypes which was observed within 6 
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h post doxycycline induction by fluorescence microscopy (Figure 4.28). Furthermore, analysis of 
kinetoplast/nucleus progression in the pTbCOX-KD RNAi cell line revealed a partial cell cycle arrest and 
failure to initiate cytokinesis. Thus, accumulation of cells with abnormal karyotypes have been regularly 
detected (Figure 4.30). 
SEM and TEM microscopy showed that the cell periphery was highly twisted; multiple nuclei and multiple 
flagella were attached to the outside of the cell, while other cells possessed a highly enlarged flagellar pocket 
(Figure 4.27 and Figure 4.29). Taken together, these data clearly suggest that pTbCOX is essential for the 
bloodstream form of the parasite in vivo. Knockdown of pTbCOX rapidly produces “monster” cells with 
multiple nuclei and multiple flagella, thus suggesting a direct or indirect role of pTbCOX in cell cycle 
coordination. At the same time, we observed also the presence of parasites with an enlarged flagellar pocket, 
the so called big eye phenotype, after RNAi induction by doxycycline. It has been shown that both phenotypes 
generally appeared when the function of an essential flagellum protein is perturbed in bloodstream form T. 
brucei (Broadhead et al., 2006; Ralston and Hill, 2008). 
The mainly described defects incriminate after the appearance of pTbCOX KD lethal phenotypes were 
cytokinesis for the multiflagellated phenotype (Brasseur et al., 2013; Broadhead et al., 2006; Hutchings et al., 
2002; Olego-Fernandez et al., 2009; Ralston and Hill, 2008) and endocytosis for the big eye phenotype 
(Adung’a et al., 2013; Allen et al., 2003; Field and Carrington, 2009; Manna et al., 2017; Morriswood and 
Schmidt, 2015). So far, we have been unable to detect which defect appear as primary event. We found that 
both phenotypes were consistently observed 6 h post doxycycline induction. 
A possible explanation for the lethal phenotype in bloodstream cells is that cytokinesis failure results as a 
primary event from the absence of correct flagellar motility. This situation will induce a multiple round of cell 
division without cytokinesis leading to new flagella and pockets formed at inappropriate location. The lack of 
the precise morphogenetic axes in the resulting “monster cells” leads to pleiotropic effects compromising 
membrane-cytoskeleton balance during morphogenesis of the pocket structure (Broadhead et al., 2006). It has 
been suggested that the monster cells phenotype will have a perturbation of endocytosis combined with the 
secretory pathways, thus will lead to the enlargement of the flagellar pocket result on big eye phenotype as 
secondary event (Broadhead et al., 2006). Another possible scenario will be that the cytokinesis failure is not 
the one inducing the endocytosis defect producing the big eye phenotype observed during the pTbCOX 
knockdown study. 
Since pTbCOX is still not fully characterized and remains a hypothetical protein, our detailed results of the 
morphological changes induced by pTbCOX knockdown give strong light on its essentiality for the parasite. 
However, further investigations are needed to reveal the precise cellular process by which pTbCOX contribute 
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to maintain cytokinesis or the endocytic system in T. brucei in balance. Thus, we hypothesized that pTbCOX 
might participate in multiple cellular processes in T. brucei. 
 
5.6 Expression of pTbCOX protein fused with eGFP in Trypanosoma 
 brucei 
In this last experiment, we tried to identify the subcellular localization of pTbCOX inside the bloodstream 
forms of T. brucei. The pTbCOX gene was successfully cloned in the pCO57 vector. This vector allows the 
expression of eGFP fusion to the C-terminus of the desired protein and contains an inducible T7 expression 
site, which is regulated by a tetracycline operator. This system is well suited to be inserted into SMB cells, 
which express T7 RNA polymerase and a tetracycline repressor. The pTbCOX-pCO57 construct was 
successfully generated and transfected into SMB cells. Surprisingly, the pTbCOX-eGFP was firstly leaky 
expressed and secondly was readily lethal, because no transfected clones were obtained despite many attempts 
of repeated transfections with or without tetracycline or doxycycline induction, and all transfected parasite 
cultures died 4 days post transfection. We initially hypothesized that the autoinduction phenomenon might be 
linked to the pCO57 vector, the fetal bovine serum with tetracycline, or so far unknown effects of pTbCOX.  
The strategy used to decipher the autoinduction mechanism was based firstly on the expression of pTbCOX 
in SMB trypanosomes using a commercially available tetracycline-free fetal bovine serum. However, since 
overexpression of pTbCOX in SMB trypanosomes was still lethal for transfected parasites following 
tetracycline or doxycycline induction, we ruled out the autoinduction phenomenon was due to fetal bovine 
serum with tetracycline. 
However, we consistently observed a fast-lethal process of the transgenic clones expressing the pTbCOX-
eGFP fusion protein within the 4 days postinduction. One reason of this lethal phenomenon could be that the 
pTbCOX protein is tightly regulated in T. brucei. 
Video fluorescence microscopy showed different morphologies in pTbCOX-eGFP transfected bloodstream 
form parasites including: stumpy forms, intermediate forms, long slender forms and multiflagellated cells. 
This fusion protein was not homogenously distributed, but appeared as single or multiple punctate within the 
transfected bloodstream form parasites. The fluorescence imaging obtained after cell fixation and DAPI 
staining localized the pTbCOX-eGFP fusion protein as a single dot near the kinetoplast or in between the 
kinetoplast and nucleus (Figure 4.35). The biological relevance of pTbCOX localization remained 
unanswered. We could speculate that the fact that knockdown of pTbCOX induce an impairment of 
cytokinesis and endocytosis requires further investigation to proof the connection of pTbCOX with the 
flagellar apparatus of T. brucei. 
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6  Future perspectives on pTbCOX as drug target  
HAT is one of the deadly neglected tropical diseases affecting people living in sub-Saharan Africa. It is caused 
by T. brucei parasites transmitted to the human host by tsetse flies. HAT therapy still relies upon drugs which 
use is limited by toxicity and rigorous treatment regimes, while development of vaccines remains up highly 
unlikely, due to the effectiveness of antigenic variation.  There is an eminent need to identify and develop 
better drugs against HAT. 
Currently, efforts have been made to identify better drugs or new lead compounds for the treatment of HAT 
using phenotypic screening or target-based approaches. Unfortunately, there is no increase of new drug 
discovery because of the lack of a defined target that is both essential and druggable validated in the 
trypanosomatids (Field et al., 2017). Therefore, identification of novel targets which are unique and different 
to the human host must be given priorities for future genetic validation and structure determination. 
A major problem with the genome sequence of T. brucei is the failure to predict the function of the gene 
encoding hypothetical proteins, that comprise approximately 50% of the total genome. Analysis of these 
hypothetical proteins could identify new drug targets, since these genes have no equivalent in the human 
genome and may, as in the case of pTbCOX, be essential for the parasite’s survival. In addition, new protein 
structures revealing new domains or motifs, and even novel metabolic pathways may appear and contribute 
to the drug discovery pipeline. 
In this thesis, I have analyzed an annotated hypothetical protein of the T. brucei genome, called pTbCOX that 
lacks human homologs, is well conserved among kinetoplastids and was demonstrated to be essential for cell 
division and morphogenesis in bloodstream form T. brucei. Our endeavors were the move forward to 
comprehensively elucidate the structure-function of pTbCOX by cloning, expressing the pTbCOX gene using 
different expression systems.  
The first challenge of this thesis was that pTbCOX expression in bacteria led consistently to the formation of 
inclusion bodies. From those, pTbCOX was extracted using strong denaturant guanidine hydrochloride and 
finally refolded by step-wise dialysis using additives like GSH/GSSH and L-arginine. Afterwards, pTbCOX 
was purified by affinity chromatography on a Ni-NTA column using the ÄKTA FPLC system. 
The second challenge was to get a better understanding of the aggregation of pTbCOX after purification and 
to obtained a correctly folded and stable pTbCOX. For this purpose, I move forward and produced a new 
construct of pTbCOX for baculovirus expression and in vivo protein crystallization.  
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Luckily, pTbCOX seems to crystallize inside Sf9 insect cells and I was able to preliminary characterize the 
pTbCOX crystals before XFEL or MicroED beam data collection.  
Interestingly, analysis of the solubilized pTbCOX crystals from Sf9 insect cells by DLS and CD spectroscopy, 
point into the possible direction how to solve pTbCOX aggregation problem. Firstly, treatment of the pTbCOX 
expressing bacteria before cell lysis or harvesting the inclusion bodies with sodium acetate as a proposed 
mechanism to obtain the soluble recombinant protein. Or, secondly, treatment of the purified recombinant 
pTbCOX in vivo crystals via the one-step purification described in this thesis with sodium acetate by overnight 
dialysis. 
Anyway, further work needs to be done to complete the full characterization of the attractive target pTbCOX 
in the future: 
 (a) Identification of the signaling pathway where pTbCOX might play a crucial role in T. brucei. As 
bioinformatic tools revealed the presence of multiple phosphorylation sites within the pTbCOX sequence, 
mass-spectrometry-based phosphoproteomics and RNA-sequencing using a pTbCOX knockdown cell line 
will shed light on the phosphorylation patterns and gene expression levels of these cells. 
(b) Elucidating the structure of pTbCOX using conventional or in vivo protein crystallography approaches is 
also important to answer the remained question “what is the function of pTbCOX?”. The discovery of the 
pTbCOX structure will shed light on its function and to explore whether or not pTbCOX is a suitable drug 
target candidate for HAT therapy. It will also make it possible to evaluate new domain motifs or to reveal new 
biochemical pathways and cascades in the Trypanosoma biochemistry. 
In Summary, pTbCOX is well conserved and expressed in Trypanosomatids and lacks human homologs. 
Genetic knockdown studies demonstrated that it is essential for cell division and morphogenesis in 
bloodstream form T. brucei. Therefore, pTbCOX seems to be a suitable drug target candidate to be added to 
the drug discovery pipeline for HAT therapy. However, the challenge is still ongoing to obtain  native 
pTbCOX, solving its X-ray crystals structure for druggability and assayability studies. 
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7  Summary 
Trypanosoma brucei comprises a group of extracellular kinetoplastid protozoa including the causative agent 
of Human African Trypanosomiasis (HAT). Sequencing of their genomes revealed approximately 50% of 
genes which are so far uncharacterized regarding their biochemical or cellular functions but are identified as 
hypothetical proteins with no homologs in the human host. This opens possibilities for new target 
identification and drug discovery. With the initial aim of identifying the gene encoding a putative T. brucei 
cyclooxygenase (pTbCOX), Western blot and mass spectrometry analyses were used to identify a protein that 
is recognized by a cyclooxygenase ovine polyclonal antibody in trypanosome lysates. This led to a list of 
hypothetical genes, encoding a cyclooxygenase-like enzyme candidate. Among them, a gene 
(Tb427.10.13790/Tb927.10.13790) encoding a hypothetical conserved protein was immunologically 
identified at 74.68 kDa using cyclooxygenase ovine polyclonal antibody during protein expression, and it 
contained highly hydrophobic amino acids. Therefore, this protein was chosen for further experimental 
investigations.  
In the first part of this work, the bioinformatic analyses of pTbCOX were performed using BLAST/NCBI, 
Pfam, Prosite, Swiss-Pro, InterPro, TMHMM, Signal P, Hydrophobicity Plot and NetPhos to describe the 
pTbCOX gene/protein. These analyses revealed no convincing homolog proteins in human or any other 
organism, except in kinetoplastida. No hit was found regarding specific domains, signal peptides or membrane 
anchors. However, blast analysis using NCBI showed 100% identity with conserved hypothetical proteins of 
other kinetoplastid species. The hydrophobicity plot analysis revealed a high content of hydrophobic amino 
acids within the sequence. Therefore, the pTbCOX is a prime example of a protein annotated as “hypothetical 
protein” in T. brucei genome which fulfilled the above criteria, i.e., no homologs in human or any other 
organisms to be selected as an attractive target for validation. In the further work, its essentiality in T. brucei 
was analyzed. 
In the second part of this work, the full-length coding sequence of the pTbCOX gene was cloned and expressed 
as a recombinant protein in E. coli BL21 (DE3). The pTbCOX was found most entirely in an insoluble form 
inside inclusion bodies. These inclusion bodies were solubilized using 4 molar guanidine hydrochloride and 
refolded step-wise by decreasing concentrations of guanidine hydrochloride, and the introduction of redox 
agents, i.e. reduced and oxidized glutathione as well as L-arginine. Expressed and refolded pTbCOX was 
purified using a Ni-NTA column on ÄKTA-FPLC system. The attempt to demonstrate the cyclooxygenase 
activity of the purified pTbCOX by radioisotope thin layer chromatography enzymatic assay using C-14 
arachidonic acid as the main substrate to produce prostaglandins was not successful.  
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This result, however, does not necessarily mean that pTbCOX is not a cyclooxygenase because the lack of 
enzyme activity might also be due to a refolding failure to produce a correct folded and active protein. In 
addition, pTbCOX was obtained in low amounts showing a high tendency to aggregate, as revealed by size 
exclusion chromatography and DLS experiments.  
In the third and fourth part of this work, the pTbCOX gene was cloned in the pFastBacHTb baculovirus 
expression vector to produce properly folded pTbCOX for in vivo crystallization experiments. The protein 
was expressed in Sf9 insect cells and produced in vivo crystals which appeared as micro-sized needle-shaped 
forms 14 days after transfection using the P3 virus stock. The isolated pTbCOX crystals were identified by 
Western blotting and scanning electron microscopy analysis. Isolated pTbCOX crystals showed diffraction 
patterns using powder diffraction and a positive signal by second harmonic generation (SONICC) analysis. 
These experiments present a preliminary characterization of the pTbCOX crystals before XFEL beam or 
MicroED for data collection. Furthermore, pTbCOX in vivo crystals were solubilized using sodium acetate 
buffer to assess the stability of the pTbCOX at the level of secondary structure using DLS and CD 
spectroscopy methods. This screening revealed optimal condition for treatment by which pTbCOX switch 
from large oligomeric aggregates to monodisperse molecules with a radius corresponding to the monomeric 
pTbCOX protein. CD spectroscopy of solubilized pTbCOX confirmed stability of the (properly) folded 
protein in 12.5 mM sodium acetate buffer at pH 3.6. Therefore, this result may also lead to a new way to 
rescue pTbCOX so far insolubly expressed in bacteria, to be easily solubilized by the addition of sodium 
acetate during bacteria cell lysis. Thus, this protocol should allow recovering pTbCOX in a soluble and 
correctly folded form for biological assays, conventional crystallography trials and structure determination of 
pTbCOX.  
In the fifth part of this work, RNAi was used to investigate and validate the physiological function of pTbCOX 
in the trypanosome SMB cell line. Therefore, a fragment of the pTbCOX gene was cloned into an RNAi 
expression vector which contained two opposing promoters and, hence, allowed transcription of double-
stranded RNA upon doxycycline induction. The recombinant vector construct was then transfected into 
bloodstream form T. brucei by electroporation. Two different transgenic clones were produced and 
quantitative real-time PCR confirmed post-transcriptional silencing of the pTbCOX gene. The level of 
TbCOX-mRNA decreased to approximately 50% and 25% respectively for each clone in comparison to the 
untreated SMB trypanosomes at various times post induction. Interestingly, the functional analysis of 
pTbCOX gene depletion resulted to a progressive decrease of growth, morphological defects including 
multiflagellated and big eye phenotypes observed by fluorescence, SEM and TEM microscopy. Furthermore, 
analysis of kinetoplast/nucleus progression in the pTbCOX RNAi cell line revealed a partial cell cycle arrest 
and failure to initiate cytokinesis.  
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These results are a genetical validation that pTbCOX is essential for cytokinesis and cell morphogenesis in 
trypanosome. However, further investigations are needed to reveal the precise cellular processes by which 
pTbCOX contribute to maintain the cytokinesis/endocytosis system in T. brucei in balance.  
Thus, we hypothesize that pTbCOX might participate in multiple cellular processes in T. brucei cell division 
and cell morphogenesis. 
In the last part of this work, the pTbCOX gene was cloned in the pCO57 vector. This vector allows the 
expression of eGFP fusion to the C-terminus of the desired protein and contains an inducible T7 expression 
site, which is regulated by a tetracycline operator. Surprisingly, pTbCOX-eGFP was expressed leaky and 
resulted in the death of the transfected cells after four days post transfection. Our data showed, that pTbCOX-
eGFP expression is lethal for bloodstream form parasites and appeared as a single dot near the kinetoplast or 
in between kinetoplast and nucleus. 
Altogether, this thesis identified a novel hypothetical protein which is essential for the bloodstream 
trypanosomes. Thus, pTbCOX could participate in multiple cellular processes in T. brucei cell division and 
cell morphogenesis. The elucidation of structure and detailed mechanism of action of this protein might 
provide valuable insight, and pTbCOX might become a suitable drug target candidate for future anti-
trypanosomatid therapy. 
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8 Zusammenfassung 
Bei den Erregern der afrikanischen Schlafkrankheit handelt es sich um extrazelluläre Protozoen der 
Trypanosoma brucei-Gruppe. Rund 50% der sequenzierten Gene sind bislang bezüglich ihrer biochemischen 
oder zellulären Eigenschaften nicht charakterisiert und kodieren für hypothetische Proteine ohne bekannte 
Homologe im Menschen. Dies eröffnet zahlreiche potentielle Möglichkeiten zur Entwicklung neuer 
Medikamente. Eines dieser Proteine, das von Antikörpern gegen ovine Cyclooxygenase im Western Blot 
detektiert und mittels Massenspektrometrie identifiziert wurde, sollte hier untersucht werden. Es handelt sich 
um eine putative T. brucei Cyclooxygenase (pTbCOX, Tb427.10.13790/Tb927.10.13790) mit einem hohen 
Anteil hydrophober Aminosäuren. 
Im ersten Teil dieser Arbeit wurde pTbCOX bioinformatisch mittels BLAST/NCBI, Pfam, Proseite, Swiss-
Pro, InterPro, TMHMM, SignalP, Hydrophobizitätsplot und NetPhos untersucht. Hierbei konnten keine 
Homologe im Menschen oder in anderen Organismen (außer Kinetoplastida) gefunden werden. Weiterhin 
konnten keine spezifischen Domänen, Signalsequenzen oder Membrananker identifiziert werden. Allerdings 
konnte gezeigt werden, dass pTbCOX zu 100% identisch zu konservierten hypothetischen Proteinen anderer 
Kinetoplasten ist. Damit ist pTbCOX ein potentiell geeigneter Kandidat für die Entwicklung neuer 
Medikamente. Im Folgenden sollte untersucht werden, ob das Gen für Trypanosoma brucei essentiell ist. 
Im zweiten Teil wurde die kodierende Sequenz von pTbCOX kloniert und in E. coli BL21(DE3) heterolog 
exprimiert; das Protein wurde fast ausschließlich in inclusion bodies gefunden. Diese wurden mit 
4M Guanidinium-HCl solubilisiert und durch schrittweise Reduktion des Guanidinium-HCl und Zuführung 
von Glutathion und L-Arginine renaturiert. pTbCOX wurde danach mittels ÄKTA-FPLC an Ni-NTA-Säulen 
aufgereinigt. Es konnte keine Cyclooxygenaseaktivität durch Umsetzung von C-14-markierter 
Arachidonsäure zu Prostaglandinen über Dünnschichtchromatographie nachgewiesen werden. Dies könnte 
auf eine unzureichende Rückfaltung, die geringe Ausbeute oder die hohe Tendenz zur Aggregation des 
Proteins (wie durch Gelpermeationschromatographie und DLS nachgewiesen) zurückzuführen sein. 
Im dritten und vierten Teil wird beschrieben, wie pTbCOX in pFastBacHTb kloniert wurde, um nativ 
gefaltenes Protein für in vivo Kristallisationsexperimente mit einem Baculovirussystem zu erhalten. Zur 
Expression wurden SF9 Insektenzellen genutzt. 14 Tage nach der Infektion mit dem P3 Virusstock wurden 
nadelförmige Mikrokristalle erhalten. Diese wurden mittels Western Blot, Rasterelektronenmikroskopie und 
SONICC analysiert. Somit wurde eine vorläufige Charakterisierung als Grundlage für 
Röntgenkristallstrukturanalysen (XFEL oder MicroED) durchgeführt.  
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Weiterhin wurden pTbCOX Kristalle mit Natriumacetatpuffer solubilisiert und eine Sekundärstrukturanalyse 
mit DLS und CD-Spektroskopie durchgeführt. Dabei wurden geeignete Bedingungen gefunden, bei denen 
oligomere Proteinaggregate zu monodispersen pTbCOX-Molekülen dissoziieren. Mittels CD-Spektroskopie 
konnte gezeigt werden, dass das solubilisierte und renaturierte Protein in 12,5mM Natriumacetatpuffer bei pH 
3,6 stabil war. Diese Methode ließe sich zukünftig nutzen, um Proteine, die in inclusion bodies exprimiert 
werden, bereits während der Zelllyse durch Zugabe von Natriumacetatpuffer zu lösen. 
Im fünften Teil dieser Arbeit wurde die physiologische Funktion von pTbCOX durch RNA Interferenz in 
SMB (single marker bloodstream form) Trypanosomen untersucht. Ein Fragment des Gens wurde in einen 
Vektor mit zwei gegenläufigen Promotorsequenzen kloniert, so dass doppelsträngige RNA nach Doxycyclin-
Induktion transkribiert wird. SMB Zellen wurden durch Elektroporation transfiziert und zwei transgene Klone 
erhalten. Der knockdown von pTbCOX wurde durch qPCR bestätigt. Verglichen mit unbehandelten SMB 
Zellen sank das Expressionslevel auf 25-50% (je nach Klon). Die Zellen zeigten ein verlangsamtes Wachstum, 
morphologische Defekte mit Multiflagellenbildung, einen big eye Phänotyp und einen partiellen 
Zellzyklusarrest. 
Diese Ergebnisse bestätigten auf genetischer Ebene die Bedeutung von pTbCOX für Zytokinese und 
Morphogenese in Trypanosomen. Weitere Untersuchungen sind nötig, um die zugrundeliegenden 
molekularen Mechanismen aufzuklären. 
Im letzten Teil wurde pTbCOX in den Vektor pCO57 kloniert, um ein C-terminales eGFP-Fusionsprotein in 
SMB-Zellen induzierbar zu exprimieren. Das Fusionsprotein war als solitärer Punkt in der Nähe des 
Kinetoplasten (bzw. zwischen Kinetoplast und Zellkern) lokalisierbar. Überraschenderweise war auch die 
Überexpression innerhalb von vier Tagen letal. 
Zusammenfassend wurde in dieser Arbeit ein hypothetisches Protein identifiziert, das essentiell für Blutform-
Trypanosomen ist. pTbCOX könnte in multiplen zellulären Prozessen (wie Zellteilung und Morphogenese) 
eine Rolle spielen. Die Strukturaufklärung und die Aufklärung der molekularen Funktionsweise könnten 
vielversprechende Ansätze für die Entwicklung neuer Medikamente gegen afrikanische Schlafkrankheit 
liefern.  
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